WO2015132276A1 - Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection - Google Patents

Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection Download PDF

Info

Publication number
WO2015132276A1
WO2015132276A1 PCT/EP2015/054454 EP2015054454W WO2015132276A1 WO 2015132276 A1 WO2015132276 A1 WO 2015132276A1 EP 2015054454 W EP2015054454 W EP 2015054454W WO 2015132276 A1 WO2015132276 A1 WO 2015132276A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenyl
oxo
thiazol
chloro
Prior art date
Application number
PCT/EP2015/054454
Other languages
French (fr)
Inventor
Lei Guo
Taishan HU
Buyu KOU
Xianfeng Lin
Hong Shen
Houguang SHI
Shixiang YAN
Weixing Zhang
Zhisen ZHANG
Mingwei Zhou
Wei Zhu
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112016020566-9A priority Critical patent/BR112016020566B1/en
Priority to CA2935811A priority patent/CA2935811C/en
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Priority to SI201530620T priority patent/SI3114128T1/en
Priority to SG11201607332UA priority patent/SG11201607332UA/en
Priority to DK15710127.0T priority patent/DK3114128T3/en
Priority to PL15710127T priority patent/PL3114128T3/en
Priority to RS20190265A priority patent/RS58384B1/en
Priority to ES15710127T priority patent/ES2714110T3/en
Priority to MYPI2016703231A priority patent/MY188114A/en
Priority to EA201691726A priority patent/EA030115B9/en
Priority to KR1020167023287A priority patent/KR101926243B1/en
Priority to JP2016572899A priority patent/JP6306750B2/en
Priority to LTEP15710127.0T priority patent/LT3114128T/en
Priority to AU2015226206A priority patent/AU2015226206B2/en
Priority to NZ721520A priority patent/NZ721520A/en
Priority to CR20160337A priority patent/CR20160337A/en
Priority to CN201580012257.1A priority patent/CN106061978B/en
Priority to EP15710127.0A priority patent/EP3114128B1/en
Priority to UAA201610076A priority patent/UA117518C2/en
Priority to KR1020187034667A priority patent/KR101933844B1/en
Priority to MX2016011515A priority patent/MX350439B/en
Publication of WO2015132276A1 publication Critical patent/WO2015132276A1/en
Priority to IL246449A priority patent/IL246449B/en
Priority to ZA2016/04784A priority patent/ZA201604784B/en
Priority to PH12016501631A priority patent/PH12016501631A1/en
Priority to HRP20190352TT priority patent/HRP20190352T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a human, and in particular to Hepatitis B virus (HBV) inhibitors by targeting on HBV capsid for the treatment of HBV infection.
  • HBV Hepatitis B virus
  • the present invention relates to novel 6-fused heteroaryldihydropyrimidines having pharmaceutical activity, their manufacture, pharmaceutical compositions containing them and their potential use as medicaments.
  • the present invention relates to compounds of formula (I)
  • R 1 to R 6 , X, Y, W and n are as described below, or to pharmaceutically acceptable salts, or to enantiomers or diastereomers thereof.
  • HBV is a species of the hepadnaviridae family of viruses. HBV is a serious public health problem worldwide, with more than 400 million people especially in Asia-pacific regions chronically infected by this small enveloped DNA virus. Although most individuals seem to
  • HBV lifecycle begins with the binding of the "Dane” particle with an unidentified receptor on the surface of hepatocyte. Following entry, viral genome is delivered into nucleus where a covalently closed circular DNA (cccDNA) is formed through DNA repair of viral relaxed circular DNA. Unlike the mechanisms of most other DNA viruses, HBV cccDNA replicates through the retro transcription of a 1.1 -genome unit-length RNA copy (pregenomic RNA). Viral pregenomic RNA interacts with other two viral components, capsid protein and polymerase, as well as some host factors, to form capsid particles where viral DNA replication occurs. Most copies of the encapsidated genome then efficiently associate with the envelope proteins for virion assembly and secretion; a minority of these genomes is shunted to the nucleus, where they are converted to cccDNA.
  • cccDNA covalently closed circular DNA
  • nucleoside (tide) analogs targeting viral polymerase (lamivudine, adefovir, tenofovir, telbivudine and entecavir) and interferon modulating host immune functions. Mutations in the primary sequence of the polymerase that confer resistance to lamivudine and adefovir have been identified clinically and underlie a rebound of serum virus titers that 70% of treated patients experience within 3 years of the start of lamivudine therapy. Although resistance to telbivudine, adefovir, and entecavir occurs more rarely, it has been recorded.
  • Interferon alpha is the other major therapy available for hepatitis B, but it is limited by a poor long-term response and debilitating side effects. Some viral genotypes do not show good responses to interferon therapy. Now, the standard of clinic cure of HBV infection is the loss and/or seroconversion of HBsAg. The majority (around or more than 90%) of treated patients fail to achieve this goal. This drawback is mainly due to the presence of a stable pool of viral cccDNA in nucleus that doesn't replicate itself, therefore, shows no accessibility to nucleoside (tide) analogs.
  • HBV capsid protein plays essential roles in HBV replication.
  • HBV has an icosahedral core comprising of 240 copies of the capsid (or core) protein.
  • the predominant biological function of capsid protein is to act as a structural protein to encapsidate pre-genomic RNA and form immature capsid particles in the cytoplasm. This step is prerequisite for viral DNA replication.
  • the HBV capsid spontaneously self-assembles from many copies of core dimers present in the cytoplasm. It has been shown that the formation of a trimeric nucleus and the subsequent elongation reactions occur by adding one dimeric subunit at a time until it is complete.
  • capsid protein regulates viral DNA synthesis through different phosphorylation status of its C-terminal phosphorylation sites.
  • capsid protein might facilitate the nuclear translocation of viral relaxed circular genome by means of the nuclear localization signals located in the Arginine-rich domain of the C-terminal region of capsid protein.
  • capsid protein could play a structural and regulatory role in the functionality of cccDNA minichromosomes.
  • Capsid protein also interacts with viral large envelope protein in endoplasmic reticulum and triggers the release of intact viral particles from hepatocytes.
  • capsid related anti-HBV inhibitors There has been a couple of capsid related anti-HBV inhibitors reported. For example, phenylpropenamide derivatives, including compounds named AT-61 and AT-130 (Feld J. et al. Antiviral Research 2007, 168-177), and a class of thiazolidin-4-ones from Valeant R&D
  • HAP Heteroaryldihydropyrimidines or HAP, including compounds named Bay 41-4109, Bay
  • HAP analogs 38-7690 and Bay 39-5493 were discovered in a tissue culture -based screening (Deres K. et al. Science 2003, 893). These HAP analogs act as synthetic allosteric activators and are able to induce aberrant capsid formation that leads to degradation of the core protein. HAP analogs also reorganized core protein from preassembled capsids into noncapsid polymers, presumably by interaction of HAP with dimers freed during capsid 'breathing', the transitory breaking of individual intersubunit bonds. Bay 41-4109 was administered to HBV infected transgenic mouse or humanized mouse models and demonstrated in vivo efficacy with HBV DNA reduction (Deres K. et al. Science 2003, 893; Brezillon N.
  • Ci_ 6 alkyl is hydrogen, halogen or Ci_ 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen, hydroxyCi_ 6 alkyl, aminocarbonyl, Ci ⁇ alkoxycarbonyl or carboxy;
  • R 6 is hydrogen, Ci-ealkoxycarbonyl or carboxy-C m H2 m -;
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -, -O- or -N(R 7 )-,
  • R is hydrogen, Ci_ 6 alkyl, haloCi_ 6 alkyl, C3_ 7 cycloalkyl-C m H 2m -, Ci_
  • W is -CH 2 -, -C(Ci_ 6 alkyl) 2 -, -O- or carbonyl;
  • n 0 or 1 ;
  • n 0-7;
  • t 1-7;
  • the invention is also relates to their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula (I) or other compounds of the present invention for the treatment or prophylaxis of HBV infection.
  • Ci_ 6 alkyl signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, iert-butyl and the like.
  • Particular "Ci_ 6 alkyl” groups are methyl, ethyl, isopropyl and iert-butyl.
  • -C m H 2m - alone or in combination signifies a saturated, linear or branched chain alkyl group containing 1 to 4 carbon atoms.
  • - C t H 2 alone or in combination signifies a saturated, linear or branched chain alkyl group containing 1 to 4 carbon atoms.
  • Ci_ 6 alkoxy alone or in combination signifies a group Ci_ 6 alkyl-0-, wherein the "Ci_ 6 alkyl” is as defined above; for example methoxy, ethoxy, propoxy, zsopropoxy, w-butoxy, zso-butoxy, 2-butoxy, iert-butoxy and the like.
  • Particular "Ci_ 6 alkoxy” groups are methoxy and ethoxy and more particularly methoxy.
  • C3_ 7 cycloalkyl refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • Particular "C 3 _ 7 cycloalkyl” groups are cyclopropyl, cyclopentyl and cyclohexyl.
  • carbonyl alone or in combination refers to the group -C(O)-.
  • sulfonyl alone or in combination refers to the group -S(0) 2 -.
  • halogen and “halo” are used interchangeably herein and refer to fluoro, chloro, bromo, or iodo.
  • haloCi_ 6 alkyl refers to an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms.
  • haloCi_ 6 alkyl include monofluoro-, difluoro- or trifluoro-methyl, - ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoroethyl or trifluoromethyl.
  • Ci_ 6 alkoxycarbonyl refers to a group Ci_ 6 alkoxy-C(0)-, wherein the "Ci_ 6 alkoxy” is as defined above.
  • Carboxy-C m H 2m - refers to a group “-C m H 2m -COOH", wherein the "-C m H 2m -" is as defined above.
  • C 3 _ 7 cycloalkyl-C m H 2m - refers to a "C 3 _ 7 cycloalkyl” group as defined above wherein one of the hydrogen atoms of the "C 3 _ 7 cycloalkyl” group is replaced by a "-C m H 2m -" group.
  • enantiomer denotes two stereoisomers of a compound which are non- superimposable mirror images of one another.
  • diastereomer denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and activities.
  • the compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula (I) or other compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid- addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as /7-toluenesulfonic acid, salicylic acid,
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability,
  • Racemates can be separated according to known methods into the enantiomers.
  • diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
  • the present invention provides (i) novel compounds having the general formula (I):
  • R 1 is hydrogen, halogen or Ci_ 6 alkyl
  • R 3 is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen, hydroxyCi_ 6 alkyl, aminocarbonyl, Ci_ 6 alkoxycarbonyl or carboxy;
  • R 6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-C m H2 m -;
  • X is carbonyl or sulfonyl
  • YY is -CH 2 -, -O- or -N(R 7 )-,
  • R is hydrogen, Ci_ 6 alkyl, haloCi_ 6 alkyl, C3_ 7 cycloalkyl-C m H 2m -, Ci_
  • W is -CH 2 -, -C(Ci_ 6 alkyl) 2 -, -O- or carbonyl;
  • n 0 or 1 ;
  • n 0-7;
  • t 1-7;
  • Another embodiment of present invention is (ii) a compound of formula I, wherein R 1 is hydrogen, chloro, bromo or methyl;
  • R is hydrogen or fhioro
  • R is hydrogen, chloro or f ioro
  • R 4 is methyl, ethyl or propyl
  • R 5 is hydrogen, hydroxymethyl, aminocarbonyl, methoxycarbonyl or carboxy
  • R 6 is hydrogen, methyl-O-carbonyl or carboxymethyl
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -, -0-, -N(R 7 )-,
  • R is hydrogen, methyl, difluoroethyl, isopropyl, isobutyl, t-butyl, cyclopropyl , cyclopropylmethyl, methyl-O-carbonylisopropyl, carboxyethyl, carboxydifluoroethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl,
  • W is -CH 2 -, -C(CH 3 ) 2 -, -O- or carbonyl;
  • n 0 or 1 ;
  • Another embodiment of the present invention is (iii) a compound of formula (IA),
  • R 1 is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen, hydroxyCi_ 6 alkyl, aminocarbonyl, Ci_ 6 alkoxycarbonyl or carboxy;
  • R 6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-C m H2 m -;
  • Y is -N(R 7 )-
  • R is hydrogen, Ci_ 6 alkyl, haloCi_ 6 alkyl, C3_ 7 cycloalkyl-C m H 2m -, Ci_
  • W is -CH 2 - or carbonyl
  • n 0-7;
  • t 1-7;
  • a further embodiment of the present invention is (iv) a compound of formula (I) or (IA) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
  • R 1 is chloro, bromo or methyl
  • R 2 is hydrogen or fluoro
  • R 3 is hydrogen, chloro or fluoro
  • R 4 is methyl, ethyl or propyl
  • R 5 is hydrogen, hydroxymethyl, aminocarbonyl, methoxycarbonyl or carboxy
  • R 6 is hydrogen, methyl-O-carbonyl or carboxymethyl
  • Y is -N(R 7 )-
  • R is hydrogen, methyl, difluoroethyl, isopropyl, isobutyl, t-butyl, cyclopropyl , cyclopropylmethyl, methyl-O-carbonylisopropyl, carboxyethyl, carboxydifluoroethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl,
  • W is -CH 2 - or carbonyl.
  • Another embodiment of the present invention is (v) a compound of formula (IAA),
  • R is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen; is hydrogen or halogen;
  • R 7 is Ci-ealkyl, haloCi_ 6 alkyl, C 3 - 7 cycloalkyl, C 3 _ 7 cycloalkyl-C m H 2m -, -C t H 2t -COOH, -C m H 2m - C 3 _ 7 cycloalkyl-COOH or carboxyphenyl;
  • n 0-7;
  • t 1-7;
  • a further embodiment of the present invention is (vi) a compound of formula (I), (IA) or (IAA) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein R 1 is chloro or methyl;
  • R 2 is hydrogen or fluoro
  • R 3 is hydrogen or fluoro
  • Another embodiment of the present invention is (vii) a compound of formula (IB),
  • n 0 or 1 ;
  • a further embodiment of the present invention is (viii) a compound according to formula (I) or (IB) or pharaiaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein R 1 is hydrogen, chloro or bromo;
  • R 2 is hydrogen or fluoro
  • R 3 is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen
  • R 6 is hydrogen or carboxymethyl
  • Y is -CH 2 - or -0-;
  • W is -CH 2 -, -C(CH 3 ) 2 - 01 -0-;
  • n 0 or 1.
  • Another embodiment of the present invention is (ix) a compound of formula (ID)
  • R 1 is halogen or Ci_ 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci-ealkyl
  • R 5 is hydrogen, aminocarbonyl or carboxy
  • R 6 is hydrogen or Ci_ 6 alkoxycarbonyl
  • X is carbonyl
  • Y is -O- or -N(R 7 )- or -CH 2 -
  • R 7 is hydrogen, Ci-6alkyl, haloCi_6alkyl, C 3 - 7 cycloalkyl, C3- 7 cycloalkyl-C m H 2 m-, - C t H 2t -COOH -C m H 2m -C 3 _ 7 cycloalkyl-COOH , hydroxy-C t H 2t -, carboxyspiro[3.3]heptyl or carboxyphenyl-C m H 2m -;
  • n 0-7;
  • t 1-7;
  • a further embodiment of the present invention is (x) a compound according to formula (I) or (ID), or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
  • R is hydrogen, methyl, isopropyl, difluoroethyl, isobutyl, t-butyl, cyclopropyl, cyclopropylmethyl, carboxy(gemdimethyl)ethyl, carboxy(methyl)ethyl,
  • carboxycyclopropylmethyl carboxyphenyl, carboxycyclopentyl, carboxycyclohexyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl, hydroxyethyl, hydroxy(gemdimethyl)ethyl or
  • Another embodiment of the present invention is (xi) a compound of formula (IE),
  • R 1 is halogen or Ci- 6 alkyl; is hydrogen or halogen;
  • R 6 is hydrogen or carboxy-C m H2 m - ;
  • Y is -0-,-N(R 7 )- or -CH 2 -,
  • R 7 is C 1-6 alkyl, C 3 _ 7 cycloalkyl, -C t H 2t -COOH, -C 3 _ 7 cycloalkyl-C m H 2m -COOH, - C m H 2m -C 3 _ 7 cycloalkyl-COOH , -(Ci- 6 alkoxy)Ci- 6 alkyl-COOH, -Ci- 6 alkyl-0-Ci- 6 alkyl- COOH, carboxyspiro[3.3]heptyl or carboxyphenyl-C m H 2m -;
  • W is -CH 2 - or -C(C 1-6 alkyl) 2 -;
  • n 0-7;
  • t 1-7;
  • a further embodiment of the present invention is (xii) a compound of formula (I) or (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
  • R 1 is chloro or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxymethyl
  • Y is -0-, -N(R 7 )- or -CH 2 -,
  • R is isopropyl, methyl, isobutyl, t-butyl, cyclopropyl, carboxyethyl,
  • W is -CH 2 - or -C(CH 3 ) 2 -.
  • Another embodiment of the present invention is (xiii) a compound of formula (IE),
  • R 1 is halogen or Ci- 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxy-C m H2 m -;
  • Y is -N(R 7 )-
  • R 7 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, -C t H 2t -COOH, -C m H 2m -C 3 _ 7 cycloalkyl- COOH or carboxyphenyl;
  • W is -CH 2 -;
  • n 0-7;
  • t 1-7;
  • a further embodiment of the present invention is (xiv) a compound according to formula (I) or (IE), or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
  • Y is -N(R 7 )-
  • R is hydrogen, methyl, t-butyl, cyclopropyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(methyl)ethyl, carboxycyclopropylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxycyclobutylmethyl or carboxyphenyl; W is -CH 2 -.
  • Another embodiment of the present invention is (xv) a compound of formula (I), (IA), (IAA), (IB), (ID) or (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers, wherein the 2-thiazolyl group is further substituted by Ci_ 6 alkyl, and all the other substituents are defined as above.
  • a further embodiment of the present invention is (xvi) a compound of formula (I), (IA), (IAA), (IB), (ID) or (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers, wherein the 2-thiazolyl group is further substituted by methyl, and all the other substituents are defined as above.
  • R 1 is hydrogen, halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci-ealkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, Ci_ 6 alkoxycarbonyl or carboxy-C m H 2m -;
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -, -O- or -N(R 7 )-,
  • R is hydrogen, Ci_ 6 alkyl, C3_ 7 cycloalkyl, Ci_ 6 alkoxycarbonyl-C m H 2m -,
  • W is -CH 2 -, -C(Ci_ 6 alkyl) 2 -, -O- or carbonyl;
  • n 0 or 1 ;
  • n 0-7;
  • R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl , methyl-O- carbonylisopropyl, carboxyethyl, carboxypropyl, carboxybutyl,
  • W is -CH 2 -, -C(CH 3 ) 2 -, -O- or carbonyl;
  • n 0 or 1 ;
  • Another embodiment of present invention is (xix) a compound of formula (IA)
  • R 1 is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci- 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, Ci_ 6 alkoxycarbonyl or carboxy-C m H 2m -;
  • Y is -N(R 7 )-
  • R is hydrogen, Ci_ 6 alkyl, C 3 _ 7 cycloalkyl, Ci_ 6 alkoxycarbonyl-C m H 2m -,
  • W is -CH 2 - or carbonyl
  • n 0-7; or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
  • R 1 is chloro, bromo or methyl
  • R is hydrogen or fluoro
  • R is hydrogen, chloro or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, methyl-O-carbonyl or carboxymethyl
  • Y is -N(R 7 )-
  • R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl , methyl-O- carbonylisopropyl, carboxyethyl, carboxypropyl, carboxybutyl,
  • W is -CH 2 - or carbonyl.
  • Another embodiment of present invention is (xxi) a compound of formula (IAA)
  • R is halogen or Ci- 6 alkyl
  • R 4 is Ci- 6 arkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen
  • R 7 is Ci_ 6 arkyl, C 3 - 7 cycloalkyl, -C m H 2m -COOH, -C m H 2m -C 3 _ 7 cycloalkyl-COOH or carboxyphenyl;
  • n 1-6;
  • R 1 is chloro or methyl
  • R 2 is hydrogen or fluoro
  • R 3 is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen; is methyl, isopropyl, t-butyl, cyclopropyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxycyclopropylmethyl, carboxycyclobutylmethyl carboxyphenyl.
  • Another embodiment of present invention is (xxiii) a compound of formula (IC)
  • R 1 is halogen
  • R 2 is hydrogen
  • R 3 is halogen
  • R 4 is Ci-ealkyl
  • R 5 is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • W is -C3 ⁇ 4-
  • Another embodiment of present invention is (xxiv) a compound of formula (ID)
  • R 1 is halogen or Ci_ 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or Q-ealkoxycarbonyl
  • X is carbonyl
  • Y is -O- or -N(R 7 )-
  • R 7 is hydrogen, C 1-6 alkyl, C 3 - 7 cycloalkyl, -C m H 2m -COOH, -C m H 2m -C 3 - 7 cycloalkyl- COOH, hydroxy-C m H 2m -, carboxyspiro[3.3]heptyl or carboxyphenyl-C t H 2t -;
  • n 1-6;
  • t 0-6;
  • R 1 is chloro, bromo or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or methyl-O-carbonyl; is carbonyl;
  • R is hydrogen, methyl, isopropyl, t-butyl cyclopropyl
  • Another embodiment of present invention is (xxvi) a compound of formula (IE)
  • R 1 is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxy-C m H2 m -;
  • Y is -O- or -N(R 7 )-
  • R 7 is Ci_ 6 alkyl, C 3 - 7 cycloalkyl, -C m H 2m -COOH, -C 3 _ 7 cycloalkyl-C m H 2m -COOH, -
  • W is -CH 2 - or -C(Ci_ 6 alkyl) 2 -; m is 0-6;
  • R 1 is chloro or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxymethyl
  • Y is -O- or -N(R 7 )-
  • R is isopropyl, methyl, t-butyl, cyclopropyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl,
  • W is -CH 2 - or -C(CH 3 ) 2 -.
  • Another embodiment of present invention is (xxviii) a compound of formula (IE)
  • R 1 is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxy-C m H2 m -;
  • Y is -0-, -N(R 7 )- or -CH 2 -,
  • R 7 is C 1-6 alkyl, C 3 - 7 cycloalkyl, -C m H 2m -COOH, -C 3 _ 7 cycloalkyl-C m H 2m -COOH, -C m H 2m - C 3 _ 7 cycloalkyl-COOH, carboxyspiro[3.3]heptyl, -(Ci_ 6 alkoxy)Ci_ 6 alkyl-COOH, -Ci_ 6 alkyl-0-Ci_ 6 alkyl-COOH, carboxypyridinyl-C m H 2m - or carboxyphenyl-C m H 2m -;
  • W is -CH 2 - or -C(Ci_ 6 alkyl) 2 -;
  • n 0-6;
  • R 1 is chloro or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxymethyl
  • Y is -0-, -N(R 7 )- or -CH 2 -,
  • R is methyl, t-butyl, isopropyl, cyclopropyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl,
  • W is -CH 2 - or -C(CH 3 ) 2 -.
  • the present invention provides (xxx) novel compounds having the general formula (I):
  • R 1 is hydrogen, halogen or Ci_ 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci- 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, Ci_ 6 alkoxycarbonyl or carboxy-C m H 2m -;
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -; -0-; -NR 7 or -N-R 8 -COOH;
  • R is hydrogen, Ci_ 6 alkyl, C3_ 7 cycloalkyl or Ci_ 6 alkoxycarbonyl-C m H 2m -;
  • R 8 is -C m H 2m -, -C t H 2t -C3_ 7 cycloalkyl-C t H 2t - or phenyl;
  • W is -CH 2 -, -O- or carbonyl
  • n 0 or 1 ;
  • n 1-6;
  • t 0-6;
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, methyl-O-carbonyl or carboxymethyl
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -; -0-; -NR 7 or -N-R 8 -COOH;
  • R is hydrogen, isopropyl, cyclopropyl or methyl-O-carbonylisopropyl
  • R is ethyl, propyl, (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, cyclopropylmethyl, cyclobutylmethyl or phenyl;
  • W is -CH 2 -, -O- or carbonyl
  • n 0 or 1 ;
  • Another embodiment of present invention is (xxxii) a compound of formula (I), wherein R 1 is hydrogen, halogen or Ci_ 6 alkyl;
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci- 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, Ci_ 6 alkoxycarbonyl or carboxy-C m H 2m -;
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -; -0-; -NR 7 or -N-R 8 -COOH;
  • R is hydrogen, Ci_ 6 alkyl, C 3 _ 7 cycloalkyl or Ci_ 6 alkoxycarbonyl-C m H 2m -;
  • R is -C m H 2m -, C 3 _ 7 cycloalkyl-C t H 2t - or phenyl;
  • W is -CH 2 -, -O- or carbonyl
  • n 0 or 1 ;
  • n 1-6;
  • t 0-6;
  • R 1 is hydrogen, chloro, bromo or methyl
  • R 2 is hydrogen or fluoro
  • R 3 is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, methyl-O-carbonyl or carboxymethyl
  • X is carbonyl or sulfonyl
  • Y is -CH 2 -; -0-; -NR 7 or -N-R 8 -COOH;
  • R is hydrogen, isopropyl, cyclopropyl or methyl-O-carbonylisopropyl
  • R is (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl,
  • w is -CH 2 -, -O- or carbonyl
  • Another embodiment of present invention is (xxxiv) a compound of formula (IA)
  • R is halogen or Ci_ 6 alkyl
  • Ci_ 6 alkyl is Ci_ 6 alkyl; R 5 is hydrogen or carboxy;
  • R 6 is hydrogen, Ci_ 6 alkoxycarbonyl or carboxy-C m H 2m -;
  • Y is -NR 7 or -N-R 8 -COOH
  • R is hydrogen, Ci_ 6 alkyl, C 3 _ 7 cycloalkyl or Ci_ 6 alkoxycarbonyl-C m H 2m -;
  • R is -C m H 2m -, C 3 - 7 cycloalkyl-C t H 2t - or phenyl;
  • W is -CH 2 - or carbonyl
  • n 1-6;
  • t 0-6;
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, methyl-O-carbonyl or carboxymethyl
  • Y is -NR 7 or -N-R 8 -COOH
  • R is hydrogen, isopropyl, cyclopropyl or methyl-O-carbonylisopropyl
  • R is (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl, cyclopropylmethyl or phenyl;
  • W is -CH 2 - or carbonyl.
  • Another embodiment of present invention is (xxxvi) a compound of formula (IAB)
  • R 1 is halogen or Ci- 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci- 6 alkyl
  • R 5 is hydrogen
  • R 6 is hydrogen
  • R 8 is -C m H 2m -, C 3 - 7 cycloalkyl-C m H 2m - or phenyl;
  • n 1-6;
  • R 2 is hydrogen or fluoro
  • R 3 is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen
  • R 6 is hydrogen
  • R 8 is (gemdimethyl)ethyl, cyclopropylmethyl or phenyl.
  • Another embodiment of present invention is (xxxviii) a compound of formula (ID)
  • R 1 is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci- 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen, Ci_ 6 alkoxycarbonyl or carboxy-C m H 2m -;
  • X is carbonyl or sulfonyl
  • Y is -0-; -NR 7 or -N-R 8 -COOH;
  • R is hydrogen, Ci_ 6 alkyl or C 3 _ 7 cycloalkyl
  • R is -C m H 2m -, C 3 _ 7 cycloalkyl-C t H 2t - or phenyl;
  • n 1-6;
  • t 0-6;
  • R 1 is chloro, bromo or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy; is hydrogen, methyl-O-carbonyl or carboxymethyl;
  • R is hydrogen, isopropyl or cyclopropyl
  • R is (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl, cyclopropylmethyl
  • Another embodiment of present invention is (xl) a compound of formula (IF)
  • R 1 is halogen or Ci_ 6 alkyl
  • R is hydrogen or halogen
  • R is hydrogen or halogen
  • R 4 is Ci- 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxy-C m H 2m -;
  • Y is -NR 7 or -N-R 8 -COOH
  • R is Ci_ 6 alkyl or C 3 _ 7 cycloalkyl
  • R is -C m H 2m -, C 3 _ 7 cycloalkyl-C t H 2t - or phenyl;
  • n 1-6;
  • t 0-6;
  • R 1 is chloro or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxymethyl
  • Y is -NR 7 or -N-R 8 -COOH
  • R is isopropyl or cyclopropyl
  • R is (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl,
  • Another embodiment of present invention is (xxxxii) a compound of formula (IF)
  • R 1 is halogen or Ci_ 6 alkyl
  • R 2 is hydrogen or halogen
  • R 3 is hydrogen or halogen
  • R 4 is Ci_ 6 alkyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxy-C m H2 m - Y is -NR 7 or -N-R 8 -COOH;
  • R is hydrogen or C3_ 7 cycloalkyl
  • R is -C m H 2m -, C 3 - 7 cycloalkyl-C m H 2m - or phenyl;
  • n 1-6;
  • R 1 is chloro or methyl
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R 4 is methyl or ethyl
  • R 5 is hydrogen or carboxy
  • R 6 is hydrogen or carboxymethyl
  • Y is -NR 7 or -N-R 8 -COOH
  • R is hydrogen or cyclopropyl
  • R is (gemdimethyl)ethyl, (methyl)ethyl, cyclopropylmethyl or phenyl.
  • FIG. 1 Further embodiment of present invention is (xliv) a compound of formula (I), formula (IA), formula( IAA), formula (IB), formula (IC), formula (ID), formula (IE), formula (IAB), or formula (IF) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein chirality at 4-position of dihydropyrimidine core is the same as formula (I-R) below, and
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, Y, W and n are as defined in any one of the above embodiment (i) to
  • More particular compounds of the present invention are the following: 3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-propanoic acid;
  • the compounds of the present invention can be prepared by any conventional means.
  • Bromide VI can be prepared by reaction of Va with a bromination reagent such as N- bromosuccinimide, in a suitable inert solvent such as carbon tetrachloride at 80-100 degrees Celsius.
  • a bromination reagent such as N- bromosuccinimide
  • a suitable inert solvent such as carbon tetrachloride at 80-100 degrees Celsius.
  • Compound of interest I can be obtained by coupling bromide VI with a fused amine VII.
  • the reaction is typically performed in a suitable solvent such as 1,2-dichloroethane at room temperature over several hours in the presence of an organic base such as N,N- dii sopropylethylamine .
  • Compound of interest I-I can be prepared in analogy to compound of interest I without SFC chiral separation of dihydropyrimidine V.
  • the 2-thiazolyl group of general formula (I), (V), (Va), (Vb), (VI), (VI-I), (I-I) and any other compounds of this invention can be further substituted by Ci_ 6 alkyl, such as methyl.
  • This invention also relates to a process for the preparation of a compound of formula (I) or other compounds of the present invention comprising the reaction of
  • the base can be for example N,N-diisopropylethylamine.
  • the invention also relates to a compound of formula (I) or other compounds of the present invention for use as therapeutically active substance.
  • compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments
  • compounds of formula (I) or other compounds of the present invention may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • physiologically acceptable carriers i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form.
  • the pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8.
  • a compound of formula (I) or a compound of the present invention is formulated in an acetate buffer, at pH 5.
  • the compounds of formula (I) and other compounds of the present invention are sterile.
  • the compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
  • compositions are formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular human being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to the suppression of serum HBV DNA levels, or HBeAg seroconversion to HBeAb, or HBsAg loss, or normalization of alanine aminotransferase levels and improvement in liver histology. For example, such amount may be below the amount that is toxic to normal cells, or the human as a whole.
  • the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.1 to 20 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day.
  • oral unit dosage forms such as tablets and capsules, contain from about 0.1 to about 1000 mg of the compound of the invention.
  • the compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
  • the compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
  • Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
  • a typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical
  • composition thereof or aid in the manufacturing of the pharmaceutical product (i.e.,
  • An example of a suitable oral dosage form is a tablet containing about 0.1 mg to 1000 mg of the compound of the invention compounded with about 30 mg to 90 mg anhydrous lactose, about 5 mg to 40 mg sodium croscarmellose, about 5 mg to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 mg to 10 mg magnesium stearate.
  • the powdered ingredients are first mixed together and then mixed with a solution of the PVP.
  • the resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using
  • an example of an aerosol formulation can be prepared by dissolving the compound, for example 5 mg to 400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired.
  • a suitable buffer solution e.g. a phosphate buffer
  • a tonicifier e.g. a salt such sodium chloride
  • the solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.
  • An embodiment therefore, includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
  • the following example A and B illustrate typical compositions of the present invention, but serve merely as representative thereof.
  • a compound of the present invention can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
  • a compound of the present invention can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
  • the compounds of the invention can inhibit HBV's de novo DNA synthesis and reduce HBV DNA levels. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of HBV infection.
  • the compounds of inventions are useful as HBV capsid inhibitors.
  • the invention relates to the use of a compound of formula (I) or a compound of the present invention for the treatment or prophylaxis of HBV infection.
  • the use of a compound of formula (I) or a compound of the present invention for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to HBV infection is an object of the invention.
  • the invention relates in particular to the use of a compound of formula (I) or a compound of the present invention for the preparation of a medicament for the treatment or prophylaxis of HBV infection.
  • Another embodiment includes a method for the treatment or prophylaxis of HBV infection which method comprises administering an effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.
  • the compounds of the invention can be used together with interferon, pegylated interferons, Lamivudine, Adefovir dipivoxil, Entecavir, Telbivudine, and Tenofovir disoproxil for the treatment or prophylaxis of HBV.
  • CC 50 concentration results in the death of 50 percent of the cells
  • DIPEA N,N-diisopropylethylamine
  • DNA deoxyribonucleic acid
  • HAP heteroaryldihydropyrimidine
  • HATU l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
  • HBeAb hepatitis B e antibody
  • HBeAg hepatitis B e antigen
  • HBsAg hepatitis B surface antigen
  • HPLC-UV high performance liquid chromatography with ultraviolet detector
  • NBS N-bromo succinimide
  • PBS phosphate buffered saline
  • pgRNA pre-genomic RNA
  • qRT-PCR quantitative real-time polymerase chain reaction
  • CYP cytochromes P450
  • Acidic condition A: 0.1% formic acid in H 2 0; B: 0.1% formic acid in acetonitrile;
  • the microwave assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer.
  • Step 1 Methyl 4-boc-piperazine-2-acetate (CAS number: 183742-33-8, Chemfinder) (1.0 g, 4 mmol) was dissolved in 10 mL of MeOH, then NaBH 4 (1.5 g, 40 mmol) was added portion wise and stirred overnight. The solvent was removed in vacuo and the residue was partitioned between EtOAC and water. The organic layer was separated, and then dried over Na 2 S0 4 and concentrated to give 3-(2-hydroxy-ethyl)-piperazine-l-carboxylic acid ie/t-butyl ester as crude oil (compound E), which was used directly without further purification.
  • Step 2 3-(2-Hydroxy-ethyl)-piperazine-l-carboxylic acid ie/t-butyl ester (58 mg, 0.25 mmol) was dissolved in 4 mL of dichloromethane and lmL of DIPEA, and then triphosgene (27 mg, 0.09 mmol) was added at room temperature. The reaction mixture was stirred for 30 minutes, and the solvent was removed in vacuo. The residue was dissolved in 3 mL of dichloromethane and 1 mL of TFA.
  • Example 2 was obtained as a light yellow solid (9 mg).
  • Example 3 was obtained as a light yellow solid (21 mg).
  • Example 4 was obtained as a light yellow solid (20 mg).
  • Compound F was prepared in analogy to Example 1 by using hexahydropyrrolo[l,2- a]pyrazin-6(2H)-one (CAS number: 117810-52-3, Bepharm; for its synthesis, please refer to: Alvaro G., Large C. PCT Int. Appl., 2008090115) instead of hexahydro-pyrazino[l,2- c][l,3]oxazin-6-one (Compound D).
  • hexahydropyrrolo[l,2- a]pyrazin-6(2H)-one CAS number: 117810-52-3, Bepharm; for its synthesis, please refer to: Alvaro G., Large C. PCT Int. Appl., 2008090115
  • Example 7 was obtained as a light yellow solid (19 mg).
  • Example 8 was obtained as a light yellow solid (8 mg).
  • Example 9 was obtained as a light yellow solid (11 mg).
  • Example 11 was obtained as a light yellow solid (11 mg).
  • Step 1 To a stirred solution of Na 2 C0 3 (118 g, 1.11 mol) in water (600 mL) was added (25 , )-piperazine-2-carboxylic acid dihydrochloride salts (30 g, 0.15 mol) at 25 °C, followed by di-iert-butyl dicarbonate (112 g, 0.56 mol) and tetrahydrofuran (300 mL). Then the mixture was stirred for additional 20 hours at room temperature. The reaction mixture was concentrated in vacuo and the resulting solution was extracted with methyl iert-butyl ether (200 mL) three times to remove nonpolar species.
  • Step 3 To a solution of Compound J (15 g, 47.41 mmol), Ph 3 P (16.17 g, 61.63 mmol) and phthalimide (9.07 g, 61.63 mmol) in anhydrous tetrahydrofuran (230 mL) was added a solution of diisopropyl azodicarboxylate (12.46 g, 61.63 mmol) in tetrahydrofuran (20 mL) at 10 °C under N 2 atmosphere. Then the mixture was stirred for additional 2 hours at 10 °C. The mixture was quenched with IN HC1 (100 mL) and then extracted with EtOAc (300 mL).
  • the organic layer was dried over Na 2 S0 4 , filtered, and then concentrated in vacuo to give the crude product (50 g).
  • Step 4 To a stirred solution of Compound K (12 g, 26.9 mmol) in ethanol (85 mL) was added methylamine alcohol solution (85 mL) at room temperature. Then the mixture was heated to reflux for additional 3 hours. The mixture was cooled to room temperature and then concentrated. The resulting residue was dissolved in water (50 mL), then acidified to pH 3 with IN HC1 solution, and then extracted with methyl-iert-butyl ether (50 mL) three times. The pH was adjusted to 10 with solid NaOH and the mixture was extracted with ethyl acetate (150 mL) three times. The organic layer was dried and filtered and the solvent was removed under reduced pressure to give Compound L (6 g crude).
  • Step 6 To a stirred solution of Compound M (2.2 g, 9.1 mmol) in 30 mL of
  • Example 12 was obtained as a lig yellow solid (13 mg).
  • Example 13 was obtained as a light yellow solid (34 mg).
  • Example 14 was obtained as a light yellow solid (34 mg).
  • Example 18 was obtained as a yellow solid (28 mg).
  • Example 19 was obtained as a light yellow solid (12 mg).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds. These compounds useful for therapy and/or prophylaxis in a human, and in particular to Hepatitis B virus (HBV) inhibitors by targeting on HBV capsid for the treatment of HBV infection.

Description

Novel 6-fused heteroaryldihydropyrimidines
for the treatment and prophylaxis of hepatitis B virus infection
The present invention relates to organic compounds useful for therapy and/or prophylaxis in a human, and in particular to Hepatitis B virus (HBV) inhibitors by targeting on HBV capsid for the treatment of HBV infection.
FIELD OF THE INVENTION
The present invention relates to novel 6-fused heteroaryldihydropyrimidines having pharmaceutical activity, their manufacture, pharmaceutical compositions containing them and their potential use as medicaments.
The present invention relates to compounds of formula (I)
Figure imgf000003_0001
wherein R1 to R6, X, Y, W and n are as described below, or to pharmaceutically acceptable salts, or to enantiomers or diastereomers thereof.
HBV is a species of the hepadnaviridae family of viruses. HBV is a serious public health problem worldwide, with more than 400 million people especially in Asia-pacific regions chronically infected by this small enveloped DNA virus. Although most individuals seem to
Yingxian Zhu /Jan. 15, 2015 resolve the infection following acute symptoms, 15-40% of HBV patients will finally develop clinical diseases during their lifespan, most notably, hepatitis, liver cirrhosis, and hepatocellular carcinoma. Every year 500,000 to 1 million people die from the end stage of liver diseases caused by HBV infection.
HBV lifecycle begins with the binding of the "Dane" particle with an unidentified receptor on the surface of hepatocyte. Following entry, viral genome is delivered into nucleus where a covalently closed circular DNA (cccDNA) is formed through DNA repair of viral relaxed circular DNA. Unlike the mechanisms of most other DNA viruses, HBV cccDNA replicates through the retro transcription of a 1.1 -genome unit-length RNA copy (pregenomic RNA). Viral pregenomic RNA interacts with other two viral components, capsid protein and polymerase, as well as some host factors, to form capsid particles where viral DNA replication occurs. Most copies of the encapsidated genome then efficiently associate with the envelope proteins for virion assembly and secretion; a minority of these genomes is shunted to the nucleus, where they are converted to cccDNA.
Currently, there are two types of anti-HBV agents on the market, nucleoside (tide) analogs targeting viral polymerase (lamivudine, adefovir, tenofovir, telbivudine and entecavir) and interferon modulating host immune functions. Mutations in the primary sequence of the polymerase that confer resistance to lamivudine and adefovir have been identified clinically and underlie a rebound of serum virus titers that 70% of treated patients experience within 3 years of the start of lamivudine therapy. Although resistance to telbivudine, adefovir, and entecavir occurs more rarely, it has been recorded. Interferon alpha is the other major therapy available for hepatitis B, but it is limited by a poor long-term response and debilitating side effects. Some viral genotypes do not show good responses to interferon therapy. Now, the standard of clinic cure of HBV infection is the loss and/or seroconversion of HBsAg. The majority (around or more than 90%) of treated patients fail to achieve this goal. This drawback is mainly due to the presence of a stable pool of viral cccDNA in nucleus that doesn't replicate itself, therefore, shows no accessibility to nucleoside (tide) analogs.
Hence, there is certainly a medical need for treatments with improved characteristics and for a diversity of approaches in the development of therapies for HBV infection.
HBV capsid protein plays essential roles in HBV replication. HBV has an icosahedral core comprising of 240 copies of the capsid (or core) protein. The predominant biological function of capsid protein is to act as a structural protein to encapsidate pre-genomic RNA and form immature capsid particles in the cytoplasm. This step is prerequisite for viral DNA replication. The HBV capsid spontaneously self-assembles from many copies of core dimers present in the cytoplasm. It has been shown that the formation of a trimeric nucleus and the subsequent elongation reactions occur by adding one dimeric subunit at a time until it is complete. Besides this function, capsid protein regulates viral DNA synthesis through different phosphorylation status of its C-terminal phosphorylation sites. When a near full-length relaxed circular DNA is formed through reverse-transcription of viral pregenomic RNA, an immature capsid becomes a mature capsid. On one hand, capsid protein might facilitate the nuclear translocation of viral relaxed circular genome by means of the nuclear localization signals located in the Arginine-rich domain of the C-terminal region of capsid protein. In nucleus, as a component of viral cccDNA minichromosome, capsid protein could play a structural and regulatory role in the functionality of cccDNA minichromosomes. Capsid protein also interacts with viral large envelope protein in endoplasmic reticulum and triggers the release of intact viral particles from hepatocytes.
There has been a couple of capsid related anti-HBV inhibitors reported. For example, phenylpropenamide derivatives, including compounds named AT-61 and AT-130 (Feld J. et al. Antiviral Research 2007, 168-177), and a class of thiazolidin-4-ones from Valeant R&D
(WO2006/033995), have been shown to inhibit pgRNA packaging. A recent study suggested that phenylpropenamides are, in fact, accelerators of HBV capsid assembly, and their actions result in the formation of empty capsids. These very interesting results illustrate the importance of the kinetic pathway in successful virus assembly.
Heteroaryldihydropyrimidines or HAP, including compounds named Bay 41-4109, Bay
38-7690 and Bay 39-5493, were discovered in a tissue culture -based screening (Deres K. et al. Science 2003, 893). These HAP analogs act as synthetic allosteric activators and are able to induce aberrant capsid formation that leads to degradation of the core protein. HAP analogs also reorganized core protein from preassembled capsids into noncapsid polymers, presumably by interaction of HAP with dimers freed during capsid 'breathing', the transitory breaking of individual intersubunit bonds. Bay 41-4109 was administered to HBV infected transgenic mouse or humanized mouse models and demonstrated in vivo efficacy with HBV DNA reduction (Deres K. et al. Science 2003, 893; Brezillon N. et al. PLoS ONE 2011, e25096). It was also shown that bis-ANS, a small molecule that acts as a molecular 'wedge' and interferes with normal capsid- protein geometry and capsid formation (Zlotnick A. et al. J. Virol. 2002, 4848-4854).
SUMMARY OF THE INVENTION The present invention relates to novel compounds of formula (I)
Figure imgf000006_0001
wherein
Figure imgf000006_0002
wherein
is hydrogen, halogen or Ci_6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen, hydroxyCi_6alkyl, aminocarbonyl, Ci ^alkoxycarbonyl or carboxy; R6 is hydrogen, Ci-ealkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl; Y is -CH2-, -O- or -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, haloCi_6alkyl, C3_7cycloalkyl-CmH2m-, Ci_
6alkoxycarbonyl-CmH2m-,-CtH2t-COOH, -haloCi_6alkyl-COOH, -(Ci_6alkoxy)Ci_6alkyl- COOH, -Ci-6alkyl-0-Ci-6alkyl-COOH, -C3-7cycloalkyl-CmH2m-COOH, -CmH2m-C3_ 7cycloalkyl-COOH, hydroxy-CtH2r, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-, carboxypyridinyl-CmH2m- ;
W is -CH2-, -C(Ci_6alkyl)2-, -O- or carbonyl;
n is 0 or 1 ;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
The invention is also relates to their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula (I) or other compounds of the present invention for the treatment or prophylaxis of HBV infection.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
As used herein, the term "Ci_6alkyl" signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, iert-butyl and the like. Particular "Ci_6alkyl" groups are methyl, ethyl, isopropyl and iert-butyl.
The term "-CmH2m-" alone or in combination signifies a saturated, linear or branched chain alkyl group containing m (m≠0) carbon atoms or a bond (m=0). In particular, "-CmH2m-" alone or in combination signifies a saturated, linear or branched chain alkyl group containing 1 to 4 carbon atoms.
The term "-CtH2 " alone or in combination signifies a chemical link or a saturated, linear or branched chain alkyl group containing t (t≠0) carbon atoms or a bond (t=0). In particular, "- CtH2 " alone or in combination signifies a saturated, linear or branched chain alkyl group containing 1 to 4 carbon atoms.
The term "Ci_6alkoxy" alone or in combination signifies a group Ci_6alkyl-0-, wherein the "Ci_6alkyl" is as defined above; for example methoxy, ethoxy, propoxy, zsopropoxy, w-butoxy, zso-butoxy, 2-butoxy, iert-butoxy and the like. Particular "Ci_6alkoxy" groups are methoxy and ethoxy and more particularly methoxy.
The term "C3_7cycloalkyl", alone or in combination, refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Particular "C3_ 7cycloalkyl" groups are cyclopropyl, cyclopentyl and cyclohexyl.
The term "carboxy" refers to the group -COOH.
The term "carbonyl" alone or in combination refers to the group -C(O)-.
The term "sulfonyl" alone or in combination refers to the group -S(0)2-. The term "halogen" and "halo" are used interchangeably herein and refer to fluoro, chloro, bromo, or iodo.
The term "haloCi_6alkyl" refers to an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloCi_6alkyl include monofluoro-, difluoro- or trifluoro-methyl, - ethyl or -propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoroethyl or trifluoromethyl.
The term "Ci_6alkoxycarbonyl" refers to a group Ci_6alkoxy-C(0)-, wherein the "Ci_ 6alkoxy" is as defined above.
The term "carboxy-CmH2m-" refers to a group "-CmH2m-COOH", wherein the "-CmH2m-" is as defined above.
The term "C3_7cycloalkyl-CmH2m-" refers to a "C3_7cycloalkyl" group as defined above wherein one of the hydrogen atoms of the "C3_7cycloalkyl" group is replaced by a "-CmH2m-" group.
The term "enantiomer" denotes two stereoisomers of a compound which are non- superimposable mirror images of one another.
The term "diastereomer" denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and activities.
The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula (I) or other compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid- addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as /7-toluenesulfonic acid, salicylic acid,
methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability,
hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et al., Organic Process Research & Development 2000, 4, 427-435; or in Ansel, H., et al., In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456- 1457. Particular are the sodium salts of the compounds of formula (I).
Compounds of the general formula (I) or other compounds of the present invention which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Particularly, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
HBV CAPSID INHIBITOR
The present invention provides (i) novel compounds having the general formula (I):
Figure imgf000010_0001
wherein
R1 is hydrogen, halogen or Ci_6alkyl;
is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen, hydroxyCi_6alkyl, aminocarbonyl, Ci_6alkoxycarbonyl or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl;
YY is -CH2-, -O- or -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, haloCi_6alkyl, C3_7cycloalkyl-CmH2m-, Ci_
6alkoxycarbonyl-CmH2m-,-CtH2t-COOH, -haloCi_6alkyl-COOH, -(Ci-6alkoxy)Ci-6alkyl- COOH, -Ci-6alkyl-0-Ci-6alkyl-COOH, -C3-7cycloalkyl-CmH2m-COOH, -CmH2m-C3_ 7cycloalkyl-COOH, hydroxy-CtH2t-, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-, carboxypyridinyl-CmH2m-;
W is -CH2-, -C(Ci_6alkyl)2-, -O- or carbonyl;
n is 0 or 1 ;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Another embodiment of present invention is (ii) a compound of formula I, wherein R1 is hydrogen, chloro, bromo or methyl;
R is hydrogen or fhioro;
R is hydrogen, chloro or f ioro;
R4 is methyl, ethyl or propyl;
R5 is hydrogen, hydroxymethyl, aminocarbonyl, methoxycarbonyl or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
X is carbonyl or sulfonyl;
Y is -CH2-, -0-, -N(R7)-,
wherein R is hydrogen, methyl, difluoroethyl, isopropyl, isobutyl, t-butyl, cyclopropyl , cyclopropylmethyl, methyl-O-carbonylisopropyl, carboxyethyl, carboxydifluoroethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl,
carboxycyclopropylmethyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl,
carboxymethoxyethyl, carboxymethoxypropyl, hydroxyethyl,
hydroxymethyl(gemdimethyl)butyl, hydroxy(gemdimethyl)ethyl, carboxyphenyl, carboxypyridinyl or carboxyphenylmethyl;
W is -CH2-, -C(CH3)2-, -O- or carbonyl;
n is 0 or 1 ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Another embodiment of the present invention is (iii) a compound of formula (IA),
Figure imgf000012_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen, hydroxyCi_6alkyl, aminocarbonyl, Ci_6alkoxycarbonyl or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
Y is -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, haloCi_6alkyl, C3_7cycloalkyl-CmH2m-, Ci_
6alkoxycarbonyl-CmH2m-,-CtH2t-COOH, -haloCi_6alkyl-COOH, -(Ci_6alkoxy)Ci_6alkyl- COOH, -Ci-6alkyl-0-Ci-6alkyl-COOH, -C3-7cycloalkyl-CmH2m-COOH, -CmH2m-C3_ 7cycloalkyl-COOH, hydroxy-CtH2r, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-, carboxypyridinyl-CmH2m- ;
W is -CH2- or carbonyl;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
A further embodiment of the present invention is (iv) a compound of formula (I) or (IA) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro, bromo or methyl; R2 is hydrogen or fluoro;
R3 is hydrogen, chloro or fluoro;
R4 is methyl, ethyl or propyl;
R5 is hydrogen, hydroxymethyl, aminocarbonyl, methoxycarbonyl or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
Y is -N(R7)-,
wherein R is hydrogen, methyl, difluoroethyl, isopropyl, isobutyl, t-butyl, cyclopropyl , cyclopropylmethyl, methyl-O-carbonylisopropyl, carboxyethyl, carboxydifluoroethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl,
carboxycyclopropylmethyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl,
carboxymethoxyethyl, carboxymethoxypropyl, hydroxyethyl,
hydroxymethyl(gemdimethyl)butyl, hydroxy(gemdimethyl)ethyl, carboxyphenyl, carboxypyridinyl or carboxyphenylmethyl;
W is -CH2- or carbonyl.
Another embodiment of the present invention is (v) a compound of formula (IAA),
Figure imgf000013_0001
wherein
R is halogen or Ci_6alkyl;
R is hydrogen or halogen; is hydrogen or halogen;
is Ci_6alkyl;
is hydrogen, aminocarbonyl or carboxy;
is hydrogen;
R7 is Ci-ealkyl, haloCi_6alkyl, C3-7cycloalkyl, C3_7cycloalkyl-CmH2m-, -CtH2t-COOH, -CmH2m- C3_7cycloalkyl-COOH or carboxyphenyl;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
A further embodiment of the present invention is (vi) a compound of formula (I), (IA) or (IAA) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein R1 is chloro or methyl;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
is methyl or ethyl;
is hydrogen, aminocarbonyl or carboxy;
is hydrogen;
Figure imgf000014_0001
is methyl, isopropyl, isobutyl, t-butyl, difluoroethyl, cyclopropyl, cyclopropylmethyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxycyclopropylmethyl, carboxycyclobutylmethyl or carboxyphenyl.
Another embodiment of the present invention is (vii) a compound of formula (IB),
Figure imgf000015_0001
wherein
R1 is
R2 is
R3 is
R4 is
R5 is
R6 is
Y is
W is
n is 0 or 1 ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
A further embodiment of the present invention is (viii) a compound according to formula (I) or (IB) or pharaiaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein R1 is hydrogen, chloro or bromo;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen;
R6 is hydrogen or carboxymethyl;
Y is -CH2- or -0-; W is -CH2-, -C(CH3)2- 01 -0-;
n is 0 or 1.
Another embodiment of the present invention is (ix) a compound of formula (ID)
Figure imgf000016_0001
wherein
R1 is halogen or Ci_6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci-ealkyl;
R5 is hydrogen, aminocarbonyl or carboxy;
R6 is hydrogen or Ci_6alkoxycarbonyl
X is carbonyl;
Y is -O- or -N(R7)- or -CH2-,
wherein R7 is hydrogen, Ci-6alkyl, haloCi_6alkyl, C3-7cycloalkyl, C3-7cycloalkyl-CmH2m-, - CtH2t-COOH -CmH2m-C3_7cycloalkyl-COOH , hydroxy-CtH2t-, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
m is 0-7;
t is 1-7;
or phannaceutically acceptable salts, or enantiomers or diastereomers thereof. A further embodiment of the present invention is (x) a compound according to formula (I) or (ID), or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
is chloro, bromo or methyl;
is hydrogen or fluoro;
is hydrogen or fluoro;
is methyl, ethyl or propyl;
is hydrogen, aminocarbonyl or carboxy;
is hydrogen or methyl-O-carbonyl;
is carbonyl;
is -0-, -N(R7)- or -CH2-,
wherein R is hydrogen, methyl, isopropyl, difluoroethyl, isobutyl, t-butyl, cyclopropyl, cyclopropylmethyl, carboxy(gemdimethyl)ethyl, carboxy(methyl)ethyl,
carboxycyclopropylmethyl , carboxyphenyl, carboxycyclopentyl, carboxycyclohexyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl, hydroxyethyl, hydroxy(gemdimethyl)ethyl or
carboxyphenylmethyl.
Another embodiment of the present invention is (xi) a compound of formula (IE),
Figure imgf000017_0001
wherein
R1 is halogen or Ci-6alkyl; is hydrogen or halogen;
is hydrogen or halogen;
is Ci_6alkyl;
is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m- ;
Y is -0-,-N(R7)- or -CH2-,
wherein R7 is C1-6alkyl, C3_7cycloalkyl, -CtH2t-COOH, -C3_7cycloalkyl-CmH2m-COOH, - CmH2m-C3_7cycloalkyl-COOH , -(Ci-6alkoxy)Ci-6alkyl-COOH, -Ci-6alkyl-0-Ci-6alkyl- COOH, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
W is -CH2- or -C(C1-6alkyl)2-;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof. A further embodiment of the present invention is (xii) a compound of formula (I) or (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxymethyl;
Y is -0-, -N(R7)- or -CH2-,
wherein R is isopropyl, methyl, isobutyl, t-butyl, cyclopropyl, carboxyethyl,
carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(methyl)ethyl, carboxycyclobutyl, carboxycyclopropylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl, carboxy(gemdimethyl)propyl,
carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutylmethyl,
carboxyspiro[3.3]heptyl, carboxymethoxyethyl, carboxymethoxypropyl,
carboxyphenylmethyl or carboxyphenyl;
W is -CH2- or -C(CH3)2-.
Another embodiment of the present invention is (xiii) a compound of formula (IE),
Figure imgf000019_0001
wherein
R1 is halogen or Ci-6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m-;
Y is -N(R7)-,
wherein R7 is hydrogen, C1-6alkyl, C3-7cycloalkyl, -CtH2t-COOH, -CmH2m-C3_7cycloalkyl- COOH or carboxyphenyl;
W is -CH2-;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
A further embodiment of the present invention is (xiv) a compound according to formula (I) or (IE), or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
is chloro or methyl;
is hydrogen or fluoro;
is hydrogen or fluoro; is methyl or ethyl;
is hydrogen or carboxy;
is hydrogen or carboxymethyl;
Y is -N(R7)-,
wherein R is hydrogen, methyl, t-butyl, cyclopropyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(methyl)ethyl, carboxycyclopropylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxycyclobutylmethyl or carboxyphenyl; W is -CH2-.
Another embodiment of the present invention is (xv) a compound of formula (I), (IA), (IAA), (IB), (ID) or (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers, wherein the 2-thiazolyl group is further substituted by Ci_6alkyl, and all the other substituents are defined as above.
A further embodiment of the present invention is (xvi) a compound of formula (I), (IA), (IAA), (IB), (ID) or (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers, wherein the 2-thiazolyl group is further substituted by methyl, and all the other substituents are defined as above.
Another embodiment of the present invention is (xvii) compounds having the general formula (I):
Figure imgf000020_0001
wherein
R1 is hydrogen, halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-ealkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl;
Y is -CH2-, -O- or -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, C3_7cycloalkyl, Ci_6alkoxycarbonyl-CmH2m-,
-CmH2m-COOH, -(Ci_6alkoxy)Ci_6alkyl-COOH, -Ci_6alkyl-0-Ci_6alkyl-COOH, -C3
7cycloalkyl-CmH2m-COOH, -CmH2m-C3-7cycloalkyl-COOH, hydroxy-CmH2m-,
carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
W is -CH2-, -C(Ci_6alkyl)2-, -O- or carbonyl;
n is 0 or 1 ;
m is 0-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xviii) a compound of formula (I), wherein is hydrogen, chloro, bromo or methyl;
hydrogen or fluoro;
hydrogen, chloro or fluoro;
is methyl or ethyl;
is hydrogen or carboxy;
is hydrogen, methyl-O-carbonyl or carboxymethyl;
is carbonyl or sulfonyl;
is -CH2-, -0-, -N(R7)-,
wherein R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl , methyl-O- carbonylisopropyl, carboxyethyl, carboxypropyl, carboxybutyl,
carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl,
carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl, carboxycyclopropylmethyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl, carboxymethoxyethyl, carboxymethoxypropyl, hydroxyethyl, hydroxymethyl(gemdimethyl)butyl, carboxyphenyl or carboxyphenylmethyl;
W is -CH2-, -C(CH3)2-, -O- or carbonyl;
n is 0 or 1 ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Another embodiment of present invention is (xix) a compound of formula (IA)
Figure imgf000022_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
Y is -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, C3_7cycloalkyl, Ci_6alkoxycarbonyl-CmH2m-,
-CmH2m-COOH, -(Ci_6alkoxy)Ci_6alkyl-COOH, -Ci_6alkyl-0-Ci_6alkyl-COOH, -C3_ 7cycloalkyl-CmH2m-COOH, -CmH2m-C3_7cycloalkyl-COOH, hydroxy-CmH2m-,
carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
W is -CH2- or carbonyl;
m is 0-7; or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xx) a compound of formula (IA) or
pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro, bromo or methyl;
R is hydrogen or fluoro;
R is hydrogen, chloro or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
Y is -N(R7)-,
wherein R is hydrogen, methyl, isopropyl, t-butyl, cyclopropyl , methyl-O- carbonylisopropyl, carboxyethyl, carboxypropyl, carboxybutyl,
carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl,
carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl, carboxycyclopropylmethyl,
carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl, carboxymethoxyethyl,
carboxymethoxypropyl, hydroxyethyl, hydroxymethyl(gemdimethyl)butyl, carboxyphenyl or carboxyphenylmethyl;
W is -CH2- or carbonyl.
Another embodiment of present invention is (xxi) a compound of formula (IAA)
Figure imgf000024_0001
R is halogen or Ci-6alkyl;
is hydrogen or halogen;
Figure imgf000024_0002
is hydrogen or halogen;
R4 is Ci-6arkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen;
R7 is Ci_6arkyl, C3-7cycloalkyl, -CmH2m-COOH, -CmH2m-C3_7cycloalkyl-COOH or carboxyphenyl;
m is 1-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxii) a compound of formula (IAA) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen; is methyl, isopropyl, t-butyl, cyclopropyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxycyclopropylmethyl, carboxycyclobutylmethyl carboxyphenyl.
Another embodiment of present invention is (xxiii) a compound of formula (IC)
Figure imgf000025_0001
R1 is halogen;
R2 is hydrogen;
R3 is halogen;
R4 is Ci-ealkyl;
R5 is hydrogen;
R6 is hydrogen;
R7 is hydrogen;
W is -C¾-;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Another embodiment of present invention is (xxiv) a compound of formula (ID)
Figure imgf000026_0001
wherein
R1 is halogen or Ci_6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or Q-ealkoxycarbonyl;
X is carbonyl;
Y is -O- or -N(R7)-,
wherein R7 is hydrogen, C1-6alkyl, C3-7cycloalkyl, -CmH2m-COOH, -CmH2m-C3-7cycloalkyl- COOH, hydroxy-CmH2m-, carboxyspiro[3.3]heptyl or carboxyphenyl-CtH2t-;
m is 1-6;
t is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxv) a compound of formula (ID) pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro, bromo or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or methyl-O-carbonyl; is carbonyl;
is -0-, -N(R7)-,
wherein R is hydrogen, methyl, isopropyl, t-butyl cyclopropyl,
carboxy(gemdimethyl)ethyl, carboxy(methyl)ethyl, carboxycyclopropylmethyl , carboxyphenyl, carboxycyclopentyl, carboxycyclohexyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl, hydroxyethyl or carboxyphenylmethyl.
Another embodiment of present invention is (xxvi) a compound of formula (IE)
Figure imgf000027_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m-;
Y is -O- or -N(R7)-,
wherein R7 is Ci_6alkyl, C3-7cycloalkyl, -CmH2m-COOH, -C3_7cycloalkyl-CmH2m-COOH, -
CmH2m-C3_7cycloalkyl-COOH , -(Ci_6alkoxy)Ci_6alkyl-COOH, -Ci_6alkyl-0-Ci_6alkyl- COOH, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
W is -CH2- or -C(Ci_6alkyl)2-; m is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxvii) a compound of formula (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxymethyl;
Y is -O- or -N(R7)-,
wherein R is isopropyl, methyl, t-butyl, cyclopropyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl,
carboxy(methyl)ethyl, carboxycyclobutyl, carboxycyclopropylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl, carboxy(gemdimethyl)propyl,
carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutylmethyl,
carboxyspiro[3.3]heptyl, carboxymethoxyethyl, carboxymethoxypropyl,
carboxyphenylmethyl or carboxyphenyl;
W is -CH2- or -C(CH3)2-.
Another embodiment of present invention is (xxviii) a compound of formula (IE)
Figure imgf000028_0001
(IE) wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m-;
Y is -0-, -N(R7)- or -CH2-,
wherein R7 is C1-6alkyl, C3-7cycloalkyl, -CmH2m-COOH, -C3_7cycloalkyl-CmH2m-COOH, -CmH2m- C3_7cycloalkyl-COOH, carboxyspiro[3.3]heptyl, -(Ci_6alkoxy)Ci_6alkyl-COOH, -Ci_6alkyl-0-Ci_ 6alkyl-COOH, carboxypyridinyl-CmH2m- or carboxyphenyl-CmH2m-;
W is -CH2- or -C(Ci_6alkyl)2-;
m is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxix) a compound of formula (IE) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxymethyl;
Y is -0-, -N(R7)- or -CH2-,
wherein R is methyl, t-butyl, isopropyl, cyclopropyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl,
carboxy(methyl)ethyl, carboxycyclobutyl, carboxycyclopentyl, carboxycyclohexyl, carboxycyclopropylmethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutylmethyl,
carboxymethylcyclopropyl, carboxyspiro[3.3]heptyl, carboxymethoxyethyl,
carboxymethoxypropyl, carboxyphenylmethyl, carboxypyridinyl or carboxyphenyl;
W is -CH2- or -C(CH3)2-. The present invention provides (xxx) novel compounds having the general formula (I):
Figure imgf000030_0001
wherein
R 1 is hydrogen, halogen or Ci_6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl;
Y is -CH2-; -0-; -NR7or -N-R8-COOH;
wherein R is hydrogen, Ci_6alkyl, C3_7cycloalkyl or Ci_6alkoxycarbonyl-CmH2m-;
R8 is -CmH2m-, -CtH2t-C3_7cycloalkyl-CtH2t- or phenyl;
W is -CH2-, -O- or carbonyl;
n is 0 or 1 ;
m is 1-6;
t is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxxi) a compound of formula (I), wherein R1 is hydrogen, chloro, bromo or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
X is carbonyl or sulfonyl;
Y is -CH2-; -0-; -NR7 or -N-R8-COOH;
wherein R is hydrogen, isopropyl, cyclopropyl or methyl-O-carbonylisopropyl;
R is ethyl, propyl, (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, cyclopropylmethyl, cyclobutylmethyl or phenyl;
W is -CH2-, -O- or carbonyl;
n is 0 or 1 ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Another embodiment of present invention is (xxxii) a compound of formula (I), wherein R1 is hydrogen, halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl;
Y is -CH2-; -0-; -NR7 or -N-R8-COOH;
wherein R is hydrogen, Ci_6alkyl, C3_7cycloalkyl or Ci_6alkoxycarbonyl-CmH2m-;
R is -CmH2m-, C3_7cycloalkyl-CtH2t- or phenyl;
W is -CH2-, -O- or carbonyl;
n is 0 or 1 ;
m is 1-6;
t is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof. Further embodiment of present invention is (xxxiii) a compound of formula (I), wherein
R1 is hydrogen, chloro, bromo or methyl;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
X is carbonyl or sulfonyl;
Y is -CH2-; -0-; -NR7 or -N-R8-COOH;
wherein R is hydrogen, isopropyl, cyclopropyl or methyl-O-carbonylisopropyl;
R is (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl,
cyclopropylmethyl or phenyl;
w is -CH2-, -O- or carbonyl;
is 0 or 1 ;
armaceutically acceptable salts, or enantiomers or diastereomers thereof.
Another embodiment of present invention is (xxxiv) a compound of formula (IA)
Figure imgf000032_0001
wherein
R is halogen or Ci_6alkyl;
is hydrogen or halogen;
is hydrogen or halogen;
is Ci_6alkyl; R5 is hydrogen or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
Y is -NR7 or -N-R8-COOH;
wherein R is hydrogen, Ci_6alkyl, C3_7cycloalkyl or Ci_6alkoxycarbonyl-CmH2m-;
R is -CmH2m-, C3-7cycloalkyl-CtH2t- or phenyl;
W is -CH2- or carbonyl;
m is 1-6;
t is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxxv) a compound of formula (IA) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein R1 is chloro, bromo or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
Y is -NR7 or -N-R8-COOH;
wherein R is hydrogen, isopropyl, cyclopropyl or methyl-O-carbonylisopropyl;
R is (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl, cyclopropylmethyl or phenyl;
W is -CH2- or carbonyl.
Another embodiment of present invention is (xxxvi) a compound of formula (IAB)
Figure imgf000034_0001
wherein
R1 is halogen or Ci-6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen;
R6 is hydrogen;
R8 is -CmH2m-, C3-7cycloalkyl-CmH2m- or phenyl;
m is 1-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxxvii) a compound of formula (IAB) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein R1 is chloro or methyl;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen;
R6 is hydrogen;
R8 is (gemdimethyl)ethyl, cyclopropylmethyl or phenyl. Another embodiment of present invention is (xxxviii) a compound of formula (ID)
Figure imgf000035_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl;
Y is -0-; -NR7 or -N-R8-COOH;
wherein R is hydrogen, Ci_6alkyl or C3_7cycloalkyl;
R is -CmH2m-, C3_7cycloalkyl-CtH2t- or phenyl;
m is 1-6;
t is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xxxix) a compound of formula (ID) pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro, bromo or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy; is hydrogen, methyl-O-carbonyl or carboxymethyl;
is carbonyl or sulfonyl;
is -0-; -NR7 or -N-R8-COOH;
wherein R is hydrogen, isopropyl or cyclopropyl;
R is (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl, cyclopropylmethyl
Another embodiment of present invention is (xl) a compound of formula (IF)
Figure imgf000036_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m-;
Y is -NR7 or -N-R8-COOH;
wherein R is Ci_6alkyl or C3_7cycloalkyl;
R is -CmH2m-, C3_7cycloalkyl-CtH2t- or phenyl;
m is 1-6;
t is 0-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof. Further embodiment of present invention is (xli) a compound of formula (IF) pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxymethyl;
Y is -NR7 or -N-R8-COOH;
wherein R is isopropyl or cyclopropyl;
R is (gemdimethyl)methyl, (gemdimethyl)ethyl, (methyl)ethyl, cyclobutyl,
cyclopropylmethyl or phenyl.
Another embodiment of present invention is (xxxxii) a compound of formula (IF)
Figure imgf000037_0001
wherein
R1 is halogen or Ci_6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m- Y is -NR7 or -N-R8-COOH;
7
wherein R is hydrogen or C3_7cycloalkyl;
R is -CmH2m-, C3-7cycloalkyl-CmH2m- or phenyl;
m is 1-6;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
Further embodiment of present invention is (xliii) a compound of formula (IE) pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxymethyl;
Y is -NR7 or -N-R8-COOH;
wherein R is hydrogen or cyclopropyl;
R is (gemdimethyl)ethyl, (methyl)ethyl, cyclopropylmethyl or phenyl.
Further embodiment of present invention is (xliv) a compound of formula (I), formula (IA), formula( IAA), formula (IB), formula (IC), formula (ID), formula (IE), formula (IAB), or formula (IF) or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein chirality at 4-position of dihydropyrimidine core is the same as formula (I-R) below, and
R1, R2, R3, R4, R5, R6, X, Y, W and n are as defined in any one of the above embodiment (i) to
Figure imgf000039_0001
Particular compounds of the present invention according to the invention are the following: Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(6-oxo-l,3,4,8,9,9a-hexahydropyrazino[l,2- c] [ 1 ,3] oxazin-2-yl)methyl] -2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(4-oxo-6,7,9,9a-tetrahydro-lH-pyrazino[2,l- c] [ 1 ,4] oxazin-8-yl)methyl] -2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7-yl]methyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7-yl]methyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4-
(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4R)-6-[[(8aR)-6-oxo- 1,3,4,7,8, 8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl] -4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Ethyl (4S)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (3,4-difluorophenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate; Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[(6-oxo-3,4,7,8,9,9a-hexahydro-lH-pyrido[l,2- a]pyrazin-2-yl)methyl] -2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl]-
4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4R)-6-[[(8aS)-3-oxo- 1,2,5,6,8, 8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl] -4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4R)-6-[[(8aR)-3-oxo- 1,2,5,6,8, 8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl] -4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7-yl]methyl]-
4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7-yl]methyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(3aS)-l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin-
5- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(3aR)-l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin- 5-yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chlorophenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2- methyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2- methyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-prop anoic acid;
Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-methoxy-l,l-dimethyl-2-oxo-ethyl)-3- oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ; Methyl 7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarb
di ydropyrimidin-6-yl]methyl] -3-oxo-2,5, 6, 8-tetrahydro-lH-imidazo[l,5-a]pyrazine-8a- carboxylate;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(2-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-cyclopropyl-3-oxo- 1 ,5,6,8-tetrahydroimidazo[ 1 ,5-a]pyrazin- 8a- yl] acetic acid;
2- [(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-isopropyl-3-oxo- 1 ,5,6,8-tetrahydroimidazo[ 1 ,5-a]pyrazin-8a- yl] acetic acid;
(R)-6-[(S)-2-(l-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
3- [(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3- methyl-butanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-3- methyl-butanoic acid;
l-[[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid; l-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbony
di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3- methyl-butanoic acid;
1- [[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
3-[(2S,8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclobutanecarboxylic acid;
3-[(8aR)-7-[[(4R)-4-(2-chloro-4-f uoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclobutanecarboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-dif uoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3-f uoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid; and
7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid.
2- [l-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclopropyl] acetic acid; 2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclopropyl] acetic acid;
2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopropyl] acetic acid;
(lR,2R)-2-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl- l,4-di ydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
(lS,2R)-2-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
(lR,2S)-2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
(lS,2S)-2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]butanoic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-butanoic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3,3- dimethyl-butanoic acid;
(R)-6-[(S)-2-(2-Carboxy-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-((R)-2-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester; (R)-6-[(S)-2-((S)-2-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2- acid methyl ester;
6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-((R)-2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-((lR,3S)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-((R)-(S)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-((lR,3R)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-((lR,3R)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[2-(4-Carboxy-benzyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[2-(4-Carboxy-benzyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
2-[2-[7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]ethoxy] acetic acid;
2-[3-[7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]propoxy] acetic acid; methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[[2-(5-hydroxy-4,4-dimethyl-pentyl)-3-oxo- 5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ;
ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-hydroxyethyl)-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate; ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-hydroxyethyl)-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chlorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
2- [[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]methyl]butanoic acid;
3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-propanoic acid;
3- [(8aS)-7-[[4-(4-chlorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4-dihydropyrimidin- 6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2- methoxy-propanoic acid;
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] spiro[3.3]heptane-6-carboxylic acid; 5-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]pentanoic acid;
3-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclobutanecarboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazine- 8-carboxylic acid; (8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl- 1 ,4-di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l,5-a]pyrazine- 8-carboxylic acid;
(8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,^
carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,^
carboxylic acid;
(8R,8aS)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidaz a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl- 1 ,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5, 6,8, 8a-tetrahydro- lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
methyl (8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-2,5, 6, 8-tetrahydro-lH-imidazo[l,5-a]pyrazine-8a- carboxylate;
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-l,l-dimethyl-3-oxo-6,8-dihydro-5H-oxazolo[3,4-a]pyrazin-8a- yl] acetic acid;
2-[(8aR)-7-[[(4R)-4-(2-chloro-4-f uoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-l,l-dimethyl-3-oxo-6,8-dihydro-5H-oxazolo[3,4-a]pyrazin-8a- yl] acetic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-methyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine- 8-carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-methyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine- 8-carboxylic acid;
Methyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ; Methyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate;
3- [(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-propoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
4- [(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-butanoic acid;
5-[7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]pyridine-2-carboxylic acid;
(S)-6-[(S)-2-(2-Carboxy-2,2-difluoro-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carbo acid ethyl ester;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-(4-methylthiazol-2- yl)- 1 ,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazin-2- yl]-2,2-dimethyl -propanoic acid;
2-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -6-oxo- 1 ,3,4,7,8,8a-hexahydropyrrolo[ 1 ,2-a]pyrazine- 1- carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-isobutyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-isobutyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5- a]pyrazine-8-carboxylic acid; (8R,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
(8S,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
Ethyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-(hydroxymethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
Ethyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-(hydroxymethyl)-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
Ethyl (4R)-6-[[(8aR)-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate; and
Ethyl (4R)-6-[[(8aS)-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-dffl
a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l^ a]pyrazine-8-carboxylic acid;
Ethyl (4R)-6-[[(8aR)-2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ;
and Ethyl (4R)-6-[[(8aS)-2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
More particular compounds of the present invention are the following: 3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-3- methyl-butanoic acid;
l-[[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
l-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
l-[[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid; and
3-[(8aS)-7-[[(4S)-4-(3,4-dif uoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-propanoic acid; 4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-butanoic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-3,3- dimethyl-butanoic acid;
(R)-6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-((R)-2-chloro-3-fluoro-phenyl)-2-thiaz
acid ethyl ester;
3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-f uoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-prop anoic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl- 1 ,4-dihydropyriirddin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine- 8-carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazine-8- carboxylic acid; (8S,8aR)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-methyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]p 8-carboxylic acid;
Methyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
Methyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-butanoic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
2-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -6-oxo- 1 ,3,4,7,8,8a-hexahydropyrrolo[ 1 ,2-a]pyrazine- 1- carboxylic acid;
(8R,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
(8S,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo a]pyrazine-8-carboxylic acid; and (8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH
a]pyrazine-8-carboxylic acid;
or pharmaceutically acceptable salts, or enantiomers or diastereomers.
SYNTHESIS
The compounds of the present invention can be prepared by any conventional means.
Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R1 to R6, X, Y, W and n are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
General synthetic route for compound I (Scheme 1)
Scheme 1
Figure imgf000054_0001
Figure imgf000054_0002
Compound of interest I can be prepared according to Scheme 1. A one-pot reaction between acetyl acetate II, benzaldehyde III and thiazole amidine IV gives dihydropyrimidine V. (-)-Enantiomer Va is then obtained by SFC chiral separation of V and its stereochemistry is determined by comparing its SFC retention time with one of its particular Compound Bl which stereochemistry is determined by X-ray diffraction study (Figure 1). Bromination of Va affords VI. Coupling VI with a suitable fused amine VII gives the compound of interest I. Dihydropyrimidine V can be prepared from condensation and cyclization sequence of acetyl acetate II, aldehyde III and thiazole amidine IV. The reaction can be carried out in a suitable alcoholic solvent such as trifluoroethanol in the presence of a base such as potassium acetate under a heating condition over several hours.
(-)-Enantiomer Va is obtained by SFC chiral separation of V.
Bromide VI can be prepared by reaction of Va with a bromination reagent such as N- bromosuccinimide, in a suitable inert solvent such as carbon tetrachloride at 80-100 degrees Celsius.
Compound of interest I can be obtained by coupling bromide VI with a fused amine VII. The reaction is typically performed in a suitable solvent such as 1,2-dichloroethane at room temperature over several hours in the presence of an organic base such as N,N- dii sopropylethylamine .
General synthetic route for the diastereoisomer mixture of compound I-I (Scheme 1-1)
Scheme 1-1
Figure imgf000055_0001
Compound of interest I-I can be prepared in analogy to compound of interest I without SFC chiral separation of dihydropyrimidine V.
For scheme 1 or scheme 1-1, the 2-thiazolyl group of general formula (I), (V), (Va), (Vb), (VI), (VI-I), (I-I) and any other compounds of this invention can be further substituted by Ci_ 6alkyl, such as methyl.
This invention also relates to a process for the preparation of a compound of formula (I) or other compounds of the present invention comprising the reaction of
(a) a compound of formula (A)
with
Figure imgf000056_0001
in the presence of a base;
wherein R1 to R6, X, Y, W and n are defined above unless otherwise indicated. In step (a), the base can be for example N,N-diisopropylethylamine.
A compound of formula (I) or other compounds of the present invention when
manufactured according to the above process is also an object of the invention. PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION
The invention also relates to a compound of formula (I) or other compounds of the present invention for use as therapeutically active substance.
Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments In one example, compounds of formula (I) or other compounds of the present invention may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) or a compound of the present invention is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) and other compounds of the present invention are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular human being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to the suppression of serum HBV DNA levels, or HBeAg seroconversion to HBeAb, or HBsAg loss, or normalization of alanine aminotransferase levels and improvement in liver histology. For example, such amount may be below the amount that is toxic to normal cells, or the human as a whole.
In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.1 to 20 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, contain from about 0.1 to about 1000 mg of the compound of the invention.
The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical
composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e.,
medicament).
An example of a suitable oral dosage form is a tablet containing about 0.1 mg to 1000 mg of the compound of the invention compounded with about 30 mg to 90 mg anhydrous lactose, about 5 mg to 40 mg sodium croscarmellose, about 5 mg to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 mg to 10 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using
conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example 5 mg to 400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.
An embodiment, therefore, includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient. The following example A and B illustrate typical compositions of the present invention, but serve merely as representative thereof.
Example A
A compound of the present invention can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
Per tablet
Active ingredient 200 mg
Microcrystalline cellulose 155 mg
Corn starch 25 mg
Talc 25 mg
Hydroxypropylmethylcellulose 20 mg
425 mg Example B
A compound of the present invention can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
Per capsule
Active ingredient 100.0 mg
Corn starch 20.0 mg
Lactose 95.0 mg
Talc 4.5 mg
Magnesium stearate 0.5 mg
220.0 mg
INDICATIONS AND METHODS OF TREATMENT
The compounds of the invention can inhibit HBV's de novo DNA synthesis and reduce HBV DNA levels. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of HBV infection.
The compounds of inventions are useful as HBV capsid inhibitors.
The invention relates to the use of a compound of formula (I) or a compound of the present invention for the treatment or prophylaxis of HBV infection. The use of a compound of formula (I) or a compound of the present invention for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to HBV infection is an object of the invention.
The invention relates in particular to the use of a compound of formula (I) or a compound of the present invention for the preparation of a medicament for the treatment or prophylaxis of HBV infection.
Another embodiment includes a method for the treatment or prophylaxis of HBV infection which method comprises administering an effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof.
COMBINATION THERAPY
The compounds of the invention can be used together with interferon, pegylated interferons, Lamivudine, Adefovir dipivoxil, Entecavir, Telbivudine, and Tenofovir disoproxil for the treatment or prophylaxis of HBV.
Brief description of the Figure
Figure 1. X-ray crystal structure of Compound Bl
EXAMPLES
The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.
Abbreviations used herein are as follows:
[α]ο : optical rotation at 20 degrees Celsius
BOMC1 benzylchloromethyl ester
calc'd: calculated
CC50: concentration results in the death of 50 percent of the cells
CCK-8: cell counting kit- 8
CC14: carbon tetrachloride
Ct: cycle threshold
d: day
DIPEA: N,N-diisopropylethylamine
DCM: dichloromethylene PE: petroleum ether
DMSO: dimethylsulfoxide
DEA: diethyl amine
DNA: deoxyribonucleic acid
EtOH: ethanol
EtOAc or EA: ethyl acetate
g: gram
EC50: half maximal effective concentration
h or hr: hour
hrs: hours
HAP: heteroaryldihydropyrimidine
HATU: l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
HBeAb: hepatitis B e antibody
HBeAg: hepatitis B e antigen
HBsAg: hepatitis B surface antigen
HC1: hydrogen chloride
HPLC: high performance liquid chromatography
HPLC-UV: high performance liquid chromatography with ultraviolet detector
Hz: hertz
IPA: isopropanol
LDA: lithium diisopropylamide
METH ANOL-d4 : deuterated methanol
MeOH: methanol
mg: milligram
MHz: megahertz
min: minute
mins: minutes
mL: milliliter
mm: millimeter
mM: mmol/L
mmol: millimole
MS: mass spectrometry MW: molecular weight
Na2S04: sodium sulfate
NaOH: sodium hydroxide
NBS: N-bromo succinimide
NMR: nuclear magnetic resonance
PBS: phosphate buffered saline
PD: pharmacodynamic s
PK: pharmacokinetics
prep-HPLC: preparative high performance liquid chromatography rt: room temperature
sat. saturated
SFC: supercritical fluid chromatography
TEA: triethylamine
Tet: tetracycline
TFA: trifluoroacetic acid
THF: tetrahydrofuran
microgram
μΐ^: microliter
μΜ: micromole
UV ultraviolet detector
OD optical density
pgRNA: pre-genomic RNA
qPCR: quantitative polymerase chain reaction
qRT-PCR: quantitative real-time polymerase chain reaction CYP: cytochromes P450
[Ir(COD)2Cl]2: bis( 1 ,5-cyclooctadiene)diiridium(I) dichloride
Cs2C03: cesium carbonate
Pd(OAc)2: palladium(II) acetate
NaBH : sodium borohydride
RuCl3: ruthenium(III) chloride
General Experimental Conditions Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge module, ii) ISCO combi-flash chromatography instrument. Silica gel brand and pore size: i) KP-SIL 60 A, particle size: 40-60 μΜ; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.
Intermediates and final compounds were purified by preparative HPLC on reversed phase column using XBridge™ Prep-C18 (5 μιη, OBDTM 30 x 100 mm) column or SunFire™ Prep- CIS (5 μιη, OBDTM 30 x 100 mm) column. Waters AutoP purification System (Column:
XBridgeTM Prep-C18, 30 x 100 mm, Sample Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile and 0.1% ammonium hydroxide in water). For SFC chiral separation, intermediates were separated by chiral column (Daicel chiralpak IC, 5 μιη, 30 x 250 mm) column using Mettler Toledo SFC-Multigram III system, solvent system: 95% C02 and 5% IPA (0.5% TEA in IP A), back pressure lOObar, detection UV@ 254nm.
LC/MS spectra of compounds were obtained using a LC/MS (Waters™ Alliance 2795- Micromass ZQ), LC/MS conditions were as follows (running time 6 min):
Acidic condition: A: 0.1% formic acid in H20; B: 0.1% formic acid in acetonitrile;
Basic condition: A: 0.1% NH3 H20 in H20; B: acetonitrile;
Neutral condition: A: H20; B: acetonitrile.
Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion (MH)+.
NMR Spectra were obtained using Bruker Avance 400 MHz.
A single crystal was mounted in a loop and cooled to 160 K in a nitrogen stream. Data were collected on a Gemini R Ultra diffractometer (Oxford Diffraction, UK) with Cu-K-alpha- radiation (1.54178A) and processed with the Crysalis-package. Structure solution and refinement was performed using the ShelXTL software (Bruker AXS, Karlsruhe)
The microwave assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer.
All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.
PREPARATIVE EXAMPLES The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.
Example 1:
Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(6-oxo-l,3,4,8,9,9a- hexahydropyrazino[l,2 ][l,3]oxazin-2-yl)methyl^
carboxylate
Figure imgf000064_0001
The title compound was prepared according to the general synthetic routes shown in Scheme 1. A detailed synthetic route is provided in Scheme 2.
Figure imgf000065_0001
Scheme 2
Preparation of Compound A:
To a stirred solution of thiazole-2-carbonitrile (1.5 g, 14 mmol) in 5 mL of dry MeOH was added dropwise a solution of sodium methoxide (0.74 g, 14 mmol) in 10 mL of dry methanol. The reaction mixture was stirred at room temperature until the disappearance of starting material. After that, ammonium chloride (1.5 g, 28 mmol) was added in one portion and the reaction mixture was stirred overnight. The undissolved material was removed by filtration and the filtrate was concentrated to afford thiazole-2-carboxamidine hydrochloride (Compound A) as a grey solid which was used directly in the next step without further purification. MS: calc'd 128 (MH+), measured 128 (MH+).
Preparation of Compound B: To a stirred solution of thiazole-2-carboxamidine hydrochloride (0.13 g, 1.0 mmol), methyl acetoacetate (0.12 g, 1.0 mmol) and 2-chloro-4-fluorobenzaldehyde (0.16 g, 1.0 mmol) in trifluoroethanol (8 mL) was added potassium acetate (0.20 g, 2.0 mmol). The reaction mixture was refluxed for 16 hours. After it was cooled to room temperature, the reaction mixture was concentrated and the residue was dissolved in ethyl acetate and then washed with brine. The organic layer was dried over sodium sulfate. The solvent was concentrated, and the residue was purified by column chromatography (ethyl acetate/petroleum ether is from 1/4 to 1/2) to afford 4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound B) as a yellow solid. MS: calc'd (MH+) 366, measured (MH+) 366.
Preparation of Compound B 1 :
The enantiomer (R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl- 1 ,4-dihydro- pyrimidine-5-carboxylic acid methyl ester (Compound Bl) was obtained through SFC (SFC- Multigram; IC: 5 x 250 mm, 5μ) chiral separation of 4-(2-chloro-4-fluoro-phenyl)-6-methyl-2- oxazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound B) eluting with a mixed solvent of 85% supercritical C02 / 15% EtOH at 100 mL/min rate. The desired (-)- enantiomer Bl was eluted out before (+) -enantiomer B2. The absolute configuration of (-)- enantiomer Bl was determined by X-ray diffraction study (Figure 1).
Compound Bl: [a]D 20 -55.0 (c 0.845, MeOH).
Compound B2: [a]D 20 +44.6 (c 0.175, MeOH).
Preparation of Compound C:
To a stirred solution of (R)-4-(2-chloro-4-fluoro-phenyl)-6-methyl-2-thiazol-2-yl-l,4- dihydro-pyrimidine-5-carboxylic acid methyl ester (0.37 g, 1.0 mmol) in CC14 (5 mL) was added NBS (0.20 g, 1.1 mmol) in portions. After the reaction mixture was stirred at room temperature for 1 hour, the solvent was removed in vacuo and the residue was purified by column
chromatography to give (R)-6-bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) as a yellow solid. MS: calc'd 445 (MH+), measured 445 (MH+).
Preparation of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D):
Figure imgf000067_0001
E D
Step 1: Methyl 4-boc-piperazine-2-acetate (CAS number: 183742-33-8, Chemfinder) (1.0 g, 4 mmol) was dissolved in 10 mL of MeOH, then NaBH4 (1.5 g, 40 mmol) was added portion wise and stirred overnight. The solvent was removed in vacuo and the residue was partitioned between EtOAC and water. The organic layer was separated, and then dried over Na2S04 and concentrated to give 3-(2-hydroxy-ethyl)-piperazine-l-carboxylic acid ie/t-butyl ester as crude oil (compound E), which was used directly without further purification.
Step 2: 3-(2-Hydroxy-ethyl)-piperazine-l-carboxylic acid ie/t-butyl ester (58 mg, 0.25 mmol) was dissolved in 4 mL of dichloromethane and lmL of DIPEA, and then triphosgene (27 mg, 0.09 mmol) was added at room temperature. The reaction mixture was stirred for 30 minutes, and the solvent was removed in vacuo. The residue was dissolved in 3 mL of dichloromethane and 1 mL of TFA. After the reaction mixture was stirred for 1 hour, the solvent was removed in vacuo to give hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one trifluoro acetitic acid salt (Compound D) as a crude product which was used directly without further purification. LC/MS: calc'd 157 (MH+), exp 157 (MH+).
Preparation of Example 1:
To a stirred solution of (R)-6-bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (0.072 g, 0.16 mmol) and hexahydro- pyrazino[l,2-c][l,3]oxazin-6-one trifluoro acetitic acid salt (Compound D, crude, 0.25 mmol) in 1,2-dichloroethane (5 mL) was added drop wise DIPEA (0.078 mL, 0.45 mmol). The reaction mixture was stirred at room temperature until the disappearance of starting material. The mixture was diluted with EtOAc (50 mL) and washed successively with saturated aqueous NH4C1 solution and brine. The organic layer was separated and then dried over Na2S04. The solvent was concentrated in vacuo and the crude product was purified by prep-HPLC to give methyl (4R)-4-
(2-chloro-4-fluoro-phenyl)-6- [(6-oxo- 1 ,3,4,8, 9,9a-hexahydropyrazino[ 1 ,2-c] [1,3] oxazin-2- yl)methyl]-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (Example 1) as a light yellow solid (11 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (dd, / = 3.01, 1.00 Hz, 1H), 7.81 (d, / = 3.01 Hz, 1H), 7.46 (dd, / = 8.66, 6.15 Hz, 1H), 7.26 (dd, / = 8.78, 2.51 Hz, 1H), 7.00 - 7.13 (m, 1H), 6.19 (d, / = 1.76 Hz, 1H), 4.19 - 4.48 (m, 4H), 4.11 (d, / = 16.06 Hz, 1H), 3.76 - 3.94 (m, 1H), 3.62 (s, 3H), 3.18 - 3.31 (m, 2H), 2.37 - 2.80 (m, 3H), 2.11 - 2.30 (m, 1H), 1.90 (qdd, / = 14.37, 14.37, 14.37, 9.22, 5.40 Hz, 1 H). MS: calc'd 520 (MH+), measured 520 (MH+).
Example 2:
Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(4-oxo-6,7,9,9a-tetrahydro-lH- pyrazino[2,l ][l,4]oxazin-8-yl)methyl]-2 hiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000068_0001
The title compound was prepared in analogy to Example 1 by using 1,6,7,8,9,9a- hexahydropyrazino[2,l-c][l,4]oxazin-4-one (WuXi AppTec (Wuhan) Co., Ltd, catalog number: WX111240; for its synthesis, please refer to: Tang, Pengcho et al, PCT Int. Appl., 2012019426) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 2 was obtained as a light yellow solid (9 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.14 Hz, 1H), 7.76 (d, / = 3.14 Hz, 1H), 7.43 (dd, / = 8.72, 6.09 Hz, 1H), 7.24 (dd, / = 8.72, 2.57 Hz, 1H), 6.96 - 7.12 (m, 1H), 6.18 (d, / = 2.26 Hz, 1H), 4.46 - 4.66 (m, 1H), 4.05 - 4.22 (m, 3H), 3.77 - 4.05 (m, 3H), 3.53 - 3.73 (m, 4H), 2.94 - 3.13 (m, 2H), 2.81 - 2.94 (m, 1H), 2.15 - 2.52 (m, 2 H). MS: calc'd 520 (MH+), measured 520 (MH+).
Example 3:
Methyl (4R)-6-[[(8aR)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000069_0001
The title compound was prepared in analogy to Example 1 by using (S)-4-N-Boc-2- hydroxymethyl-piperazine (CAS number: 314741-40-7, Bepharm) instead of 3-(2-hydroxy- ethyl)-piperazine-l-carboxylic acid ie/t-butyl ester(Compound E). Example 3 was obtained as a light yellow solid (21 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.93 - 8.00 (m, 1H), 7.73 - 7.84 (m, 1H), 7.40 - 7.50 (m, 1H), 7.25 (dd, / = 8.66, 2.64 Hz, 1H), 7.00 - 7.12 (m, 1H), 6.15 - 6.22 (m, 1H), 4.42 - 4.57 (m, 1H), 4.25 (d, / = 16.81 Hz, 1H), 4.13 - 4.22 (m, 1H), 3.99 - 4.13 (m, 2H), 3.78 - 3.90 (m, 1H), 3.56 - 3.67 (m, 3H), 3.29 - 3.39 (m, 1H), 3.25 (d, / = 9.03 Hz, 1H), 2.96 (d, / = 11.04 Hz, 1H), 2.30 - 2.61 (m, 2 H). MS: calc'd 506 (MH+), measured 506 (MH+).
Example 4:
Methyl (4R)-6-[[(8aS)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000069_0002
The title compound was prepared in analogy to Example 1 by using (R)-4-N-boc-2- hydroxymethyl-piperazine (CAS number: 278788-66-2, Bepharm) instead of 3-(2-hydroxy- ethyl)-piperazine-l-carboxylic acid tert-butyl ester (Compound E). Example 4 was obtained as a light yellow solid (20 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.92 - 8.00 (m, 1H), 7.78 (d, / = 3.26 Hz, 1H), 7.44 (dd, / = 8.78, 6.02 Hz, 1H), 7.25 (dd, / = 8.66, 2.64 Hz, 1H), 7.01 - 7.12 (m, 1H), 6.14 - 6.21 (m, 1H), 4.46 (t, / = 8.53 Hz, 1H), 4.18 - 4.26 (m, 1H), 4.08 - 4.18 (m, 1H), 3.97 - 4.08 (m, 2H), 3.82 - 3.93 (m, 1H), 3.53 - 3.67 (m, 3H), 3.34 - 3.40 (m, 1H), 3.08 (d, / = 10.54 Hz, 2H), 2.46 - 2.60 (m, 1H), 2.28 - 2.44 (m, 1 H). MS: calc'd 506 (MH+), measured 506 (MH+).
Example 5:
Methyl (4R)-6-[[(8aS)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2- yl]methyl]-4-(2-chloro-4-fluoro-phen l)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000070_0001
The title compound was prepared by SFC chiral separation of methyl (4R)-4-(2-chloro-4- fluoro-phenyl)-6-[(6-oxo- 1,3,4,7, 8, 8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl)methyl]-2-thiazol-2- yl-l,4-dihydropyrimidine-5-carboxylate (Compound F). Example 5 was obtained as a light yellow solid (14 mg). 1H NMR (400 MHz, METHANOL-d ) d ppm 7.90 - 7.99 (m, 1H), 7.72 - 7.82 (m, 1H), 7.36 - 7.52 (m, 1H), 7.20 - 7.31 (m, 1H), 7.06 (td, / = 8.41, 2.76 Hz, 1H), 6.18 (s, 1H), 4.18 (d, / = 17.07 Hz, 1H), 3.97 - 4.04 (m, 2H), 3.86 - 3.97 (m, 1H), 3.61 (s, 3H), 3.21 (d, / = 9.29 Hz, 1H), 3.03 - 3.16 (m, 1H), 2.83 - 2.95 (m, 1H), 2.36 - 2.56 (m, 2H), 2.19 - 2.35 (m, 3H), 1.66 - 1.82 (m, 1 H). MS: calc'd 504 (MH+), measured 504 (MH+).
Figure imgf000071_0001
Example 5 Example 6
Preparation of methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(6-oxo-l,3,4,7,8,8a- hexahydropyrrolo[l,2-a]pyrazin-2-yl)methyl]-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (Compound F):
Compound F was prepared in analogy to Example 1 by using hexahydropyrrolo[l,2- a]pyrazin-6(2H)-one (CAS number: 117810-52-3, Bepharm; for its synthesis, please refer to: Alvaro G., Large C. PCT Int. Appl., 2008090115) instead of hexahydro-pyrazino[l,2- c][l,3]oxazin-6-one (Compound D). Example 6:
Methyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000071_0002
The title compound was prepared by SFC chiral separation of methyl (4R)-4-(2-chloro-4- fluoro-phenyl)-6-[(6-oxo- 1,3,4,7, 8, 8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl)methyl]-2-thiazol-2- yl-l,4-dihydropyrimidine-5-carboxylate (Compound F) in Example 5. Example 6 was obtained as a light yellow solid (14 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.87 - 8.01 (m, 1H), 7.71 - 7.81 (m, 1H), 7.36 - 7.49 (m, 1H), 7.19 - 7.29 (m, 1H), 7.06 (td, / = 8.41, 2.51 Hz, 1H), 6.18 (s, 1H), 4.11 - 4.21 (m, 1H), 4.06 (dd, / = 12.55, 3.01 Hz, 1H), 3.95 - 4.02 (m, 1H), 3.89 (dtd, / = 10.73, 7.25, 7.25, 3.64 Hz, 1H), 3.53 - 3.65 (m, 3H), 3.01 - 3.19 (m, 3H), 2.33 - 2.54 (m, 3H), 2.22 (dddd, / = 13.08, 9.38, 7.65, 4.02 Hz, 1H), 2.12 (t, / = 10.92 Hz, 1H), 1.61 - 1.76 (m, 1 H). MS: calc'd 504 (MH+), measured 504 (MH+).
Example 7:
Methyl (4R)-6-[[(8aR)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000072_0001
The title compound was prepared in analogy to Example 1 by using 2-bromo-4- fluorobenzaldehyde and (8aR)-2,3,4,7,8,8a-hexahydro-lH-pyrrolo[l,2-a]pyrazin-6-one (for its synthesis, refer to: Tang P., et al, PCT Int. AppL, 2012019426) instead of 2-chloro-4- fluorobenzaldehyde and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 7 was obtained as a light yellow solid (19 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95 (d, / = 3.26 Hz, 1H), 7.76 (d, / = 3.01 Hz, 1H), 7.35 - 7.48 (m, 2H), 7.11 (td, / = 8.41, 2.76 Hz, 1H), 6.17 (s, 1H), 4.09 - 4.19 (m, 1H), 4.05 (dd, / = 12.80, 2.76 Hz, 1H), 3.93 - 4.01 (m, 1H), 3.89 (dtd, / = 10.63, 7.23, 7.23, 3.76 Hz, 1H), 3.61 (s, 3H), 2.95 - 3.18 (m, 3H), 2.31 - 2.54 (m, 3H), 2.15 - 2.28 (m, 1H), 2.08 (t, / = 10.92 Hz, 1H), 1.61 - 1.75 (m, 1 H). MS: calc'd 548 (MH+), measured 548 (MH+).
Example 8:
Ethyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]- 4-(2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000073_0001
The title compound was prepared in analogy to Example 1 by using 2-bromo-4- fluorobenzaldehyde, ethyl acetoacetate and (8aR)-2,3,4,7,8,8a-hexahydro-lH-pyrrolo[l,2- a]pyrazin-6-one (for its synthesis, refer to: Tang P., et al, PCT Int. AppL, 2012019426) instead of 2-chloro-4-fluorobenzaldehyde, methyl acetoacetate and hexahydro-pyrazino[l,2-c][l,3]oxazin- 6-one (Compound D). Example 8 was obtained as a light yellow solid (8 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95 (d, / = 3.01 Hz, 1H), 7.76 (d, / = 3.26 Hz, 1H), 7.36 - 7.53 (m, 2H), 7.12 (td, / = 8.34, 2.64 Hz, 1H), 6.18 (s, 1H), 4.11 - 4.17 (m, 1H), 4.05 (q, / = 6.86 Hz, 2H), 3.97 (d, / = 16.81 Hz, 1H), 3.83 - 3.93 (m, 1H), 2.94 - 3.19 (m, 3H), 2.30 - 2.53 (m, 3H), 2.22 (ddd, / = 16.75, 12.86, 3.51 Hz, 1H), 2.07 (t, / = 10.67 Hz, 1H), 1.61 - 1.75 (m, 1H), 1.15 (t, J = 7.15 Hz, 3 H). MS: calc'd 562 (MH+), measured 562 (MH+).
Example 9:
Ethyl (4S)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]- 4-(3,4-difluorophenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000073_0002
The title compound was prepared in analogy to Example 1 by using 3,4- difluorobenzaldehyde, ethyl acetoacetate and (8aR)-2,3,4,7,8,8a-hexahydro-lH-pyrrolo[l,2- a]pyrazin-6-one (for its synthesis, refer to: Tang P., et al, PCT Int. AppL, 2012019426) instead of 2-chloro-4-fluorobenzaldehyde, methyl acetoacetate and hexahydro-pyrazino[l,2-c][l,3]oxazin- 6-one (Compound D). Example 9 was obtained as a light yellow solid (11 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.94 - 8.05 (m, 1H), 7.81 (d, / = 3.01 Hz, 1H), 7.14 - 7.33 (m, 3H), 5.74 (s, 1H), 4.07 - 4.23 (m, 3H), 4.03 (dd, / = 13.05, 2.51 Hz, 1H), 3.83 - 3.94 (m, 2H), 3.09 (t, / = 12.55 Hz, 1H), 2.98 (d, / = 10.54 Hz, 2H), 2.28 - 2.52 (m, 3H), 2.20 (ddt, / = 17.00, 9.29, 3.80, 3.80 Hz, 1H), 2.05 (t, / = 10.92 Hz, 1H), 1.59 - 1.73 (m, 1H), 1.24 (t, J = 7.15 Hz, 3 H). MS: calc'd 502 (MH+), measured 502 (MH+). Example 10:
Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[(6-oxo-3,4,7,8,9,9a-hexahydro-lH- pyrido[l,2-a]pyrazin-2-yl)methyl]-2 hiazol-2- l-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000074_0001
The title compound was prepared in analogy to Example 1 by using 2-chloro,3- fluorobenzaldehyde, ethyl acetoacetate and 1,2,3,4,7, 8,9, 9a-octahydropyrido[l,2-a]pyrazin-6-one hydrochloride salt (J & W Pharm Lab, CAS number: 151665-85-9; for its synthesis, please refer to: Ghelardini C. et al. PCT Int. AppL, 2009103176) instead of 2-chloro-4-fluorobenzaldehyde, methyl acetoacetate and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 10 was obtained as a light yellow solid (6 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.02 (d, / = 3.26 Hz, 1 H), 7.96 (d, / = 3.26 Hz, 1H), 7.23 - 7.38 (m, 2H), 7.10 - 7.21 (m, 1H), 6.23 (s, 1 H), 4.56 - 4.78 (m, 2H), 3.82 - 4.21 (m, 5H), 3.05 - 3.28 (m, 4H), 2.40(m, 2H), 1.5- 2.21(m, 4 H), 1.21(m, 3 H). MS: calc'd 532 (MH+), measured 532 (MH+).
Example 11: Methyl (4R)-6-[[(8aR)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000075_0001
The title compound was prepared in analogy to Example 1 by using (8aS)-2,5,6,7,8,8a- hexahydro-lH-imidazo[l,5-a]pyrazin-3-one (Compound H) instead of hexahydro-pyrazino[l,2- c][l,3]oxazin-6-one (Compound D). Example 11 was obtained as a light yellow solid (11 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.93 - 8.01 (m, 1H), 7.72 - 7.81 (m, 1H), 7.38 - 7.49 (m, 1H), 7.24 (dd, / = 8.66, 2.64 Hz, 1H), 7.06 (td, / = 8.47, 2.64 Hz, 1H), 6.18 (s, 1H), 4.04 - 4.17 (m, 1H), 3.95 - 4.02 (m, 1H), 3.89 - 3.95 (m, 1H), 3.84 (dd, / = 13.43, 2.38 Hz, 1H), 3.61 (s, 3H), 3.53 (t, / = 8.91 Hz, 1H), 3.11 - 3.21 (m, 1H), 3.06 (dd, / = 9.41, 4.64 Hz, 1H), 2.92 (dd, 7 = 9.79, 1.51 Hz, 1H), 2.84 (dd, J = 11.17, 2.64 Hz, 1H), 2.38 (td, / = 11.67, 3.51 Hz, 1H), 2.19 - 2.29 (m, 1 H . MS: calc'd 505 (MH+), measured 505 (MH+).
Figure imgf000075_0002
Preparation of (8aS)-2,5,6,7,8,8a-hexahydro-lH-imidazo[l,5-a]pyrazin-3-one
(Compound H):
Figure imgf000076_0001
Step 1: To a stirred solution of Na2C03 (118 g, 1.11 mol) in water (600 mL) was added (25,)-piperazine-2-carboxylic acid dihydrochloride salts (30 g, 0.15 mol) at 25 °C, followed by di-iert-butyl dicarbonate (112 g, 0.56 mol) and tetrahydrofuran (300 mL). Then the mixture was stirred for additional 20 hours at room temperature. The reaction mixture was concentrated in vacuo and the resulting solution was extracted with methyl iert-butyl ether (200 mL) three times to remove nonpolar species. The aqueous layer was cooled to below 0 °C and then treated with 3.0 M HC1 until to pH 2 to3. Then it was extracted with ethyl acetate (500 mL) three times. The combined organic layer was dried over Na2S04, and then filtered and concentrated under vacuum to give Compound I (39 g).
Step 2: To a solution of Compound I (39 g, 0.12 mol) in tetrahydrofuran (200 mL) was added dropwise BH3.THF complex (240 mL, 0.24 mol) at 0 °C under N2 atmosphere. Then the mixture was warmed to room temperature and heated to reflux for 2-3 hours. The mixture was quenched with MeOH (100 mL) at 0 °C and the obtained solution was concentrated in vacuo. The residue was re-dissolved into MeOH (200 mL) and the solution was refluxed for 3 to 4 hours. Then the solvent was removed to give the crude product (45 g). The crude product was purified by column chromatography on silica (petroleum ether/EtOAc = 10: 1 to 1: 1) to give Compound J (31 g).
Step 3: To a solution of Compound J (15 g, 47.41 mmol), Ph3P (16.17 g, 61.63 mmol) and phthalimide (9.07 g, 61.63 mmol) in anhydrous tetrahydrofuran (230 mL) was added a solution of diisopropyl azodicarboxylate (12.46 g, 61.63 mmol) in tetrahydrofuran (20 mL) at 10 °C under N2 atmosphere. Then the mixture was stirred for additional 2 hours at 10 °C. The mixture was quenched with IN HC1 (100 mL) and then extracted with EtOAc (300 mL). The organic layer was dried over Na2S04, filtered, and then concentrated in vacuo to give the crude product (50 g). The crude product was triturated with petroleum ether/EtOAc (200 mL, V/V=5: l) to get crude product (25 g) with removal of triphenylphosphine oxide and other impurities. The crude product was purified by column chromatography on silica (petroleum ether/EtOAc=20: l) to get the pure product K (12 g) as a white solid and some impure compound K (4 g).
Step 4: To a stirred solution of Compound K (12 g, 26.9 mmol) in ethanol (85 mL) was added methylamine alcohol solution (85 mL) at room temperature. Then the mixture was heated to reflux for additional 3 hours. The mixture was cooled to room temperature and then concentrated. The resulting residue was dissolved in water (50 mL), then acidified to pH 3 with IN HC1 solution, and then extracted with methyl-iert-butyl ether (50 mL) three times. The pH was adjusted to 10 with solid NaOH and the mixture was extracted with ethyl acetate (150 mL) three times. The organic layer was dried and filtered and the solvent was removed under reduced pressure to give Compound L (6 g crude).
Step 5: To a stirred suspension of sodium hydride (1.0 g, 25 mmol) in tetrahydrofuran (50 mL) was added Compound L (6 g, 19 mmol, crude) at 0 °C. Then the mixture was heated to reflux for 2 hours. And then additional NaH (1.0 g, 25 mmol) was added into the mixture at room temperature. After the reaction mixture was refluxed for 1 hour, the reaction was quenched with ice- water (100 mL) and then extracted with EtOAc (300 mL). The organic layer was evaporated in vacuo to give the crude product (5 g). The crude product was purified by column chromatography on silica gel (EtOAc/MeOH = 200:1) to give Compound M (2.2 g, 40%).
Step 6: To a stirred solution of Compound M (2.2 g, 9.1 mmol) in 30 mL of
dichloromethane was added dropwise 10 mL of TFA. After the reaction mixture was stirred for 1 hour, the solvent was removed in vacuo to give (8aS)-2,5, 6,7,8, 8a-hexahydro-lH-imidazo[ 1,5- a]pyrazin-3-one trifluoro acetitic acid salt (Compound H) as a crude product which was used directly without further purification.
Example 12:
Methyl (4R)-6-[[(8aS)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000078_0001
The title compound was prepared in analogy to Example 11 by using (2R)-piperazine-2- carboxylic acid instead of (25,)-piperazine-2-carboxylic acid. Example 12 was obtained as a lig yellow solid (13 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.91 - 8.01 (m, 1H), 7.71 - 7.81 (m, 1H), 7.42 (dd, / = 8.66, 6.15 Hz, 1H), 7.24 (dd, / = 8.66, 2.64 Hz, 1H), 7.05 (td, / = 8.41, 2.51 Hz, 1H), 6.18 (s, 1H), 4.12 (d, / = 17.32 Hz, 1H), 3.95 - 4.05 (m, 1H), 3.91 (d, / = 17.32 Hz, 1H), 3.77 (dd, / = 13.18, 1.88 Hz, 1H), 3.61 (s, 3H), 3.56 - 3.60 (m, 1H), 3.08 - 3.21 (m, 2H), 3.01 (dd, / = 10.79, 2.76 Hz, 1H), 2.74 (d, / = 11.29 Hz, 1H), 2.39 (t, / = 10.92 Hz, 1H), 2.24 (td, / = 11.67, 3.26 Hz, 1 H). MS: calc'd 505 (MH+), measured 505 (MH+).
Example 13:
Ethyl (4R)-6-[[(8aS)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl]- 4-(2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000078_0002
The title compound was prepared in analogy to Example 11 by using 2-bromo-4- fluorobenzaldehyde and ethyl acetoacetate instead of 2-chloro-4-fluorobenzaldehyde and methyl acetoacetate. Example 13 was obtained as a light yellow solid (34 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.91 - 8.02 (m, 1H), 7.78 (d, / = 3.01 Hz, 1H), 7.34 - 7.53 (m, 2H), 7.12 (td, / = 8.41, 2.76 Hz, 1H), 6.18 (s, 1H), 4.15 - 4.31 (m, 1H), 3.93 - 4.13 (m, 4H), 3.76 - 3.89 (m, 1H), 3.61 (t, / = 8.91 Hz, 1H), 3.07 - 3.25 (m, 3H), 2.83 - 3.03 (m, 1H), 2.55 (br. s., 1H), 2.40 (br. s., 1H), 1.14 (t, / = 7.15 Hz, 3 H). MS: calc'd 563 (MH+), measured 563 (MH+).
Example 14:
Ethyl (4R)-6-[[(8aR)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate
Figure imgf000079_0001
The title compound was prepared in analogy to Example 12 by using 2-bromo-4- fluorobenzaldehyde and ethyl acetoacetate instead of 2-chloro-4-fluorobenzaldehyde and methyl acetoacetate. Example 14 was obtained as a light yellow solid (34 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.92 - 8.01 (m, 1H), 7.78 (d, / = 3.26 Hz, 1H), 7.35 - 7.56 (m, 2H), 7.12 (td, / = 8.41, 2.76 Hz, 1H), 6.18 (s, 1H), 4.17 - 4.32 (m, 1H), 3.96 - 4.16 (m, 4H), 3.89 (dd, / = 13.55, 2.51 Hz, 1H), 3.49 - 3.64 (m, 1H), 3.17 - 3.28 (m, 1H), 2.97 - 3.17 (m, 3H), 2.31 - 2.68 (m, 2H), 1.14 (t, / = 7.15 Hz, 3 H). MS: calc'd 563 (MH+), measured 563 (MH+).
Example 15:
Methyl (4R)-6-[[(8aR)-l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000080_0001
The title compound was prepared by SFC chiral separation of methyl (4R)-4-(2-chloro-4- fluoro-phenyl)-6-[(l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7-yl)methyl]-2-thiazol-2- yl-l,4-dihydropyrimidine-5-carboxylate (Compound N). Example 15 was obtained as a yellow solid (11 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.89 - 7.97 (m, 1H), 7.71 - 7.81 (m, 1H), 7.38 - 7.53 (m, 1H), 7.24 (dd, / = 8.78, 2.76 Hz, 1H), 7.07 (td, / = 8.41, 2.76 Hz, 1H), 6.19 (s, 1H), 4.28 - 4.40 (m, 1H), 4.15 - 4.26 (m, 1H), 3.92 - 4.07 (m, 2H), 3.61 (s, 3H), 3.36 (d, / = 4.77 Hz, 1H), 3.20 - 3.29 (m, 1H), 2.78 - 2.86 (m, 1H), 2.42 (t, / = 11.17 Hz, 1H), 2.29 (td, / = 11.86, 3.64 Hz, 1 H). MS: calc'd 519 (MH+), measured 519 (MH+).
Figure imgf000080_0002
Preparation of methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(l,3-dioxo-5,6,8,8a- tetrahydroimidazo[l,5-a]pyrazin-7-yl)methyl]-2 hiazol-2-yl-l,4-dihydropyrimidine carboxylate (Compound N):
The title compound was prepared in analogy to Example 1 by using 6,7,8,8a-tetrahydro-
5H-imidazo[l,5-a]pyrazine-l,3-dione (For its synthesis, please refer to: WO2010/23480) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 16:
Methyl (4R)-6-[[(8aS)-l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate
Figure imgf000081_0001
The title compound was prepared by SFC chiral separation of methyl (4R)-4-(2-chloro-4- fluoro-phenyl)-6-[(l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7-yl)methyl]-2-thiazol-2- yl-l,4-dihydropyrimidine-5-carboxylate (Compound N) in Example 15. Example 16 was obtained as a yellow solid (10 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.90 - 7.97 (m,
1H), 7.76 (d, / = 3.26 Hz, 1H), 7.37 - 7.49 (m, 1H), 7.24 (dd, / = 8.78, 2.76 Hz, 1H), 7.06 (td, / = 8.41, 2.76 Hz, 1H), 6.19 (s, 1H), 4.24 - 4.36 (m, 1H), 4.13 - 4.22 (m, 1H), 4.09 (dd, / = 13.43, 2.89 Hz, 1H), 3.98 - 4.06 (m, 1H), 3.61 (s, 3H), 3.27 (td, / = 12.67, 3.76 Hz, 1H), 3.18 (dd, / = 11.04, 4.27 Hz, 1H), 2.97 - 3.04 (m, 1H), 2.44 (td, / = 11.80, 3.76 Hz, 1H), 2.29 (t, / = 11.17 Hz, 1 H). MS: calc'd 519 (MH+), measured 519 (MH+).
Example 17:
Methyl (4R)-6-[[(3aS)-l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3- a]pyrazin-5-yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine- 5-carboxylate
Figure imgf000082_0001
The title compound was prepared by SFC chiral separation of methyl (4R)-4-(2-chloro-4- fluoro-phenyl)-6-[(l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin-5- yl)methyl]-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (Compound O). Example 17 was obtained as a yellow solid (14 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.93 - 8.00 (m, 1H), 7.77 (d, / = 3.01 Hz, 1H), 7.44 (dd, / = 8.78, 6.02 Hz, 1H), 7.25 (dd, / = 8.66, 2.64 Hz, 1H), 7.06 (td, / = 8.41, 2.76 Hz, 1H), 6.18 (s, 1H), 4.12 - 4.26 (m, 1H), 3.97 - 4.10 (m, 1H), 3.58 - 3.70 (m, 4H), 3.42 - 3.55 (m, 2H), 3.03 - 3.20 (m, 4H), 2.63 - 2.76 (m, 1H), 2.42 (t, / = 10.54 Hz, 1 H). MS: calc'd 541 (MH+), measured 541 (MH+).
Figure imgf000082_0002
Preparation of methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(l,l-dioxo-2,3,3a,4,6,7- hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin-5-yl)methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate (Compound O):
The title compound was prepared in analogy to Example 1 by using hexahydro-l-thia- 2,5,7a-triaza-indene 1,1 -dioxide (Compound P) instead of hexahydro-pyrazino[l,2- c][l,3]oxazin-6-one (Compound D). Preparation of hexahydro-l-thia-2,5,7a-triaza-indene 1,1-dioxide (Compound P):
Figure imgf000083_0001
P
To a stirred solution of 3-aminomethyl-piperazine-l-carboxylic acid tert-b tyl ester (CAS number: 1376099-80-7, Bepharm) (215 mg, 1.0 mmol) in 2 mL of pyridine was added sulfamide (1.5 mmol). The reaction mixture was heated to 150°C for 6 hours under microwave. The solvent was removed in vacuo, and the residue was dissolved in 3 mL of dichloromethane and 1 mL of TFA. The reaction mixture was stirred for 1 hour, and the solvent was removed in vacuo to give the crude Compound P which was used directly without further purification. LC/MS: calc'd 178 (MH+), measured 178(MH+).
Example 18:
Methyl (4R)-6-[[(3aR)-l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3- a]pyrazin-5-yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine- 5-carboxylate
Figure imgf000083_0002
The title compound was prepared by SFC chiral separation of methyl (4R)-4-(2-chloro-4- fluoro-phenyl)-6-[(l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin-5- yl)methyl]-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (Compound O) in Example 17. Example 18 was obtained as a yellow solid (28 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.26 Hz, 1H), 7.79 (d, / = 3.26 Hz, 1H), 7.45 (dd, / = 8.78, 6.02 Hz, 1H), 7.25 (dd, / = 8.78, 2.51 Hz, 1H), 7.07 (td, / = 8.41, 2.76 Hz, 1H), 6.19 (s, 1H), 4.32 (d, / = 16.81 Hz, 1H), 4.09 (d, / = 16.81 Hz, 1H), 3.67 - 3.81 (m, 1H), 3.58 - 3.66 (m, 3H), 3.46 - 3.58 (m, 2H), 3.29 - 3.31 (m, 1H), 3.23 (dd, / = 9.79, 8.78 Hz, 1H), 3.02 - 3.19 (m, 2H), 2.69 (q, / = 10.79 Hz, 2 H). MS: calc'd 541 (MH+), measured 541 (MH+).
Example 19:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6^
2,2-dimethyl-propanoic acid
Figure imgf000084_0001
The title compound was prepared in analogy to Example 1 by using 2-chloro,3- fluorobenzaldehyde, ethyl acetoacetate and 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2-yl] -2,2-dimethyl-propanoic acid (Compound Q) instead of 2-chloro-4- fluorobenzaldehyde, methyl acetoacetate and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 19 was obtained as a light yellow solid (12 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.92 - 8.02 (m, 1H), 7.70 - 7.80 (m, 1H), 7.21 - 7.36 (m, 2H), 7.10 - 7.21 (m, 1H), 6.19 - 6.28 (m, 1H), 3.99 - 4.14 (m, 3H), 3.81 - 3.96 (m, 3H), 3.47 - 3.56 (m, 1H), 3.38 - 3.44 (m, 1H), 3.27 - 3.32 (m, 1H), 3.15 - 3.25 (m, 1H), 3.07 - 3.14 (m, 1H), 2.79 - 2.96 (m, 2H), 2.30 - 2.41 (m, 1H), 2.13 - 2.23 (m, 1H), 1.20 (d, / = 2.76 Hz, 6H), 1.13 (m, 3H). MS: calc'd 619 (MH+), measured 619 (MH+).
Preparation of 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-propanoic acid (compound Q):
Figure imgf000085_0001
Figure imgf000085_0002
Step 1: To a stirred solution of (R)-4-N-boc-2-hydroxymethyl-piperazine (CAS number: 314741-40-7, Bepharm; for its synthesis, please refer to: Gao H., Renslo A. R. J. Org. Chem. 2007, 72, 8591-8592) (6 g, 27.8 mmol) in saturated NaHC03 (45 mL) and EtOAc (45 mL) was added benzyl chloroformate (7.13 g, 41.7 mmol) dropwise at 0 °C. Then the reaction mixture was stirred at room temperature for 15 hours. The reaction was diluted with EtOAc (60 mL), and the organic layer was separated and aqueous layer was extracted with EtOAc (35 mL). The combined organic layer was dried over Na2S04 and the solution was concentrated to give a crude product. The crude product was purified by column chromatography on silica (Petroleum ether: EtOAc = 10: 1 to 1: 1) to give Compound R (6.7 g).
Step 2: To a stirred solution of oxalyl chloride (3.64 g, 28.65 mmol) in anhydrous dichloromethane (80 mL) at -78 °C was added dimethyl sulfoxide (4.47 g, 57.3 mmol) dropwise. After 10 minutes, a solution of Compound R (6.7 g, 19.1 mmol) in dichloromethane (20 mL) was added dropwise. After the mixture was stirred for 30 minutes at -78 °C, N,N- diisopropylethylamine (14.78 g, 114.6 mmol) was added and the reaction mixture was stirred for 30 minutes. After the reaction mixture was slowly warmed to 0 °C over 30 minutes, it was diluted with dichloromethane (80 mL), washed with 5% aqueous citric acid (10 mL), brine and then dried over Na2S04. After filtration, the mixture was concentrated in vacuo to get the crude product S (7 g).
Step 3: To a stirred solution of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt
(3.4 g, 18.6 mmol) in anhydrous DCM (100 mL) was added DIPEA (2.6 g, 27.3 mmol) at room temperature. Then Compound S (7 g, 20 mmol) was added, followed by NaBH(OAc)3 (6.3 g, 29.8 mmol) and AcOH (1.5 mL). The reaction mixture was stirred for 16 hours at room temperature. Water (100 mL) was added and the mixture was extracted with DCM (100 mL). The organic layer was dried and concentrated in vacuo to dryness to give crude Compound T (7.3 g).
Step 4: To the solution of Compound T (3.3 g, 6.9 mmol) in EtOH (100 mL) was added
Pd/C (1 g). Then the mixture was stirred at 50 °C for 3 hours under hydrogen atmosphere (50 Psi). The reaction mixture was filtered and the filtrate was concentrated in vacuo to get the Compound U (1.8 g).
Step 5: To the solution of Compound U (1.8 g, 5.24 mmol) in anhydrous dichloromethane (60 mL) was added N,N-diisopropylethylamine (3.4 g, 26.2 mmol) at 0°C. Then triphosgene (783 mg, 2.62 mmol) was added at 0 °C and the mixture was stirred at 10-15 °C for 16 hours. Water (50 mL) was added and the mixture was extracted with dichloromethane (60 mL), and then dried over Na2S04. The solvent was removed in vacuo to give the crude product. The crude product was purified by column chromatography on silica (petroleum ether: EtOAc=5: l to 1 : 1) to obtain Compound V (1.3 g).
Step 6: To a stirred solution of Compound V (240 mg, 0.64 mmol) in THF (3 ml) was added a solution of LiOH H20 (215 mg, 5.10 mmol) in H20 (1 mL) at room temperature. After the reaction mixture was stirred at room temperature overnight, it was acidified to PH 3 to 4 with 1 N HC1 at 0 °C. The mixture was then concentrated and azeotropically dried with toluene to give the crude product which was dissolved in dichloromethane (2 mL) and treated with trifluoroacetic acid (2 mL) at room temperature. After the reaction mixture was stirred at room temperature for 1 hour, the solvent was removed in vacuo to give 3-[(8aS)-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid (Compound Q) which was used directly.
Example 20:
3-[(8aS)-7-[[(4R)-4-(2-chlorophenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8^
2-methyl-propanoic acid
Figure imgf000087_0001
The title compound was prepared in analogy to Example 19 by using 2- chlorobenzaldehyde and methyl 3-amino-2-methyl-propanoate hydrochloride salt (Compound W) instead of 2-chloro-4-fluorobenzaldehyde and ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt. Example 20 was obtained as a light yellow solid (20 mg). 1H NMR (400
MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.01 Hz, 1H), 7.75 (d, / = 3.01 Hz, 1H), 7.42 (d, / = 7.78 Hz, 2H), 7.14 - 7.36 (m, 2H), 6.22 (s, 1H), 3.97 - 4.16 (m, 3H), 3.79 - 3.97 (m, 3H), 3.43 - 3.59 (m, 2H), 3.26 - 3.43 (m, 2H), 3.05 - 3.26 (m, 2H), 2.80 - 2.99 (m, 2H), 2.65 - 2.80 (m, 1H), 2.35 (t, / = 10.79 Hz, 1H), 2.19 (q, / = 10.46 Hz, 1H), 1.06 - 1.24 (m, 5 H). MS: calc'd 587 (MH+), measured 587 (MH+).
Preparation of methyl 3-amino-2-methyl-propanoate hydrochloride salt (compound
W):
Figure imgf000087_0002
w
To the solution of DL-3-aminoisobutyric acid (CAS number: 144-90-1, Aldrich) (2.7 g, 26.4 mmol) in MeOH (50 mL) was added SOCl2 (6.17 g, 52.8 mmol) dropwise at 0 °C under N2 atmosphere. The reaction was refluxed for 18 hours. The solvent was removed in vacuo to give crude Compound W which was used directly in the next step.
Example 21:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2-methyl-propanoic acid
Figure imgf000088_0001
The title compound was prepared in analogy to Example 19 by using methyl 3-amino-2- methyl-propanoate hydrochloride salt (Compound W) instead of ethyl 3-amino-2,2-dimethyl- propanoate hydrochloride salt. Example 21 was obtained as a light yellow solid (10 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.26 Hz, 1H), 7.76 (d, / = 3.26 Hz, 1H), 7.21 - 7.36 (m, 2H), 7.10 - 7.21 (m, 1H), 6.24 (s, 1H), 3.98 - 4.17 (m, 3H), 3.79 - 3.98 (m, 3H), 3.42 - 3.58 (m, 2H), 3.24 - 3.42 (m, 2H), 3.08 - 3.24 (m, 2H), 2.79 - 2.96 (m, 2H), 2.73 (ddt, / = 10.63, 7.00, 3.73, 3.73 Hz, 1H), 2.30 - 2.43 (m, 1H), 2.13 - 2.27 (m, 1H), 1.08 - 1.24 (m, 5 H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 22:
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]-2,2-dimethyl-propanoic acid
Figure imgf000088_0002
The title compound was prepared in analogy to Example 19 by using 2-methyl-3,4- difluorobenzaldehyde instead of 2-chloro-4-fluorobenzaldehyde. Example 22 was obtained as a light yellow solid (2 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.88 - 8.00 (m, 1H), 7.69 - 7.80 (m, 1H), 6.95 - 7.13 (m, 2H), 5.88 - 5.99 (m, 1H), 4.03 - 4.16 (m, 2H), 3.79 - 3.97 (m, 3H), 3.47 - 3.54 (m, 1H), 3.36 - 3.44 (m, 2H), 3.28 - 3.31 (m, 1 H), 3.07 - 3.24 (m, 2H), 2.76 - 2.94 (m, 2H), 2.57 (d, / = 2.26 Hz, 3H), 2.31 - 2.42 (m, 1H), 2.12 - 2.22 (m, 1H), 1.10 - 1.24 (m, 9 H). MS: calc'd 617 (MH+), measured 617 (MH+).
Example 23:
Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-methoxy-l,l-dimethyl-2-oxo-ethyl)- 3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate
Figure imgf000089_0001
The title compound was prepared in analogy to Example 19 by using methyl 3-amino-2- methyl-propanoate hydrochloride salt instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt. Example 23 was obtained as a light yellow solid (4 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.94 - 8.03 (m, 1H), 7.72 - 7.82 (m, 1H), 7.22 - 7.38 (m, 2H), 7.11 - 7.20 (m, 1H), 6.25 (s, 1H), 4.10 - 4.22 (m, 1H), 3.85 - 4.02 (m, 2H), 3.76 - 3.84 (m, 1H), 3.74 (d, / = 1.00 Hz, 2H), 3.59 - 3.71 (m, 1H), 3.12 - 3.30 (m, 2H), 2.76 - 3.03 (m, 2H), 2.20 - 2.52 (m, 2H), 1.50 (t, / = 7.78 Hz, 6H), 1.14 (t, / = 7.03 Hz, 3 H). MS: calc'd 619 (MH+), measured 619 (MH+).
Example 24: Methyl 7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-2,5,6,8 etrahydro-lH-imidazo[l,5-a]pyrazine-8 carboxylate
Figure imgf000090_0001
The title compound was prepared in analogy to Example 1 by using 2-chloro,3- fluorobenzaldehyde, ethyl acetoacetate and methyl 3-oxo- 1,2,5, 6,7, 8-hexahydroimidazo[ 1,5- a]pyrazine-8a-carboxylate (Compound X) instead of 2-chloro-4-fluorobenzaldehyde, methyl acetoacetate and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 24 was obtained as a light yellow solid (5 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.26 Hz, 1H), 7.76 (d, / = 3.26 Hz, 1H), 7.27 - 7.35 (m, 1H), 7.26 (s, 1H), 7.16 (s, 1H), 6.22 (s, 1H), 3.97 - 4.14 (m, 3H), 3.87 - 3.95 (m, 1H), 3.78 - 3.85 (m, 1H), 3.67 (s, 3H), 3.46 (d, / = 9.79 Hz, 2H), 3.35 - 3.42 (m, 2H), 2.87 - 2.99 (m, 1H), 2.45 - 2.55 (m, 1H), 2.29 - 2.42 (m, 1H), 1.12 (t, J = 7.15 Hz, 3 H). MS: calc'd 577 (MH+), measured 577 (MH+).
Preparation of methyl 3-oxo-l,2,5,6,7,8-hexahydroimidazo[l,5-a]pyrazine-8a- carboxylate (Compound X):
Figure imgf000091_0001
AA Λ
Stepl: Piperazine-l,3-dicarboxylic acid l-ie/t-butyl ester 3-methyl ester (244 mg, 1.0 mmol) was dissolved in 5 mL of dichloromethane followed by sequential addition of TEA (202 mg, 2.0 mmol) and benzyl chloroformate (170 mg, 1.0 mmol) at room temperature. After the reaction was stirred for 1 hour, it was diluted with dichloromethane, and then washed with water and brine. The solvent was concentrated to give crude Compound Y, which was used directly without further purification.
Step 2: Piperazine-l,2,4-tricarboxylic acid 1 -benzyl ester 4-ie/t-butyl ester 2-methyl ester (Compound Y) from previous step was dissolved in 5 mL of THF at -78°C, then LDA (2 M, 1 mL, 2 mmol) was added dropwise. After the reaction mixture was stirred for 2 hours at -78 °C, 2- bromomethyl-isoindole-l,3-dione (239 mg, 1 mmol) in 2 mL of THF was added. The reaction mixture was stirred overnight. The solvent was removed in vacuo and the residue was triturate with petroleum ether. The solid was collected by filtration, washed with water and then dried in vacuo to give Compound Z.
Step 3: 2-(l,3-Dioxo-l,3-dihydro-isoindol-2-ylmethyl)-piperazine-l,2,4-tricarboxylic acid 1 -benzyl ester 4-iert-butyl ester 2-methyl ester (Compound Z) from Step 2 was dissolved in 3 mL of EtOH and 1 mL of N2H4 solution. The reaction mixture was stirred at room temperature overnight. The solid was filtered off and the filtrate was concentrated in vacuo. The crude oil was dissolved in 10 mL of MeOH and stirred with 50 mg of Pd/C under H2 atmosphere overnight. After filtration, the solvent was concentrated in vacuo to give 100 mg of crude Compound AA as oil, which was used directly without further purification in the next step.
Step 4: 3-Aminomethyl-piperazine-l,3-dicarboxylic acid l-ie/t-butyl ester 3-methyl ester (Compound AA) from Step 3 was dissolved in 4 mL of dichloromethane and lmL of DIPEA, then triphosgene (108 mg, 0.36 mmol) was added at room temperature. After the reaction mixture was stirred for 30 minutes, the solvent was removed in vacuo. The residue was dissolved in 3 mL of dichloromethane and 1 mL of TFA. The reaction mixture was stirred for 1 hour at room temperature, and the solvent was removed in vacuo to give the crude Compound X which was used directly without further purification.
Example 25:
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester
Figure imgf000092_0001
The title compound was prepared in analogy to Example 1 by using 4-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AB) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 25 was obtained as a light yellow solid (45 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.93-8.06 (m, 3H), 7.79 (d, 1H), 7.64-7.75 (m, 2H), 7.45 (m, 1H), 7.25 (m, 1H), 7.08 (m, 1H), 6.19 (s, 1H), 4.22 (d, 1H), 3.95-4.15 (m, 4H), 3.53-3.66 (m, 4H), 3.29 (d, 1H), 3.09 (d, 2H), 3.03-3.17 (m, 2H), 2.50-2.63 (m, 1H), 2.35 (br. s., 1H). MS: calc'd 625 (MH+), measured 625 (MH+). Preparation of 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]benzoic acid (compound AB):
Figure imgf000093_0001
Step 1: A mixture of ie/t-butyl (8aR)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5- a]pyrazine-7-carboxylate (Compound M, 200 mg, 0.83 mmol), xantphos (46 mg, 0.08 mmol), CS2CO3 (378 mg, 1.16 mmol), Pd(OAc)2 (18 mg, 0.08 mmol) and 4-iodo-benzoic acid methyl ester (282 mg, 1.08 mmol) in dioxane (6 mL) was degassed with argon atmosphere three times. The mixture was stirred at room temperature for 5 minutes under argon atmosphere, and then heated at 90 °C overnight. The mixture was diluted with EtOAc (20 mL), and filtered through celite. The filtrate was concentrated and purified on silica gel to give Compound AC (240 mg).
Step 2: To a solution of Compound AC (240 mg, 0.64 mmol) in THF (3 mL) was added a solution of LiOH H20 (215 mg, 5.10 mmol) in H20 (1 mL) at room temperature. After the reaction mixture was stirred at room temperature overnight, it was acidified to PH 3 to 4 with 1 N HCl at 0 °C. The mixture was then concentrated and azeotropically dried with toluene to give Compound AD (231 mg) which was used directly without further purification in the next step.
Step 3: To a solution of Compound AD (231 mg, 0.64 mmol) in dichloromethane (2 mL) was added TFA (2 mL) at room temperature. The mixture was stirred at room temperature for 1 hour, then concentrated to give methyl 4-(3-oxo- 1,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)benzoic acid (Compound AB) (240 mg). Example 26:
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]- 4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000094_0001
The title compound was prepared in analogy to Example 25 by using 2-chloro,3- fluorobenzaldehyde and ethyl acetoacetate instead of 2-chloro-4-fluorobenzaldehyde and methyl acetoacetate. Example 26 was obtained as a light yellow solid (76 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.85-7.96 (m, 3H), 7.79 (d, IH), 7.61 (d, 2H), 7.23-7.30 (m, 2H), 7.08- 7.19 (m, IH), 6.16 (s, IH), 4.62 (d, IH), 4.43 (d, IH), 4.22 (m, IH), 4.02-4.16 (m, 2H), 3.97 (m, 2H), 3.57-3.73 (m, 3H), 3.36-3.49 (m, IH), 3.02-3.16 (m, 2H), 0.95-1.08 (m, 3H). MS: calc'd 639 (MH+), measured 639 (MH+).
Example 27:
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]- 4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000095_0001
The title compound was prepared in analogy to Example 25 by using 2-chloro,3- fluorobenzaldehyde, ethyl acetoacetate and 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2-yl]benzoic acid (Compound AE) instead of 2-chloro-4-fluorobenzaldehyde, methyl acetoacetate and 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AB). Example 27 was obtained as a light yellow solid (20 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.11 (s, IH), 7.90 (d, IH), 7.75-7.82 (m, 2H), 7.66 (d, IH), 7.37 (m, IH), 7.23-7.29 (m, 2H), 7.07-7.17 (m, IH), 6.16 (s, IH), 4.59 (d, IH), 4.34-4.45 (m, IH), 4.15- 4.25 (m, IH), 4.01-4.13 (m, 2H), 3.97 (m, 2H), 3.52-3.67 (m, 3H), 3.36-3.46 (m, IH), 3.02-3.16 (m, 2H), 1.01 (m, 3H). MS: calc'd 639 (MH+), measured 639 (MH+).
Preparation of 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl] benzoic acid (Compound AE):
Compound AE was prepared in analogy to Compound AB in Example 25 by using 3-iodo- benzoic acid methyl ester instead of 4-iodo-benzoic acid methyl ester.
Example 28:
(R)-6-[(S)-2-(2-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]- 4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000096_0001
The title compound was prepared in analogy to Example 25 by using 2-chloro,3- fluorobenzaldehyde and ethyl acetoacetate and 2-[(8aS)-3-oxo-l,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AF) instead of 2-chloro-4- fluorobenzaldehyde and methyl acetoacetate and 4-[(8aS)-3-oxo-l,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AB). Example 28 was obtained as a light yellow solid (95 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.83-7.93 (m, 2H), 7.80 (d, IH), 7.53 (m, IH), 7.24-7.35 (m, 4H), 7.08-7.19 (m, IH), 6.16 (s, IH), 4.66 (d, IH), 4.48 (d, IH), 4.20-4.29 (m, IH), 4.06-4.11 (m, IH), 3.92-4.04 (m, 3H), 3.65 (d, 2H), 3.29-3.55 (m, 3H), 3.13 (m, IH), 1.02 (m, 3H). MS: calc'd 639 (MH+), measured 639 (MH+).
Preparation of 2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl] benzoic acid (compound AF):
The title compound was prepared in analogy to Compound AB in Example 25 by using 2- iodo-benzoic acid methyl ester instead of 4-iodo-benzoic acid methyl ester.
Example 29:
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester
Figure imgf000097_0001
The title compound was prepared in analogy to Example 25 by using 3-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AE) instead of 4- [(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AB). Example 29 was obtained as a light yellow solid (220 mg). 1H NMR (400 MHz, METHANOL- d4) d ppm 8.20-8.26 (m, IH), 8.03 (d, IH), 7.85-7.96 (m, 2H), 7.78 (m, IH), 7.56 (m, IH), 7.49 (m, IH), 7.30 (m, IH), 7.13 (m, IH), 6.21 (s, IH), 4.78 (d, IH), 4.55-4.63 (m, IH), 4.36 (dm, IH), 4.13-4.29 (m, 2H), 3.72-3.90 (m, 3H), 3.65 (s, 3H), 3.51-3.61 (m, IH), 3.35-3.40 (m, IH), 3.26-3.31 (m, IH). MS: calc'd 625 (MH+), measured 625 (MH+).
Example 30:
2-[7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-l,5,6,8 etrahydroimidazo[l,5- a]pyrazin-8a-yl]acetic acid
Figure imgf000097_0002
The title compound was prepared in analogy to Example 1 by using 4-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AG) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 30 was obtained as a light yellow solid (48 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.93 (d, / = 3.0 Hz, 1H), 7.73 (d, / = 3.0 Hz, 1H), 7.43 (dd, / = 6.1, 8.7 Hz, 1H), 7.24 (dd, / = 2.5, 8.8 Hz, 1H), 7.06 (d, / = 2.8 Hz, 1H), 6.16 (s, 1H), 4.14 (d, / = 16.6 Hz, 1H), 3.85 - 3.71 (m, 2H), 3.60 (s, 3H), 3.46 (d, / = 9.8 Hz, 1H), 3.30 - 3.15 (m, 3H), 3.06 (d, J = 11.3 Hz, 1H), 2.95 - 2.82 (m, 2H), 2.45 (d, / = 5.0 Hz, 1H), 2.39 - 2.29 (m, 1H), 2.22 (d, J = 11.5 Hz, 1H), 0.83 - 0.53 (m, 4H). MS: calc'd 604(MH+), measured 604(MH+).
Preparation of 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]benzoic acid (compound AG):
Figure imgf000098_0001
Step 1: To a solution of piperazine-l,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (10.6 g, 43mmol) in 250 mL of dichloromethane was added (Boc)20 (19 g, 86mmol) at 0°C. The reaction mixture stirred for 4 hours at room temperature, and then quenched with water and then extracted with dichloromethane. After the organic layer was dried over anhydrous Na2S04, the filtrate was concentrated. The residue was purified by silica gel column chromatography to give Compound AH (yield 13.6 g, 92%).
Step 2: To a solution of Compound AH (13.4g, 38.9 mmol) in 200 mL of anhydrous THF was added freshly prepared LDA (2M in THF, 38 mL) at -78°C. The reaction mixture was stirred for 30 minutes at -78°C and then warmed to room temperature for 30 minutes. The mixture was cooled down to -78°C and a solution of allyl bromide (6.7 mL, 77.9 mmol) in 10 mL of THF was added. After the mixture was warmed to room temperature and stirred overnight, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to afford Compound AI (yield 13.6 g, 91%). Step 3: To a solution of Compound AI (1.0 g, 2.6 mmol) in 20 mL of anhydrous THF was added LAH (2M in THF, 1.3 mL) at -78°C. The reaction mixture was stirred for 30 minutes at - 78°C and then warmed to room temperature and stirred overnight. Anhydrous Na2S04 was added. After 1 hour, the filtrate was concentrated. The residue was purified by silica gel column chromatography to afford Compound AJ (yield 0.7 g, 75%).
Step 4: To a solution of Compound AJ (3 g, 8.4 mmol) in 50 mL of anhydrous
dichloromethane was added Dess-Martin periodinane (6 g, 14.1 mmol) at 0 °C. The reaction mixture was stirred for 2 hours at room temperature, and then quenched with water. The filtrate was extracted with dichloromethane, and then dried over anhydrous Na2S04, and the filtrate was concentrated to give Compound AK without further purification.
Step 5: To a stirred solution of Compound AK (1.5 g, 4.2 mmol) in dichloromethane (15 mL) was added successively acetic acid and cyclopropylamine (0.29 mL, 4.2 mmol). The reaction mixture was stirred for 2 hours at room temperature, then sodium triacetoxyborohydride (520 mg, 8.4 mmol) was added and the reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was quenched with saturated NH4C1. Then water (20 mL) was added followed by dichloromethane (40 mL). The organic layer was separated and then washed with brine, and then dried over Na2S04. The filtrate was concentrated to give Compound AL without further purification.
Step 6: To a solution of Compound AL (1.5 g, 3.8 mmol) in 20 mL of anhydrous THF was added NaH (0.26 g, 9.4 mmol) at 0°C. The reaction mixture was stirred over night at 85°C. Then the reaction was cooled to room temperature, quenched with water and extracted with
dichloromethane. The organic layer was dried over anhydrous Na2S04 and then concentrated in vacuo. The residue was purified by silica gel column chromatography to give Compound AM (yield 1.0 g, 82%).
Step 7: To a solution of Compound AM (700 mg, 2.2 mmol) in H20 (1 mL) and CH3CN
(6 mL) under nitrogen atmosphere was added RuCl3-H20 (18 mg, 0.086 mmol), followed by NaI04 (2.7 g, 12.6 mmol). The reaction was stirred at room temperature overnight. The mixture was diluted with water and ethyl ether, filtered through a celite pad, and the pad was washed with ethyl ether. The aqueous layer was extracted with dichloromethane. The combined organic layers were dried over Na2S04, and concentrated to give Compound AN (yield 450 mg, 60%).
Step 8: To a solution of Compound AN (600 mg, 1.76mmol) in dichloromethane (8 mL) was added TFA (2 mL) at 0°C. After the reaction mixture was stirred for 2 hours at room temperature, it was concentrated to give Compound AG without further purification. Example 31:
2-[7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-l,5,6,8 etrahydroimidazo[l,5-a]p
8a-yl] acetic acid
Figure imgf000100_0001
The title compound was prepared in analogy to Example 30 by using 2-(2-isopropyl-3-oxo- 5,6,7, 8-tetrahydro-lH-imidazo[l,5-a]pyrazin-8a-yl)acetic acid (Compound AO) instead of 4- [(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]benzoic acid (Compound AG). Example 31 was obtained as a light yellow solid (8 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.94 (d, / = 3.0 Hz, 1H), 7.73 (d, / = 3.3 Hz, 1H), 7.43 (dd, / = 6.0, 8.8 Hz, 1H), 7.24 (dd, 7 = 2.8, 8.8 Hz, 1H), 7.11 - 7.02 (m, 1H), 6.16 (s, 1H), 4.18 - 4.04 (m, 2H), 3.79 (d, / = 16.6 Hz, 2H), 3.61 (s, 3H), 3.47 (d, / = 9.5 Hz, 1H), 3.29 - 3.24 (m, 1H), 3.20 (d, / = 9.5 Hz, 1H), 3.09 (d, / = 11.5 Hz, 1H), 2.90 (d, / = 15.6 Hz, 2H), 2.38 - 2.12 (m, 3H), 1.18 (d, 7 = 7.0 Hz, 3H), 1.12 (d, / = 6.8 Hz, 3H). MS: calc'd 606(MH+), measured 606(MH+).
Preparation of 2-(2-isopropyl-3-oxo-5,6,7,8-tetrahydro-lH-imidazo[l,5-a]pyrazin-8a- yl)acetic acid (Compound AO):
The title compound was prepared in analogy to Compound AG in Example 30 by using /so-propyl amine instead of cyclopropyl amine.
Example 32:
(R)-6-[(S)-2-(l-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000101_0001
The title compound was prepared in analogy to Example 19 by using methyl 2-amino-2- methyl-propanoate hydrochloride salt instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt. Example 32 was obtained as a light yellow solid (60 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.98 (d, IH), 7.79 (d, IH), 7.23-7.38 (m, 2H), 7.09-7.23 (m, IH), 6.25 (s, IH), 4.23 (br. s., IH), 4.06 (m, 3H), 3.78-3.97 (m, 2H), 3.59-3.71 (m, IH), 3.14-3.29 (m, 2H), 2.89-3.14 (m, 2H), 2.54 (br. s., 2H), 1.40-1.57 (m, 6H), 1.04-1.19 (m, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 33:
3-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6^
3-methyl-butanoic acid
Figure imgf000101_0002
The title compound was prepared in analogy to Example 19 by using 2-chloro-4- fluorobenzaldehyde, methyl acetoacetate and 3-[(8aS)-3-oxo-l,5,6,7,8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]-3-methyl-butanoic acid (Compound AP) instead of 2- chloro-3-fluorobenzaldehyde, ethyl acetoacetate and 3-[(8aS)-3-oxo- 1,5,6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid (Compound Q). Example 33 was obtained as a light yellow solid (381 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00 - 8.01 (d, / = 4.0Hz, 1H), 7.90 - 7.91 (d, / = 4.0Hz, 1H), 7.55 (m, 1H), 7.29 (m, 1H), 7.13 (m, 1H), 6.20 (s, 1H), 4.76 (d, / = 16.0 Hz, 1H), 4.60 (d, / = 16.0 Hz, 1H), 4.12 (m, 1H), 4.02- 4.06 (m, 1H), 3.70-3.80 (m, 3H), 3.65 (s, 3H), 3.32-3.44(m, 2H), 3.20 (m, 2H), 3.09 - 3.05 (d, / = 16.0Hz, 1H), 2.79-2.83 (d, / = 16.0Hz, 1H), 1.47 (s, 6H). MS: calc'd 605 (MH+), measured 605 (MH+).
Preparation of 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-3- methyl-butanoic acid (Compound AP):
The title compound was prepared in analogy to Compound Q in Example 19 by using methyl 3-amino-3-methyl-butanoate hydrochloride salt (Compound AP-1) instead of ethyl 3- amino-2,2-dimethyl-propanoate hydrochloride salt.
Preparation of methyl 3-amino-3-methyl-butanoate hydrochloride salt (Compound AP-1):
Figure imgf000102_0001
HCI
AP-1
Compound AP-1 was prepared in analogy to Compound W in Example 20 by using 3- amino-3-methyl- butyric acid instead of DL-3-aminoisobutyric acid.
Example 34:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 3-methyl-butanoic acid
Figure imgf000103_0001
The title compound was prepared in analogy to Example 19 by using 3-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-3-methyl-butanoic acid (Compound AP) instead of 3-[(8aS)-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl- propanoic acid (Compound Q). Example 34 was obtained as a light yellow solid (26 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.99-8.00 (d, / = 4.0Hz, IH), 7.83- 7.84 (d, / = 4.0Hz, IH), 7.35 (m, 2H), 7.20 (m, IH), 6.25 (s, IH), 4.20-4.40 (m, 2H), 4.10 (m, 2H), 3.94 (m, 2H), 3.70 (m, 2H), 3.29 (m, 5H), 3.02-3.06(d, / = 16.0Hz, IH), 2.80 - 2.84 (d, / = 16.0Hz, IH), 1.46 (s, 6H), 1.11-1.15 (t, J;=8.0Hz, J2=16.0Hz, 3H). MS: calc'd 619 (MH+), measured 619 (MH+).
Example 35:
l-[[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dmydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid
Figure imgf000104_0001
The title compound was prepared in analogy to Example 19 by using 2-chloro-4- fluorobenzaldehyde, methyl acetoacetate and methyl l-(aminomethyl)cyclopropanecarboxylate hydrochloride salt (Compound AQ) instead of 2-chloro,3-fluorobenzaldehyde, ethyl acetoacetate and ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt. Example 35 was obtained as a light yellow solid (760 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00 - 8.01 (d, / = 4.0Hz, 1H), 7.90 - 7.91 (d, / = 4.0Hz, 1H), 7.55 (m, 1H), 7.29 (m, 1H), 7.13 (m, 1H), 6.20 (s, 1H), 4.77 (d, / = 16.0 Hz, 1H), 4.59 (d, / = 16.0 Hz, 1H), 4.19 (m, 1H), 4.07-4.10 (m, 1H), 3.73-3.77 (m, 3H), 3.65 (s, 3H), 3.36-3.50(m, 4H), 3.15 - 3.24 (m, 2 H), 1.29 (m, 2H), 1.02 (m, 2H). MS: calc'd 603 (MH+), measured 603 (MH+).
Preparation of methyl l-(aminomethyl)cyclopropanecarboxylate hydrochloride salt (Compound AQ):
The title compound was prepared in analogy to Compound W in Example 20 by using 1- (aminomethyl)cyclopropanecarboxylic acid (CAS number: 139132-50-6, J&K; for its synthesis, please refer to: Mertin A., et al. Synlett, 1991, 2, 87-9) instead of DL-3-aminoisobutyric acid.
Example 36:
l-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid
Figure imgf000105_0001
The title compound was prepared in analogy to Example 19 by using methyl 1- (aminomethyl)cyclopropanecarboxylate hydrochloride salt (Compound AQ) instead ethyl 3- amino-2,2-dimethyl-propanoate hydrochloride salt. Example 36 was obtained as a light yellow solid (170 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00 - 8.01 (d, / = 4.0Hz, 1H), 7.92 - 7.91 (d, / = 4.0Hz, 1H), 7.38 (m, 2H), 7.26 (m, 1H), 6.27 (s, 1H), 4.77 (d, / = 16.0 Hz, 1H), 4.59 (d, / = 16.0 Hz, 1H), 4.11 (m, 1H), 4.07-4.10 (m, 3H), 3.72-3.78 (m, 3H), 3.36- 3.47 (m, 4H), 3.15 - 3.24 (m, 2 H), 1.29 (m, 2H), 1.13(t, J7=8.0Hz, J2=l 6.0Hz, 3H), 1.02 (m, 2H). MS: calc'd 617 (MH+), measured 617 (MH+).
Example 37:
l-[[(8aS)-7-[[(4S)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid
Figure imgf000105_0002
The title compound was prepared in analogy to Example 19 by using 2-methyl-3,4- difluorobenzaldehyde, methyl acetoacetate and 3-[(8aS)-3-oxo-l, 5,6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]-3-methyl-butanoic acid (Compound AP) instead of 2- chloro-3-fluorobenzaldehyde, ethyl acetoacetate and 3-[(8aS)-3-oxo- 1,5,6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid (Compound Q). Example 37 was obtained as a light yellow solid (153 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00 - 8.01 (d, / = 4.0Hz, 1H), 7.90 - 7.91 (d, / = 4.0Hz, 1H), 7.26 (m, 1H), 7.10 (m, 1H), 5.95 (s, 1H), 4.74 (d, / = 16.0 Hz, 1H), 4.57 (d, / = 16.0 Hz, 1H), 4.10 (m, 2H), 3.70-3.80 (m, 3H), 3.66 (s, 3H), 3.36-3.42(m, 2H), 3.20 (m, 2H), 3.09 - 3.05 (d, / = 16.0Hz, 1H), 2.79-2.83 (d, / = 16.0Hz, 1H), 2.53 (s, 3H), 1.47 (s, 6H). MS: calc'd 603 (MH+), measured 603 (MH+).
Example 38:
l-[[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid
Figure imgf000106_0001
The title compound was prepared in analogy to Example 35 by using 2-methyl-3,4- difluorobenzaldehyde instead of 2-chloro-4-fluorobenzaldehyde. Example 38 was obtained as a light yellow solid (54 mg). 1H NMR (400 MHz, METHANOL-d ) d ppm 8.00 - 8.01 (d, / = 4.0Hz, 1H), 7.90 - 7.91 (d, / = 4.0Hz, 1H), 7.26 (m, 1H), 7.12 (m, 1H), 5.95 (s, 1H), 4.74 (d, / = 16.0 Hz, 1H), 4.56 (d, / = 16.0 Hz, 1H), 4.07-4.17 (m, 2H), 3.70-3.77 (m, 3H), 3.66 (s, 3H), 3.35-3.46(m, 4H), 3.15 - 3.22 (m, 2H), 2.51 (s, 3H), 1.29 (m, 2H), 1.02 (m, 2H). MS: calc'd 601 (MH+), measured 601 (MH+). Example 39:
3-[(2S,8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin yl]cyclobutanecarboxylic acid
Figure imgf000107_0001
The title compound was prepared in analogy to Example 19 by using 2-chloro-4- fluorobenzaldehyde, methyl acetoacetate and methyl iraws-S-amino-cyclobutanecarboxylate hydrochloride (CAS number: 74316-29-3; for its synthesis, please refer to: Grygorenko O. O., et al. Synthetic Communications, 2011, 41, 1644-1649) instead of 2-chloro-3-fluorobenzaldehyde, ethyl acetoacetate and ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride. Example 39 was obtained as a light yellow solid (44 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (dd, / = 4.0, 3.3 Hz, 1H), 7.77 (dd, / = 3.1, 1.4 Hz, 1H), 7.43 (ddd, / = 8.7, 6.1, 2.5 Hz, 1H), 7.20- 7.28 (m, 1H), 6.99-7.13 (m, 1H), 6.18 (s, 1H), 4.58-4.73 (m, 1H), 4.11 (dd, J = 16.9, 4.6 Hz, 1H), 3.73-3.97 (m, 3H), 3.61 (s, 3H), 2.82-3.28 (m, 5H), 2.74 (d, / = 11.8 Hz, 1H), 2.15-2.65 ppm (m, 6H). MS: calc'd 603(MH+), measured 603(MH+).
Example 40:
3-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclobutanecarboxylic acid
Figure imgf000108_0001
The title compound was prepared in analogy to Example 19 by using 2-chloro-4- fluorobenzaldehyde, methyl acetoacetate and methyl ds-S-amino-cyclobutanecarboxylate hydrochloride (CAS number: 1212304-86-3; for its synthesis, please refer to: Grygorenko O. O., et al. Synthetic Communications, 2011, 41, 1644-1649) instead of 2-chloro-3- fluorobenzaldehyde, ethyl acetoacetate and ethyl 3-amino-2,2-dimethyl-propanoate
hydrochloride. Example 40 was obtained as a light yellow solid (5 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.92-8.02 (m, 1H), 7.77 (dd, J = 3.1, 1.4 Hz, 1H), 7.38-7.48 (m, 1H), 7.24 (d, / = 6.3 Hz, 1H), 6.98-7.15 (m, 1H), 6.18 (s, 1H), 4.58-4.75 (m, 1H), 4.04-4.19 (m, 1H), 3.72-3.97 (m, 3H), 3.61 (s, 4H), 2.81-3.27 (m, 6H), 2.33-2.63 ppm (m, 5H). MS: calc'd
603(MH+), measured 603(MH+).
Example 41:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid
Figure imgf000109_0001
The title compound was prepared in analogy to Example 19 by using methyl acetoacetate instead of ethyl acetoacetate. Example 41 was obtained as a light yellow solid (250 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, IH), 7.76 (d, / = 3.0 Hz, IH), 7.09-7.36 (m, 3H), 6.23 (s, IH), 4.04-4.15 (m, IH), 3.78-3.98 (m, 3H), 3.61 (s, 3H), 3.36-3.55 (m, 3H), 3.04-3.28 (m, 2H), 2.76-2.99 (m, 2H), 2.12-2.45 (m, 2H), 1.15-1.25 ppm (m, 6H). MS: calc'd 605(MH+), measured 605(MH+).
Example 42:
3-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid
Figure imgf000109_0002
The title compound was prepared in analogy to Example 19 by using 2-chloro-4- fluorobenzaldehyde and methyl acetoacetate instead of 2-chloro-3-fluorobenzaldehyde and ethyl acetoacetate. Example 42 was obtained as a light yellow solid (260 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.0 Hz, IH), 7.76 (d, / = 3.3 Hz, IH), 7.42 (dd, / = 8.5, 6.0 Hz, IH), 7.24 (dd, / = 8.7, 2.6 Hz, IH), 7.06 (td, / = 8.4, 2.8 Hz, IH), 6.17 (s, IH), 4.09 (d, / = 16.8 Hz, IH), 3.79-3.98 (m, 3H), 3.61 (s, 3H), 3.51 (t, / = 8.9 Hz, IH), 3.36-3.44 (m, IH), 3.04- 3.26 (m, 3H), 2.75-3.00 (m, 2H), 2.11-2.43 (m, 2H), 1.20 ppm (d, / = 3.0 Hz, 6H). MS: calc'd 605(MH+), measured 605(MH+). Example 43:
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]-2,2-dimethyl-propanoic acid
Figure imgf000110_0001
The title compound was prepared in analogy to Example 19 by using 2-methyl-3,4- difluorobenzaldehyde and methyl acetoacetate instead of 2-chloro-3-fluorobenzaldehyde and ethyl acetoacetate. Example 43 was obtained as a light yellow solid (110 mg). 1H NMR (400 MHz, METHANOL-d ) d ppm 7.95 (d, / = 3.3 Hz, IH), 7.75 (d, / = 3.3 Hz, IH), 6.96-7.09 (m, 2H), 5.93 (s, IH), 4.04-4.16 (m, IH), 3.78-3.98 (m, 3H), 3.62 (s, 3H), 3.36-3.56 (m, 3H), 3.05- 3.26 (m, 2H), 2.74-2.97 (m, 2H), 2.57 (d, / = 2.3 Hz, 3H), 2.36 (td, / = 11.7, 3.6 Hz, IH), 2.18 (t, / = 10.9 Hz, IH), 1.20 ppm (d, / = 3.3 Hz, 6H). MS: calc'd 603(MH+), measured 603(MH+).
Example 44: 3-[(8aS)-7-[[(4S)-4-(3-fluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8^
2,2-dimethyl-propanoic acid
Figure imgf000111_0001
The title compound was prepared in analogy to Example 19 by using 2-methyl-3- fluorobenzaldehyde and methyl acetoacetate instead of 2-chloro-3-fluorobenzaldehyde and ethyl acetoacetate. Example 44 was obtained as a light yellow solid (74 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95 (d, / = 3.0 Hz, IH), 7.74 (d, / = 3.3 Hz, IH), 7.03-7.21 (m, 2H), 6.88-6.99 (m, IH), 5.98 (s, IH), 4.03-4.17 (m, IH), 3.79-3.99 (m, 4H), 3.62 (s, 3H), 3.41-3.56 (m, 2H), 3.07-3.26 (m, 2H), 2.75-2.98 (m, 2H), 2.53 (d, / = 2.0 Hz, 3H), 2.29-2.45 (m, IH), 2.18 (t, J = 11.2 Hz, IH), 1.20 ppm (d, / = 3.3 Hz, 6H). MS: calc'd 585(MH+), measured 585(MH+).
Example 45:
7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid
Figure imgf000112_0001
Preparation of Exam le 45:
Figure imgf000112_0002
Example 45
The solution of methyl 7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-8-carboxylate (Compound AQ, 150 mg, 0.25 mmol) in tetrahydrofuran (1.5 mL) was added lithium hydroxide monohydrate (52 mg, 1.25 mmol) in water (1.5 mL). After the reaction mixture was stirred at room temperature for 2 hours, it was neutralized by IN hydrochloride solution to pH 3.0. The mixture was extracted with ethyl acetate (30 mL) three times. The combined organic phase was dried over Na2S04, filtrated and then concentrated. The residue was purified by Prep-HPLC to give Example 45 as a mixture of two diastereomers (5 mg). 1H NMR (400 MHz, METHANOL-d ) d ppm 8.06 - 7.95 (m, 1H), 7.87 (s, 1H), 7.55 - 7.44 (m, 1H), 7.32 - 7.23 (m, 1H), 7.15 - 7.03 (m, 1H), 6.18 (s, 1H), 4.37 - 4.21 (m, 1H), 4.09 - 3.91 (m, 1H), 3.91 - 3.77 (m, 2H), 3.62 (d, / = 2.0 Hz, 4H), 3.52 - 3.39 (m, 2H), 3.22 - 2.96 (m, 2H), 2.75 - 2.58 (m, 1H), 2.50 - 2.42 (m, 1H), 0.74 (d, / = 1.5 Hz, 4H). MS: calc'd 589 (MH+), measured 589 (MH+). -I l l-
Preparation of 7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-8-carboxylate (Compound AQ)
The title compound was prepared in analogy to Example 1 by using methyl 2-cyclopropyl- 3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (Compound AR) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D).
Preparation of cis-methyl 2-cyclopropyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazine-8-carboxylate (Compound AR)
Figure imgf000113_0001
AW AX
AV
Figure imgf000113_0002
AY AR
Step 1: To a solution of dimethyl maleate (7.2 g, 50 mmol) in tetrachloromethane (150 mL) was added dropwise bromine (8.8 g, 55 mmol) in tetrachloromethane (10 mL) at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at 0 °C overnight. The reaction mixture was quenched by adding ice- water, and then washed with Na2S03 solution. The organic phase was washed with water, separated, dried over Na2S04 and then concentrated to give crude Compound AS (15.2g, crude). Step 2: To a solution of Compound AS (10.6 g, 35 mmol) in benzene (120 mL) was added dropwise N,N-dibenzylethylenediamine (8.4 g, 35 mmol) and triethyl amine (9.7, 70 mmol) in benzene (20 mL) at 40 °C under nitrogen atmosphere. The reaction mixture was stirred for 10 minutes and heated to reflux overnight. The reaction mixture was cooled down by adding ice- water, and then extracted with petroleum ether/ ethyl acetate = 10/ 1 (50 mL) three times, the combined organic phase was dried over Na2S04, filtrated and then concentrated. The residue was purified by column chromatography to give Compound AT (3.3g).
Step 3: To a solution of Compound AT (4.5 g, 11.8 mmol) in THF (60 mL) was added di- ie/t-butyl dicarbonate and palladium hydroxide on carbon (1.0 g). The reaction mixture was heated to 45 °C overnight under pressure hydrogen atmosphere. The reaction mixture was filtrated and concentrated. The residue was purified by column chromatography to give
Compound AU (3.6g).
Step 4: To a solution of Compound AU (760 mg, 1.89 mmol) in methanol (4.0 mL) at 55°C was added dropwise sodium hydroxide (98 mg, 2.46 mmol) in water (1 mL). The reaction mixture was stirred at 55°C for 2 hours. The reaction mixture was cooled down and neutralized to pH 3.0, and then extracted with ethyl acetate (30 mL) three times. The combined organic phase was dried over Na2S04, filtrated and then concentrated to give crude Compound AV (660 mg).
Step 5: To a solution of Compound AV (776 mg, 2.0 mmol) in dichloromethane (8.0 mL) was added cyclopropyl amine (120 mg, 2.0 mmol), HATU (950 mg, 2.5 mmol) and
diisopropylethylamine (0.5 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched by adding ice-water, and then extracted with
dichloromethane (30 mL) three times. The combined organic phase was dried over Na2S04, and then filtrated and concentrated to give crude Compound AW (578 mg).
Step 6: To a mixture of phenylsilane (1.5 mL) and [Ir(COD)2Cl]2 (7 mg, 0.01 mmol) in dichloromethane (1.5 mL) was added Compound AW (128 mg, 2.0 mmol). The reaction mixture was stirred at 40°C overnight. The reaction mixture was concentrated and then diluted with dichloromethane (20 mL), then quenched by adding 3 drops of hydrochloride in dioxane solution (3N). The reaction mixture was washed with water. The organic phase was separated and dried over Na2S04, and then filtrated and concentrated. The residue was purified by column
chromatography to give crude Compound AX (70 mg).
Step 7: To a solution of Compound AX (72 mg, 0.174 mmol) in dichloromethane (2.0 mL) was added 4-nitrophenyl chloroformate (70 mg, 0.35 mmol) and diisopropylethylamine (5 drops). After the reaction mixture was heated to 40°C for 2 hours, it was concentrated and the residue was purified by column chromatography to give Compound AY (81 mg).
Step 8: The mixture of Compound AY (578 mg, 1.0 mmol) and TFA/DCM=2/1 (9 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated and added toluene for co-evaporation to remove trifluoroacetic acid. The residue was dissolved in dichloromethane (8.0 mL), and then diisopropylethylamine (2 mL) was added. The reaction mixture was heated to 40°C for 3 hours. The reaction mixture was concentrated to give Compound AR (239 mg, crude).
Example 46:
2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-3-o^
yl]cyclopropyl] acetic acid
Figure imgf000115_0001
Preparation of Example 46:
Figure imgf000116_0001
The title compound was prepared in analogy to Example 1 by using 4-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]butanoic acid (Compound 46-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 46 was obtained as a light yellow solid (65 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.42 (dd, / = 6.1, 8.7 Hz, 1H), 7.24 (dd, / = 2.8, 8.8 Hz, 1H), 7.05 (dt, / = 2.5, 8.4 Hz, 1H), 6.17 (s, 1H), 4.15 - 4.02 (m, 1H), 3.96 - 3.71 (m, 3H), 3.66 - 3.53 (m, 4H), 3.22 - 3.07 (m, 2H), 2.90 (d, / = 11.0 Hz, 1H), 2.80 (d, / = 9.0 Hz, 1H), 2.68 - 2.56 (m, 1H), 2.55 - 2.46 (m, 1H), 2.37 (dt, / = 3.1, 11.6 Hz, 1H), 2.18 (t, / = 10.9 Hz, 1H), 1.03 - 0.81 (m, 4H), MS: calc'd 603 (MH+), measured 603 (MH+).
Preparation of 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yljbutanoic acid (Compound 46-A):
Figure imgf000116_0002
46-B 46-C 46-A
Step 1: iert-Butyl (3S)-3-formyl-4-methyl-piperazine-l-carboxylate (Compound S, 346 mg, 1 mmol) in dichloromethane (3 mL) and Et3N (0.5 mL) was added 4-aminobutanoic acid (103 mg,l mmol). The reaction mixture was stirred for 1 hour at room temperature, then concentrated under reduced pressure. Then methanol (5 mL) and sodium cyanoborohydride (248 mg, 4 mmol) was added and the reaction mixture was stirred for another 3 hours at room temperature. The mixture was concentrated under reduced pressure to give crude compound 46-B.
Step 2: Compound 46-B in THF (10 mL) was added potassium ie/t-butoxide (224 mg, 2 mmol), the reaction mixture was stirred at 80 °C for 4 h. The solution was cooled to room temperature and acidified to pH 5 with aqueous HC1 solution. The mixture was then extracted with ethyl acetate 3 times. The combined organic layers were washed with brine, dried over Na2S04, and concentrated under reduced pressure to give crude compound 46-C (301mg).
Step 3: To a stirred solution of compound 46-C (301 mg, 0.92mmol) was dissolved in dichloromethane (4 mL) and treated with trifluoroacetic acid (2 mL) at room temperature. After the reaction mixture was stirred at room temperature for 1 hour, the solvent was removed in vacuo to give 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]butanoic acid (Compound 46-A) which was used directly.
Example 47:
2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopropyl] acetic acid
Figure imgf000117_0001
Preparation of Example 47:
Figure imgf000118_0001
The title compound was prepared in analogy to Example 1 by using 2-[l-[(8aR)-3-oxo- 1,5, 6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazin-2yl]cyclopropyl] acetic acid (Compound 47-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 47 was obtained as a light yellow solid (62 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.42 (dd, / = 6.1, 8.7 Hz, 1H), 7.24 (dd, / = 2.8, 8.8 Hz, 1H), 7.05 (dt, / = 2.5, 8.4 Hz, 1H), 6.17 (s, 1H), 4.15 - 4.02 (m, 1H), 3.96 - 3.71 (m, 3H), 3.66 - 3.53 (m, 4H), 3.22 - 3.07 (m, 2H), 2.90 (d, / = 11.0 Hz, 1H), 2.80 (d, / = 9.0 Hz, 1H), 2.68 - 2.56 (m, 1H), 2.55 - 2.46 (m, 1H), 2.37 (dt, / = 3.1, 11.6 Hz, 1H), 2.18 (t, / = 10.9 Hz, 1H), 1.03 - 0.81 (m, 4H). MS: calc'd 603 (MH+), measured 603 (MH+).
Preparation of 2-[l-[(8aR)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin- 2yl]cyclopropyl]acetic acid (Compound 47-A):
Compound 47-A was prepared in analogy to compound Q in Example 19 by using methyl 2-(l-aminocyclopropyl)acetate hydrochloride salt (for its synthesis, refer to: Sandstroem A., et al, Bioorganic & Medicinal Chemistry, 16(10), 5590-5605; 2008) instead of ethyl 3-amino-2,2- dimethyl-propanoate hydrochloride salt.
Example 48:
2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopropyl] acetic acid
Figure imgf000119_0001
Figure imgf000119_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6-
(bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-l) and 2-[l-[(8aR)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2yl]cyclopropyl]acetic acid (Compound 47-A) instead of (R)-6-bromomethyl-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 48 was obtained as a light yellow solid (76 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95 (s, 1H), 7.76 (s, 1H), 7.37 - 7.23 (m, 2H), 7.21 - 7.10 (m, 1H), 6.24 (s, 1H), 4.04 (d, / = 7.0 Hz, 3H), 3.95 - 3.77 (m, 3H), 3.66 - 3.54 (m, 1H), 3.20 - 3.08 (m, 2H), 2.95 - 2.86 (m, 1H), 2.86 - 2.74 (m, 1H), 2.67 - 2.57 (m, 1H), 2.55 - 2.45 (m, 1H), 2.42 - 2.30 (m, 1H), 2.23 - 2.12 (m, 1H), 1.13 (t, / = 7.2 Hz, 3H), 1.01 - 0.81 (m, 4H). MS: calc'd 617 (MH+), measured 617 (MH+).
Preparation of ethyl (4R)-6-(bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2- yl-l,4-dihydropyrimidine-5-carboxylate (compound C-l): Compound C-1 was prepared in analogy to compound C by using ethyl acetoacetate and 2- chloro-3-fluorobenzaldehyde instead of methyl acetoacetate and 2-chloro-4-fluorobenzaldehyde.
Example 49:
(lS,2R)-2-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl- 1 ,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin- 2-yl]cyclopentanecarboxylic acid
Figure imgf000120_0001
Preparation of Exam le 49:
Figure imgf000120_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and (lR,2R)-2-[(8aS)-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazin-2-yl]cyclopentanecarboxylic acid (Compound 49-A) instead of (R)-6-bromomethyl-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 49 was obtained as a light yellow solid (48 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.3 Hz, 1H), 7.27 (s, 2H), 7.21 - 7.12 (m, 1H), 6.24 (s, 1H), 4.47 - 4.38 (m, 1H), 4.17 - 3.98 (m, 3H), 3.97 - 3.86 (m, 2H), 3.83 - 3.75 (m, 1H), 3.59 (s, 1H), 3.25 - 3.11 (m, 2H), 3.03 - 2.94 (m, 1H), 2.93 - 2.82 (m, 1H), 2.77 - 2.68 (m, 1H), 2.45 - 2.35 (m, 1H), 2.29 - 2.17 (m, 1H), 2.11 - 1.84 (m, 3H), 1.82 - 1.68 (m, 3H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Preparation of (lR,2R)-2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin- 2-yl]cyclopentanecarboxylic acid (Compound 49-A):
Compound 49-A was prepared in analogy to compound Q in Example 19 by using ethyl (lR,2R)-2-aminocyclopentanecarboxylate (Accela Chembio Co., Ltd, SY024586) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 50:
(lR,2R)-2-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin- 2-yl]cyclopentanecarboxylic acid
Figure imgf000121_0001
Preparation of Example 50:
Figure imgf000122_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and (lS,2R)-2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2-yl]cyclopentanecarboxylic acid (Compound 50-A) instead of (R)-6-bromomethyl-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 50 was obtained as a light yellow solid (30 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 6.97-7.39 (m, 2H), 6.24 (s, 1H), 4.42 (d, / = 9.8 Hz, 2H), 3.73-4.19 (m, 5H), 3.52 (m, 4H), 3.12-3.23 (m, 2H), 2.66-2.96 (m, 2H), 2.11-2.47 (m, 3H), 1.60-2.05 (m, 4H), 1.13 ppm (t, / = 7.2 Hz, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Preparation of (lS,2R)-2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin- 2-yl]cyclopentanecarboxylic acid (Compound 50-A):
Compound 50-A was prepared in analogy to compound Q in Example 19 by using ethyl
(lS,2R)-2-aminocyclopentanecarboxylate trifluoroacetic acid salt (compound 50-B) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Preparation of ethyl (lS,2R)-2-aminocyclopentanecarboxylate trifluoroacetic acid salt (compound 50-B):
Figure imgf000122_0002
(lR,2S)-2-(Boc-amino)cyclopentanecarboxylate (CAS: 1140972-29-7, TCI) (1 mmol) was dissolved in CH2CI2 (3 mL) followed by the slow addition of TFA (1 mL) at 0 °C. The reaction mixture was stirred at rt for 1 hour and then the solvent was removed under vacuum to give the crude product 50-B, which was used directly in the next step.
Example 51:
(lR,2S)-2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5- a]pyrazin-2-yl]cyclopentanecarboxyli
Figure imgf000123_0001
Preparation of Example 51:
Figure imgf000123_0002
The title compound was prepared in analogy to Example 1 by using (lR,2S)-2-[(8aS)-3- oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]cyclopentanecarboxylic acid TFA salt (Compound 51-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 51 was obtained as a light yellow solid (68 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.07 - 7.89 (m, 1H), 7.78 (d, / = 3.0 Hz, 1H), 7.44 (t, / = 6.9 Hz, 1H), 7.25 (dd, / = 2.5, 8.8 Hz, 1H), 7.06 (dt, / = 2.5, 8.4 Hz, 1H), 6.18 (s, 1H), 4.41 (q, / = 8.6 Hz, 1H), 4.19 (d, / = 16.8 Hz, 1H), 4.05 - 3.79 (m, 3H), 3.64 - 3.57 (m, 4H), 3.27 - 3.14 (m, 1H), 3.10 (dd, / = 4.3, 9.0 Hz, 1H), 2.99 (br. s., 1H), 2.94 - 2.77 (m, 2H), 2.48 (br. s., 1H), 2.29 (br. s., 1H), 2.08 - 1.84 (m, 3H), 1.84 - 1.69 (m, 3H). MS: calc'd 617 (MH+), measured 617 (MH+).
Preparation of (lR,2S)-2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin- 2-yl]cyclopentanecarboxylic acid TFA salt (Compound 51-A):
Compound 51-A was prepared in analogy to compound Q in Example 19 by using ethyl (lR,2S)-2-aminocyclopentanecarboxylate (Accela Chembio Co., Ltd, CAS: 197916-36-2) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 52:
(lS,2S)-2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazin-2-yl]cyclopentanecarboxylic acid
Figure imgf000124_0001
Preparation of Example 52:
Figure imgf000124_0002
The title compound was prepared in analogy to Example 1 by using (lS,2S)-2-[(8aS)-3- oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]cyclopentanecarboxylic acid TFA salt (Compound 52-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 52 was obtained as a light yellow solid (1.7 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 1H NMR (MeOD, 400MHz): d = 7.97 (d, / = 3.0 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.42 (dd, / = 6.0, 8.8 Hz, 1H), 7.24 (dd, / = 2.8, 8.8 Hz, 1H), 7.06 (dt, / = 2.8, 8.4 Hz, 1H), 6.18 (s, 1H), 4.50 - 4.25 (m, 1H), 4.09 (d, / = 17.1 Hz, 1H), 3.98 - 3.72 (m, 3H), 3.61 (s, 3H), 3.52 (t, / = 8.9 Hz, 1H), 3.26 - 3.01 (m, 2H), 2.96 - 2.72 (m, 3H), 2.41 - 2.17 (m, 2H), 2.05 - 1.84 (m, 3H), 1.81 - 1.67 (m, 3H). MS: calc'd 617 (MH+), measured 617 (MH+).
Preparation of (lS,2S)-2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]cyclopentanecarbox lic acid TFA salt (Compound 52-A):
Compound 52-A was prepared in analogy to compound Q in Example 19 by using ethyl (lS,2S)-2-aminocyclopentanecarboxylate (Accela Chembio Co., Ltd, CAS: 752181-59-2) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 53:
4-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]butanoic acid
Figure imgf000125_0001
Preparation of Example 53:
Figure imgf000126_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and 4-[(8aS)-3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazin- 2-yl]butanoic acid (Compound 46-A) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro- phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 53 was obtained as a light yellow solid (2 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.3 Hz, 1H), 7.27 (s, 2H), 7.16 (s, 1H), 6.24 (s, 1H), 4.18 - 4.01 (m, 3H), 3.92 (d, / = 16.8 Hz, 3H), 3.49 (s, 1H), 3.30 - 3.25 (m, 1H), 3.25 - 3.15 (m, 2H), 3.12 - 3.04 (m, 1H), 2.97 - 2.81 (m, 2H), 2.33 (s, 3H), 2.26 - 2.14 (m, 1H), 1.85 (d, / = 7.0 Hz, 2H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 54:
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-butanoic acid
Figure imgf000127_0001
Preparation of Example 54:
Figure imgf000127_0002
The title compound was prepared in analogy to Example 1 by using 4-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-butanoic acid TFA salt
(Compound 54-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D).
Example 54 was obtained as a light yellow solid (23 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.01 (d, / = 3.0 Hz, 1H), 7.90 (d, / = 3.0 Hz, 1H), 7.53 (dd, / = 5.9, 8.7 Hz, 1H), 7.29 (dd, / = 2.6, 8.7 Hz, 1H), 7.17 - 7.06 (m, 1H), 6.20 (s, 1H), 4.77 - 4.64 (m, 1H), 4.57 - 4.42 (m, 1H), 4.27 - 4.12 (m, 1H), 4.07 (dd, / = 3.3, 14.8 Hz, 1H), 3.75 - 3.62 (m, 5H), 3.58 (t, / = 9.0 Hz, 1H), 3.51 - 3.37 (m, 2H), 3.27 - 3.02 (m, 4H), 1.95 - 1.82 (m, 1H), 1.80 - 1.66 (m, 1H), 1.31 - 1.19 (m, 6H).. MS: calc'd 619 (MH+), measured 619 (MH+).
Preparation of 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-butanoic acid TFA salt (Compound 54-A):
Figure imgf000128_0001
54-E
Step 1: A mixture of 2,2-dimethylbutyrolactone (6.84 g, 60 mmol) and KOH (3.36 g) in H20 (60 mL) was heated at reflux for 2 h. The solution was cooled to room temperature and acidified to pH 5 with aqueous HCl solution. The mixture was then extracted with ethyl acetate 3 times. The combined organic layers were washed with brine, dried over Na2S04, concentrated under reduced pressure to give 4-hydroxy-2,2-dimethyl-butanoic acid compound 54-B (4 g).
Step 2: To the mixture of compound 54-B (2.2 g, 16.6 mmol) in ethyl ether (16 mL) and methanol (24 mL) at 0 °C was added a hexane solution (2.0 M) of trimethylsilyldiazomethane (12.5 mL, 25 mmol). The reaction mixture was stirred at 0 °C for 1 h. The solvent was evaporated and the residue was taken up in ethyl acetate, washed successively with diluted aqueous HCl solution, saturated NaHC03 solution and brine. The mixture was dried over Na2S04 and concentrated to give 4-hydroxy-2,2-dimethyl-butyric acid methyl ester compound 54-C (1.5 g).
Step 3: To a solution of the alcohol 54-C (45 mg, 0.34 mmol) in THF (4 mL) at 0°C were added Ph3P (136 mg, 0.52 mmol), imidazole (71 mg, 1.04 mmol), and I2 (132 mg, 0.52 mmol). After 1 h, the reaction mixture was quenched with saturated Na2S203 solution. The aqueous layer was extracted twice with hexanes. The organic layer were dried over Na2S04 and concentrated under vacuum to give compound 54-D as a crude product.
Step 4: To a stirred solution of compound M (256 mg, 1 mmol) in DMF (2 mL ) was added NaH (48 mg, 2 mmol) at room temperature. The reaction mixture was stirred 20 min at room temperature, then compound 54-D (256 mg, 1 mmol) was added. After the reaction mixture was stirred for 4 hours at room temperature, EA was added and the mixture was washed with water and brine. The mixture was dried over Na2S04, and concentrated under reduced pressure to give the crude product, which was purified by column to give compound 54-E (150 mg).
Step 5: To a stirred solution of compound 54-E (150 mg, 0.4 mmol) in THF (5 mL) and water (2 mL) was added LiOH (96 mg 2.4 mmol). After the reaction mixture was stirred at 80 °C for 18 h, it was concentrated under reduced pressure to give the crude product, which was dissolved in DCM (4 mL) and treated with TFA (4 mL). The mixture was stirred for 2 hours at room temperature, then it was concentrated under reduced pressure to give the crude product 54- A which was used directly.
Example 55:
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 3,3-dimethyl-butanoic acid
Figure imgf000129_0001
Preparation of Example 55:
Figure imgf000130_0001
The title compound was prepared in analogy to Example 1 by using 4-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-3,3-dimethyl-butanoic acid TFA salt (Compound 55-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D).
Example 55 was obtained as a light yellow solid (22 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.3 Hz, 1H), 7.50 - 7.35 (m, 1H), 7.29 - 7.20 (m, 1H), 7.12 - 7.01 (m, 1H), 6.18 (s, 1H), 4.20 - 4.06 (m, 1H), 3.94 (s, 3H), 3.61 (s, 4H), 3.19 (d, / = 14.6 Hz, 3H), 3.08 - 2.99 (m, 1H), 2.97 - 2.82 (m, 2H), 2.47 - 2.34 (m, 1H), 2.27 (s, 3H), 1.07 (s, 6H). MS: calc'd 619 (MH+), measured 619 (MH+).
Preparation of 4-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-3,3- dimethyl-butanoic acid TFA salt (Compound 55-A):
Figure imgf000131_0001
55-B
Figure imgf000131_0002
Step 1: 4,4-Dimethyl-2-pyrrolidinone (2.52 g, 22.3 mmol) was added to a mixture of concentrated HC1 (50 mL) and water (50 mL) and the resulting mixture was refluxed at 120 °C for 20 hours. After it was cooled to room temperature, the mixture was washed twice with dichloromethane. The aqueous layer was evaporated to give 4-amino-3,3-dimethyl-butyric acid hydrochloride compound 55-B (3.4 g) as a white solid.
Step 2: Aldehyde S (346 mg, 1 mmol) in dichloromethane (3 mL) and Et3N (0.5 mL) was added compound 55-B (131 mg, 1 mmol). The reaction mixture was stirred for 1 hour at room temperature, then concentrated under reduced pressure. Methanol (5 mL) was added followed by the addition of sodium cyanoborohydride (248 mg, 4 mmol). After the reaction mixture was stirred at room temperature for 1 h, it was concentrated under reduced pressure to give crude product 55-C.
Step 3: Compound 55-C in THF (10 mL) was added potassium ie/t-butoxide (224 mg, 2 mmol), then the reaction mixture was stirred at 80 °C for 4 h. The solution was cooled to room temperature and acidified to pH 5 with aqueous HC1 solution. The mixture was then extracted with ethyl acetate 3 times. The combined organic layers were washed with brine, dried over Na2S04, and concentrated under reduced pressure to give crude product 55-D.
Step 4: To a stirred solution of compound 55-D(301mg, 0.92mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (2 mL) at room temperature. After the reaction mixture was stirred at room temperature for 1 hour, the solvent was removed under vacuum to give crude product 55-A which was used directly.
Example 56:
(R)-6-[(S)-2-(2-Carboxy-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]- 4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000132_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and 3-[(8aS)-3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l, 5-a]pyrazin- 2-yl] propanoic acid TFA salt (Compound 56-A) instead of (R)-6-bromomethyl-4-(2-chloro-4- fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 56 was obtained as a light yellow solid (60 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95-8.00 (m, 1H), 7.79 (d, 1H), 7.25-7.36 (m, 2H), 7.12-7.22 (m, 1H), 6.25 (s, 1H), 4.24 (d, 1H), 4.06 (m, 3H), 3.86-4.00 (m, 2H), 3.50-3.62 (m, 2H), 3.36-3.50 (m, 1H), 3.24 (m, 1H), 3.15 (m, 1H), 3.04 (d, 2H), 2.56 (m, 3H), 2.40 (br. s., 1H), 1.13 (m, 3H). MS: calc'd 591 (MH+), measured 591 (MH+).
Preparation of 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]propanoic acid TFA salt (Compound 56-A):
Figure imgf000133_0001
Step 1. To a stirred solution of compound M (150 mg, 0.62 mmol) in THF (3 mL) was added methyl acrylate (534 mg, 6.20 mmol) at room temperature, followed by a small amount of NaOH as a catalyst. LC-MS indicated compound M was consumed completely and the product 56-B was formed already. The resulting mixture was stirred at rt for 6 hours. The reaction mixture was then concentrated and directly used in the next step without further purification. The crude product amount was 180 mg.
Step 2. To a solution of compound 56-B (180 mg, 0.55 mmol) in THF (3 mL) was added a solution of lithium hydroxide monohydrate (116 mg, 2.75 mmol) in H20 (1 mL) at room temperature. The resulting mixture was stirred at room temperature for 3 hours. LC-MS showed starting material 56-B was consumed completely. The mixture was adjusted to pH 4-5 with 1 N HC1, then concentrated. The residue was used directly in the next step and the amount of crude product 56-C was 300 mg.
Step 3. To a solution of 56-C (crude 300 mg, 0.55 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (3 mL) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and the residue was directly used in the next step. The amount of crude product 56-A was 350 mg.
Example 57:
(R)-6-[(S)-2-((R)-2-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin- 7-ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carboxylic acid ethyl ester
Figure imgf000134_0001
Figure imgf000134_0002
o
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate (compound C-1) and (3R)-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2-yl]butanoic acid TFA salt (Compound 57-A) instead of (R)-6-bromomethyl-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[ l,2-c] [l,3]oxazin-6-one (Compound D). Example 57 was obtained as a light yellow solid (48 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.02 (d, IH), 7.91 (d, IH), 7.33-7.41 (m, 2H), 7.21-7.29 (m, IH), 6.27 (s, IH), 4.72 (d, IH), 4.54 (d, IH), 4.27-4.38 (m, IH), 4.03-4.19 (m, 4H), 3.60-3.74 (m, 3H), 3.38-3.48 (m, IH), 3.04-3.25 (m, 3H), 2.56-2.66 (m, IH), 2.47-2.56 (m, IH), 1.27 (d, 3H), 1.13 (m, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Preparation of (3R)-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]butanoic acid TFA salt (Compound 57-A): Compound 57-A was prepared in analogy to compound Q in Example 19 by using methyl (3R)-3-aminobutanoate hydrochloride salt (compound 57-B) instead of ethyl 3-amino-2,2- dimethyl-propanoate hydrochloride salt.
Preparation of methyl (3R)-3-aminobutanoate hydrochloride salt (compound 57-B): Compound 57-B was prepared in analogy to compound W in Example 20 by using (R)-3- aminobutanoic acid instead of DL-3-aminoisobutyric acid.
Example 58:
(R)-6-[(S)-2-((S)-2-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin- 7-ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carbox lic acid ethyl ester
Figure imgf000135_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-l) and (3S)-3-[(8aS)-3-oxo- 1,5, 6,7,8, 8a-hexahydroimidazo[ 1,5- a]pyrazin-2-yl]butanoic acid TFA salt (Compound 58-A) instead of (R)-6-bromomethyl-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[ l,2-c] [l,3]oxazin-6-one (Compound D). Example 58 was obtained as a light yellow solid (50 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.01 (d, IH), 7.90 (d, IH), 7.33-7.40 (m, 2H), 7.21-7.28 (m, IH), 6.27 (s, IH), 4.66 (d, IH), 4.49 (d, IH), 4.34-4.42 (m, IH), 4.20-4.20 (m, IH), 4.04-4.19 (m, 4H), 3.56-3.66 (m, 3H), 3.42-3.50 (m, IH), 3.22 (m, IH), 3.01-3.13 (m, 2H), 2.50-2.62 (m, 2H), 1.23 (d, 3H), 1.13 (m, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Preparation of (3S)-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]butanoic acid TFA salt (Compound 58-A):
Compound 58-A was prepared in analogy to compound Q in Example 19 by using methyl (3S)-3-aminobutanoate hydrochloride salt (compound 58-B) instead of ethyl 3-amino-2,2- dimethyl-propanoate hydrochloride salt.
Preparation of methyl (3R)-3-aminobutanoate hydrochloride salt (compound 58-B):
Compound 58-B was prepared in analogy to compound W in Example 20 by using (S)-3- aminobutanoic acid instead of DL-3-aminoisobutyric acid.
Example 59:
(R)-6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin- 7-ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carboxylic acid methyl ester
Figure imgf000136_0001
Preparation of Example 59:
Figure imgf000137_0001
The title compound was prepared in analogy to Example 1 by using l-[[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]methyl]cyclobutanecarboxylic acid TFA salt (Compound 59-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D).
Example 59 was obtained as a light yellow solid (15 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96 (d, IH), 7.76 (d, IH), 7.42 (m, IH), 7.24 (m, IH), 7.06 (m, IH), 6.17 (s, IH), 4.08 (d, IH), 3.90 (d, 2H), 3.82-3.86 (m, IH), 3.66-3.72 (m, IH), 3.61 (s, 3H), 3.54 (d, IH), 3.47 (m, IH), 3.14-3.23 (m, IH), 3.05 (m, IH), 2.90 (d, IH), 2.80 (d, IH), 2.39-2.47 (m, 2H), 2.31-2.39 (m, IH), 2.16 (m, IH), 1.99-2.09 (m, 3H), 1.89-1.98 (m, IH). MS: calc'd 617 (MH+), measured 617 (MH+).
Preparation of l-[[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl] methyl] cyclobutanecarboxylic acid TFA salt (Compound 59-A):
Compound 59-A was prepared in analogy to compound Q in Example 19 by using 1- aminomethyl-cyclobutanecarboxylic acid ethyl ester (for its synthesis, please refer to: Cao, Sheldon X. et al PCT Int. Appl. (2009), WO 2009067547) instead of ethyl 3-amino-2,2- dimethyl-propanoate hydrochloride salt.
Example 60:
6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-((R)-2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carboxylic acid ethyl ester
Figure imgf000138_0001
Preparation of Exam le 60:
Figure imgf000138_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate (compound C-1) and l-[[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin- 2-yl] methyl] cyclobutanecarboxylic acid TFA salt (Compound 59-A) instead of (R)-6- bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 59 was obtained as a light yellow solid (15 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.96 (d, IH), 7.76 (d, IH), 7.23-7.35 (m, 2H), 7.16 (m, IH), 6.24 (s, IH), 4.02-4.13 (m, 3H), 3.81-3.97 (m, 3H), 3.65-3.74 (m, IH), 3.43-3.57 (m, 2H), 3.20 (m, IH), 3.05 (m, IH), 2.92 (d, IH), 2.83 (d, IH), 2.31-2.48 (m, 3H), 2.17 (br. s., IH), 1.92-2.12 (m, 4H), 1.09- 1.17 (m, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Example 61 (mixture of 2 isomers): (R)-6-[(S)-2-((lR,3S)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5- a]pyrazin-7-ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine- 5-carboxylic acid methyl ester and (R)-6-[(S)-2-((lS,3R)-3-Carboxy-cyclopentyl)-3-oxo- hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester
Figure imgf000139_0001
Preparation of Example 61:
Figure imgf000139_0002
mixture of two cis isomers on cyclopentane The title compound was prepared in analogy to Example 1 by using c 5,-3-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]cyclopentanecarboxylic acid TFA salt (Compound 61-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 61 was obtained as a light yellow solid (30 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (m, 1H), 7.76 (d, 1H), 7.42 (m, 1H), 7.24 (m, 1H), 7.06 (m, 1H), 6.17 (s, 1H), 4.24- 4.35 (m, 1H), 4.10 (d, 1H), 3.82-3.94 (m, 3H), 3.61 (s, 3H), 3.53 (m, 1H), 3.03-3.23 (m, 2H), 2.77-2.93 (m, 3H), 2.36 (m, 1H), 2.04-2.23 (m, 2H), 1.67-2.00 (m, 5H). MS: calc'd 617 (MH+), measured 617 (MH+).
Preparation of ci*s-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]cyclopentanecarbox lic acid TFA salt (Compound 61-A):
Compound 61-A was prepared in analogy to compound Q in Example 19 by using dimethyl 3-aminocyclopentanecarboxylate methyl ester hydrochloride salt (compound 61-B) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Preparation of cis-methyl 3-aminocyclopentanecarboxylate methyl ester
hydrochloride salt (compound 61-B):
Compound 61-B was prepared in analogy to compound W in Example 20 by using cis-3- aminocyclopentanecarboxylic acid (Accela Chembio Co., Ltd, CAS: 49805-32-5) instead of DL- 3-aminoisobutyric acid. Example 62(mixture of 2 isomers):
(R)-6-[(S)-2-((lR,3S)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5- a]pyrazin-7-ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine- 5-carboxylic acid ethyl ester and (R)-6-[(S)-2-((lS,3R)-3-Carboxy-cyclopentyl)-3-oxo- hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid eth l ester
Figure imgf000140_0001
Preparation of Example 62:
Figure imgf000141_0001
mixture of two cis isomers on cyclopentane
62
mixture of two cis isomers on cyclopentane
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and c 5,-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2-yl]cyclopentanecarboxylic acid TFA salt (Compound 61-A) instead of (R)-6- bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 62 was obtained as a light yellow solid (50 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.97 (m, IH), 7.76 (d, IH), 7.23-7.34 (m, 2H), 7.09-7.19 (m, IH), 6.24 (s, IH), 4.23-4.34 (m, IH), 4.01-4.15 (m, 3H), 3.83-3.95 (m, 3H), 3.53 (m, IH), 3.04-3.23 (m, 2H), 2.77-2.95 (m, 3H), 2.36 (m, IH), 2.03-2.22 (m, 2H), 1.90-2.00 (m, 2H), 1.68-1.90 (m, 3H), 1.13 (m, 3H). MS: calc'd 631 (MH+), measured 631(MH+). Example 63 (mixture of two isomers):
(R)-6-[(S)-2-((lR,3R)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5- a]pyrazin-7-ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine- 5-carboxylic acid methyl ester and (R)-6-[(S)-2-((lS,3S)-3-Carboxy-cyclopentyl)-3-oxo- hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester
Figure imgf000142_0001
Preparation of Example 63:
Figure imgf000142_0002
mixture of two trans isomers on cyclopentane
The title compound was prepared in analogy to Example 1 by using trans -3-[(&aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]cyclopentanecarboxylic acid TFA salt (Compound 63-A) instead of hexahydro-pyrazino[ l,2-c] [l,3]oxazin-6-one (Compound D).
Example 63 was obtained as a light yellow solid (10 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, IH), 7.76 (d, IH), 7.42 (m, IH), 7.24 (m, IH), 7.06 (m, IH), 6.17 (s, IH), 4.39 (d, IH), 4.10 (d, IH), 3.84-3.92 (m, 3H), 3.61 (s, 3H), 3.49-3.53 (m, IH), 3.18 (d, IH), 3.06 (d, IH), 2.89 (br. s., 3H), 2.38 (d, IH), 2.07-2.19 (m, 3H), 1.86-1.97 (m, 3H), 1.70 (br. s., IH). MS: calc'd 617 (MH+), measured 617 (MH+). Preparation of tra«s-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]cyclopentanecarbox lic acid TFA salt (Compound 63-A):
Compound 63-A was prepared in analogy to compound Q in Example 19 by using trans- methyl 3-aminocyclopentanecarboxylate methyl ester hydrochloride salt (compound 63-B) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Preparation of tra«s-methyl 3-aminocyclopentanecarboxylate methyl ester
hydrochloride salt (compound 63-B):
Compound 63-B was prepared in analogy to compound W in Example 20 by using trans- 3-aminocyclopentanecarboxylic acid (for its synthesis, please refer to: Allan, Robin D.; Fong, Joyce Australian Journal of Chemistry (1986), 39(6), 855-64.) instead of DL-3-aminoisobutyric acid.
Example 64 (mixture of two isomers):
(R)-6-[(S)-2-((lR,3R)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5- a]pyrazin-7-ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine- 5-carboxylic acid ethyl ester and (R)-6-[(S)-2-((lS,3S)-3-Carboxy-cyclopentyl)-3-oxo- hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000143_0001
Preparation of Example 64: ,F
Figure imgf000144_0001
63-A
mixture of two trans isomers on cyclopentane
64
mixture of two trans isomers on cyclopentane
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and iraw5,-3-[(8aS)-3-oxo-l,5, 6,7,8, 8a-hexahydroimidazo[l,5- a]pyrazin-2-yl]cyclopentanecarboxylic acid TFA salt (Compound 63-A) instead of (R)-6- bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 64 was obtained as a light yellow solid (10 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.97 (m, IH), 7.76 (d, IH), 7.24-7.34 (m, 2H), 7.12-7.19 (m, IH), 6.24 (s, IH), 4.34-4.42 (m, IH), 4.02-4.14 (m, 3H), 3.83-3.94 (m, 3H), 3.51 (m, IH), 3.14-3.22 (m, IH), 3.04-3.10 (m, IH), 2.82-2.94 (m, 3H), 2.36 (m, IH), 2.05-2.20 (m, 3H), 1.81-1.98 (m, 3H), 1.65-1.74 (m, IH), 1.13 (m, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Example 65:
(R)-6-[2-(4-Carboxy-benzyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester
Figure imgf000145_0001
Preparation of Example 65:
Figure imgf000145_0002
The title compound was prepared in analogy to Example 1 by using 4-[(3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazin-2-yl)methyl]benzoic acid TFA salt (Compound 65- A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 65 was obtained as a light yellow solid (90 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00-8.06 (m, 3H), 7.91 (m, IH), 7.53 (m, IH), 7.40-7.45 (m, 2H), 7.30 (m, IH), 7.08-7.15 (m, IH), 6.20 (d, IH), 4.75 (m, IH), 4.48-4.62 (m, 3H), 4.12-4.25 (m, 2H), 3.68-3.78 (m, 2H), 3.65 (d, 3H), 3.44-3.58 (m, 2H), 3.16-3.28 (m, 2H), 3.09-3.15 (m, IH). MS: calc'd 639 (MH+), measured 639 (MH+).
Preparation of 4-[(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)methyl] benzoic acid TFA salt (Compound 65 -A): Compound 65-A was prepared in analogy to compound Q in Example 19 by using 4 aminomethyl-benzoic acid methyl ester hydrochloride instead of ethyl 3-amino-2,2-dimethyl propanoate hydrochloride salt.
Example 66:
(R)-6-[2-(4-Carboxy-benzyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester
Figure imgf000146_0001
Preparation of Example 66:
Figure imgf000146_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-l) and 4-[(3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)methyl]benzoic acid TFA salt (Compound 65-A) instead of (R)-6-bromomethyl-4-(2-chloro- 4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester
(Compound C) and hexahydro-pyrazino[ l,2-c] [l,3]oxazin-6-one (Compound D). Example 66 was obtained as a light yellow solid (82 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.99- 8.07 (m, 3H), 7.90 (m, IH), 7.40-7.46 (m, 2H), 7.32-7.39 (m, 2H), 7.21-7.29 (m, IH), 6.26 (d, IH), 4.75 (m, IH), 4.47-4.61 (m, 3H), 4.13-4.25 (m, 2H), 4.06-4.13 (m, 2H), 3.68-3.78 (m, 2H), 3.44-3.58 (m, 2H), 3.18-3.31 (m, IH), 3.07-3.17 (m, 2H), 1.13 (m, 3H). MS: calc'd 653 (MH+), measured 653 (MH+).
Example 67:
2-[2-[7-[[(4R)-4-(2-chloro-3-fluoro-pheny
dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2 yl]ethoxy]acetic acid
Figure imgf000147_0001
Preparation of Example 67:
Figure imgf000148_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and 2-[2-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)ethoxy] acetic acid (Compound 67-A) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro- phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 67 was obtained as a light yellow solid (2.5 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00 - 8.01 (d, / = 4.0Hz, 1 H), 7.90-7.89 (d, / = 4.0Hz, 1 H), 7.35-7.38 (m, 2 H), 7.24 (m, 1 H), 6.26 (s, 1 H), 4.66 (m, 1 H), 4.51 (m, 1 H), 4.05-4.40 (m, 5 H), 3.70-3.83 (m, 3 H), 3.52-3.70 (m, 3H), 3.40 (m, 3H), 3.32 (m, 2 H), 1.13 (m, 3H). MS: calc'd 621 (MH+), measured 621 (MH+).
Preparation of 2-[2-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)ethoxy]acetic acid (Compound 67-A):
Figure imgf000149_0001
Step 1: The mixture of methyl (+)-4-Boc-piperazine-2-carboxylate (CAS: 129799-08-2, 2.44g, 0.01 mol), TEA (1.52g, 0.015 mol) in DCM (10 mL) was added to a solution of (4- nitrophenyl) carbonochloridate (2.42 g, 0.012 mol) in DCM (10 mL). After 1 hour at rt, the organic layer was washed with water and saturated sodium bicarbonate solution, dried over sodium sulfate. After removal of solvent, the crude product 67-B was obtained and used in the next step without purification. MS: calc'd 410 (MH+), measured 410 (MH+).
Step 2: The mixture of compound 67-B (1.0 g, 2.44 mmol), 2-aminoethanol (1.0 g, 16.4 mmol), TEA (0.49 g, 4.88 mmol), nitromethane (2 mL) was heated at 130 °C with microwave for 3 hours. After removal of solvent, the residue was treated with water, extracted with ethyl acetate. Removal of solvent gave the crude product 67-C. MS: calc'd 300 (MH+), measured 300 (MH+).
Step 3: A mixture of compound 67-C (730 mg, 2.44 mmol) and BH3.THF (1M, 4.88 mL). After stirring for 24 hours at rt, the mixture was treated with saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate. After removal of solvent, the product 67-D was obtained . MS: calc'd 286 (MH+), measured 286 (MH+).
Step 4: A mixture of compound 67-D (0.5 g, 1.75 mmol) in THF (15 mL) was added t- BuOK (0.294g, 2.63 mmol). After stirring for 30 minutes, i-butyl bromoacetate (0.68 g, 3.5 mmol) was added into it. Then the mixture was stirred for another 2 hours at rt, quenched with water, extracted with ethyl acetate. After removal of solvent, the crude product 67-E was obtained and used in the next step. MS: calc'd 400 (MH+), measured 400 (MH+). Step 5: A mixture of compound 67-E (0.70 g, 1.75 mmol) in DCM (5 mL) was treated with TFA (2mL). After stirring for 1 hour at rt, the solvent and residue TFA was removed under reduced pressure to afford the product 67-A. MS: calc'd 244 (MH+), measured 244 (MH+).
Example 68:
2-[3-[7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6^
yl]propoxy] acetic acid
Figure imgf000150_0001
Preparation of Example 68:
Figure imgf000150_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and 2-[3-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)propoxy] acetic acid (Compound 68-A) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro- phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 68 was obtained as a light yellow solid (6.5 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.99 - 7.98 (d, / = 4.0Hz, 1 H), 7.81-7.82 (d, / = 4.0Hz, 1 H), 7.32 (m, 2 H), 7.21 (m, 1 H), 6.25 (s, 1 H), 3.90-4.35 (m, 6 H), 3.56 (m, 3 H), 3.10-3.40 (m, 4H), 2.60 (m, 2H), 1.85 (m, 2H), 1.15 (m, 3H). MS: calc'd 635 (MH+), measured 635 (MH+).
Preparation of 2-[3-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)propoxy] acetic acid (Compound 68-A):
Compound 68-A was prepared in analogy to Compound 67-A by using 3-aminopropan- l- ol instead of 2-aminoethanol.
Example 69:
Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[[2-(5-hydroxy-4,4-dimethyl-pentyl)-3- oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate
Figure imgf000151_0001
Preparation of Example 69:
Figure imgf000152_0001
The title compound was prepared in analogy to Example 1 by using 2-(5-hydroxy-4,4- dimethyl-pentyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-3-one (Compound 69-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 69 was obtained as a light yellow solid (55 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 - 7.98 (d, / = 4.0Hz, 1 H), 7.80-7.81 (d, / = 4.0Hz, 1 H), 7.45-7.48 (m, 1 H), 7.27 (m, 1 H), 7.08 (m, 1H), 6.18 (s, 1 H), 3.80-4.40 (m, 4 H), 3.65 (s, 3 H), 3.55 (m, 1H), 3.10-3.30 (m, 6 H), 2.50 (m, 2H), 1.50 (m, 2H), 1.25 (m, 2H), 0.89 (s, 6H). MS: calc'd 619 (MH+), measured 619 (MH+).
Preparation of 2-(5-hydroxy-4,4-dimethyl-pentyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-3-one (Compound 69-A):
Figure imgf000152_0002
69-B 69-A
ie/t-Butyl 2-(5-hydroxy-4,4-dimethyl-pentyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-7-carboxylate (Compound 69-B) (1 mmol) was dissolved in CH2CI2 (3 mL) followed by the slow addition of TFA (1 mL) at 0 °C. The reaction mixture was stirred at rt for 1 hour and then the solvent was removed under vacuum to give the crude product 69-A, which was used directly in the next step.
Preparation of tert-butyl 2-(5-hydroxy-4,4-dimethyl-pentyl)-3-oxo-5,6,8,8a- tetrahydro-lH-imidazo[l,5-a]pyrazine-7-carboxylate (Compound 69-B): Compound 69-B was prepared in analogy to Compound 67-D by using 5-amino-2,2- dimethyl-pentan- l-ol instead of 2-aminoethanol.
Example 70:
Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-hydroxyethyl)-3-oxo-5,6,8,8a- tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2 ^
carbox late
Figure imgf000153_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate (compound C-1) and 2-(2-hydroxyethyl)- 1,5, 6,7,8, 8a-hexahydroimidazo[ 1,5- a]pyrazin-3-one (Compound 70-A) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro-phenyl)- 2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 70 was obtained as a light yellow solid (45 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.01 - 8.02 (d, / = 4.0Hz, 1 H), 7.91-7.92 (d, / = 4.0Hz, 1 H), 7.38 (m, 2 H), 7.27 (m, 1 H), 6.27 (s, 1 H), 4.55-4.78 (m, 2 H), 4.10-4.25 (m, 4 H), 3.72 (m, 5 H), 3.45 (m, 2H), 3.10-3.35 (m, 7 H). MS: calc'd 563 (MH+), measured 563 (MH+).
Preparation of 2-(2-hydroxyethyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-3-one (Compound 70-A):
Figure imgf000154_0001
tert- tyl 2-(2-hydroxyethyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazine-7- carboxylate (Compound 67-D) (1 mmol) was dissolved in CH2C12 (3 mL) followed by the slow addition of TFA (1 mL) at 0 °C. The reaction mixture was stirred at rt for 1 hour and then the solvent was removed in vacuum to give the crude product 70-A, which was used directly in the next step.
Example 71:
Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-hydroxyethyl)-3-oxo-5,6,8,8a- tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carboxylate
Figure imgf000154_0002
Preparation of Example 71:
Figure imgf000155_0001
The title compound was prepared in analogy to Example 1 by using 2,2-dimethyl-5-(3- oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl)pentanoic acid (Compound 71-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 71 was obtained as a light yellow solid (45 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.01 - 8.02 (d, / = 4.0Hz, 1 H), 7.91-7.92 (d, / = 4.0Hz, 1 H), 7.53 (m, 1 H), 7.40 (m, 1 H), 7.10 (m, 1H), 6.20 (s, 1 H), 4.52-4.75 (m, 2 H), 4.10-4.25 (m, 2 H), 3.65 (m, 5 H), 3.45 (m, 1H), 3.10-3.35 (m, 4 H), 1.55 (m, 4H), 1.20 (s, 6H). MS: calc'd 563 (MH+), measured 563 (MH+).
Preparation of 2,2-dimethyl-5-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)pentanoic acid (Compound 71-A):
Figure imgf000155_0002
69-B 71-B 'Ί "Α
Step 1: A mixture of ie/t-butyl 2-(5-hydroxy-4,4-dimethyl-pentyl)-3-oxo-5,6,8,8a- tetrahydro-lH-imidazo[l,5-a]pyrazine-7-carboxylate (compound 69-B) (0.4g, 1.1 mmol) and pyridinium dichromate (1.7 g, 4.4 mmol) in DMF (10 mL) was stirred for 12 hours, then treated with water, adjusted pH<7 with acetic acid, extracted with ethyl acetate. After removal of solvent, the crude product 71-B was obtained. MS: calc'd 370 (MH+), measured 370 (MH+). Step 2: A mixture of compound 71-B (0.41g, 1.1 mmol), TFA (2 mL) in DCM (2 mL) was stirred for 1.2 hours at rt. After removal of solvent and TFA, the crude product 71 -A was obtained and used in the next step. MS: calc'd 270 (MH+), measured 270 (MH+).
Example 72:
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6^
yl]cyclohexanecarboxylic acid
Figure imgf000156_0001
Preparation of Example 72:
Figure imgf000156_0002
The title compound was prepared in analogy to Example 1 by using c ,s-4-[(2R)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]cyclohexanecarboxylic acid TFA salt (Compound 72-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 72 was obtained as a light yellow solid (30 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.42 (dd, / = 8.8, 6.3 Hz, 1H), 7.24 (dd, / = 8.8, 2.5 Hz, 1H), 7.06 (td, / = 8.5, 2.6 Hz, 1H), 6.17 (s, 1H), 4.10 (d, / = 16.8 Hz, 1H), 3.79- 3.97 (m, 3H), 3.55-3.70 (m, 4H), 3.48 (t, / = 8.9 Hz, 1H), 3.11-3.26 (m, 1H), 3.03 (dd, / = 9.3, 4.0 Hz, 1H), 2.71-2.96 (m, 3H), 2.04-2.42 (m, 5H), 1.77 (br. s., 2H), 1.46-1.62 ppm (m, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Preparation of ci*s-4-[(2R)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid TFA salt (Compound 72-A):
Compound 72-A was prepared in analogy to compound Q in Example 19 by using methyl c 5,-4-aminocyclohexanecarboxylate hydrochloride (CAS: 61367-16-6, TCI) instead of ethyl 3- amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 73:
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid
Figure imgf000157_0001
Preparation of Example 73:
Figure imgf000158_0001
The title compound was prepared in analogy to Example 1 by using trans-4-[(2R)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]cyclohexanecarboxylic acid TFA salt
(Compound 73-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D).
Example 73 was obtained as a light yellow solid (46 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.0 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.42 (dd, / = 8.8, 6.3 Hz, 1H), 7.24 (dd, / = 8.5, 2.8 Hz, 1H), 7.06 (td, / = 8.5, 2.5 Hz, 1H), 6.17 (s, 1H), 4.10 (d, / = 17.1 Hz, 1H), 3.78- 3.97 (m, 3H), 3.61 (s, 3H), 3.41-3.52 (m, 1H), 3.19 (d, / = 11.0 Hz, 1H), 3.03 (dd, / = 9.5, 4.0 Hz, 1H), 2.75-2.94 (m, 2H), 2.36 (dd, J = 11.7, 7.9 Hz, 2H), 1.93-2.24 (m, 5H), 1.77 (br. s., 2H), 1.53 ppm (d, / = 10.0 Hz, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Preparation of tra«s-4-[(2R)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid TFA salt (Compound 73-A):
Compound 73-A was prepared in analogy to compound Q in Example 19 by using methyl- iraw5,-4-amino-cyclohexanecarboxylic acid methyl ester (CAS: 61367-07-5, TCI) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 74:
3-[(8aS)-7-[[(4R)-4-(2-chlorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid
Figure imgf000159_0001
Preparation of Example 74:
Figure imgf000159_0002
The title compound was prepared in analogy to Example 1 by using methyl (4R)-6- (bromomethyl)-4-(2-chlorophenyl)-2-thiazol-2-yl- l,4-dihydropyrimidine-5-carboxylate
(Compound C-2) and 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-prop anoic acid (Compound Q) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro- phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 74 was obtained as a light yellow solid (6 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.3 Hz, 1H), 7.41 (td, / = 7.4, 1.8 Hz, 2H), 7.19-7.33 (m, 2H), 6.21 (s, 1H), 4.08 (d, J = n.l Hz, 1H), 3.79-3.96 (m, 3H), 3.60 (s, 2H), 3.51 (t, / = 9.2 Hz, 1H), 3.37-3.42 (m, 1H), 3.07-3.28 (m, 3H), 2.74-2.94 (m, 2H), 2.12-2.41 (m, 4H), 1.39 (d, / = 6.3 Hz, 2H), 1.18 ppm (d, / = 4.0 Hz, 3H). MS: calc'd 587 (MH+), measured 587 (MH+).
Preparation of methyl (4R)-6-(bromomethyl)-4-(2-chlorophenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate (Compound C-2): Compound C-2 was prepared in analogy to compound C by using 2-chlorobenzaldehyde instead of 2-chloro-4-fluorobenzaldehyde.
Example 75:
2-[[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrah^
yl] methyl] butanoic acid
Figure imgf000160_0001
Preparation of Example 75:
Figure imgf000160_0002
The title compound was prepared in analogy to Example 1 by using 2-[[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]methyl]butanoic acid TFA salt (Compound 75-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 75 was obtained as a light yellow solid (50 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.96-7.97 (m, 1H), 7.92 (d, / = 3.3 Hz, 1H), 7.54 (dd, / = 8.8, 6.0 Hz, 1H), 7.30 (dd, / = 8.7, 2.6 Hz, 1H), 7.12 (td, / = 8.3, 2.6 Hz, 1H), 6.20 (s, 1H), 4.64-4.81 (m, 2H), 4.46-4.60 (m, 1H), 4.01-4.26 (m, 2H), 3.60-3.78 (m, 5H), 3.35-3.57 (m, 3H), 3.03-3.29 (m, 3H), 2.62 (dtd, / = 14.1, 8.4, 5.5 Hz, 1H), 1.50-1.74 (m, 2H), 0.99 ppm (t, / = 7.4 Hz, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Preparation of 2-[[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl] methyl] butanoic acid TFA salt (Compound 75 -A):
Compound 75-A was prepared in analogy to compound Q by using methyl 2- (aminomethyl)butanoate (for its synthesis, please refer to: Kaptein, Bernardus; et al PCT Int. Appl. 2005, WO 2005085462) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 76:
3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid
Figure imgf000161_0001
Preparation of Example 76:
Figure imgf000162_0001
The title compound was prepared in analogy to Example 1 by using ethyl (4S)-6- (bromomethyl)-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl- l,4-dihydropyrimidine-5- carboxylate (Compound C-3) and 3-[(8aS)-3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazin- 2-yl]-2,2-dimethyl-propanoic acid (Compound Q) instead of (R)-6-bromomethyl-4-(2-chloro-4- fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 76 was obtained as a light yellow solid (132 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95 (d, / = 3.3 Hz, IH), 7.75 (d, / = 3.3 Hz, IH), 7.08-7.23 (m, 2H), 6.95 (t, / = 8.8 Hz, IH), 5.99 (s, IH), 4.02- 4.17 (m, 3H), 3.79-4.00 (m, 3H), 3.36-3.57 (m, 2H), 3.26-3.33 (m, IH), 3.17-3.25 (m, IH), 3.11 (dd, / = 9.3, 4.0 Hz, IH), 2.78-2.99 (m, 2H), 2.53 (d, / = 2.0 Hz, 3H), 2.39 (dd, / = 11.2, 8.2 Hz, IH), 2.14-2.26 (m, IH), 1.21 (d, / = 2.8 Hz, 6H), 1.15 ppm (t, / = 7.2 Hz, 3H). MS: calc'd 599 (MH+), measured 599 (MH+).
Preparation of ethyl (4S)-6-(bromomethyl)-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2- yl-l,4-dihydropyrimidine-5-carboxylate (Compound C-3):
Compound C-3 was prepared in analogy to compound C by using 2-methyl-3- fluorobenzaldehyde instead of 2-chloro-4-fluorobenzaldehyde and ethyl acetoacetate instead of methyl acetoacetate. Example 77:
3-[(8aS)-7-[[4-(4-chlorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid
Figure imgf000163_0001
Figure imgf000163_0002
The title compound was prepared in analogy to Example 1 by using methyl 6- (bromomethyl)-4-(4-chlorophenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate
(Compound C-4) and 3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-prop anoic acid (Compound Q) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro- phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 77 was obtained as a light yellow solid (60 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.99 (dd, / = 3.1, 1.4 Hz, 1H), 7.80 (d, / = 3.3 Hz, 1H), 7.26-7.42 (m, 4H), 5.64-5.82 (m, 1H), 4.06 (dd, / = 16.8, 4.3 Hz, 1H), 3.72-3.90 (m, 3H), 3.69 (s, 3H), 3.37-3.61 (m, 2H), 3.00-3.24 (m, 2H), 2.55-2.97 (m, 3H), 2.11-2.39 (m, 2H), 1.19 ppm (dd, / = 4.4, 2.9 Hz, 6H). MS: calc'd 587 (MH+), measured 587 (MH+). Preparation of methyl 6-(bromomethyl)-4-(4-chlorophenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate (Compound C-4):
Compound C-4 was prepared in analogy to compound C by using 4-chlorobenzaldehyde instead of 2-chloro-4-fluorobenzaldehyde without chiral SFC separation of dihydropyrimidine intermediate in Scheme 1- 1.
Example 78:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2-methoxy-propanoic acid
Figure imgf000164_0001
Pre aration of Example 78:
Figure imgf000164_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate (compound C-1) and 2-methoxy-3-(3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazin-2-yl)propanoic acid TFA salt (Compound 78-A) instead of (R)-6-bromomethyl-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 78 was obtained as a light yellow solid (25 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.01 (d, / = 3.3 Hz, 1H), 7.92 (d, / = 3.0 Hz, 1H), 7.33-7.43 (m, 2H), 7.19-7.30 (m, 1H), 6.27 (s, 1H), 4.76 (d, / = 16.1 Hz, 1H), 4.58 (d, / = 16.1 Hz, 1H), 3.96-4.21 (m, 6H), 3.41-3.83 (m, 10H), 3.10-3.31 (m, 5H), 1.13 ppm (t, / = 7.2 Hz, 3H). MS: calc'd 621 (MH+), measured 621 (MH+).
Preparation of 2-methoxy-3-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)propanoic acid TFA salt (Compound 78- A):
Compound 78-A was prepared in analogy to compound Q in Example 19 by using methyl 2-(aminomethyl)butanoate (for its synthesis, please refer to: Liang, Congxin; Feng, Yangbo U.S. Pat. Appl. Publ. 2007, US 20070072934) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 79:
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]spiro[3.3]heptane-6-carboxylic acid
Figure imgf000165_0001
Preparation of Example 79:
Figure imgf000166_0001
The title compound was prepared in analogy to Example 1 by using 2-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]spiro[3.3]heptane-6-carboxylic acid TFA salt (Compound 79-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D).
Example 79 was obtained as a light yellow solid (7 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.00 - 7.92 (m, 1H), 7.77 (d, / = 3.3 Hz, 1H), 7.42 (dd, / = 6.3, 8.5 Hz, 1H), 7.24 (dd, / = 2.5, 8.8 Hz, 1H), 7.06 (dt, / = 2.5, 8.4 Hz, 1H), 6.18 (s, 1H), 4.33 - 4.20 (m, 1H), 4.10 (dd, J = 4.4, 16.9 Hz, 1H), 3.96 - 3.73 (m, 4H), 3.66 - 3.58 (m, 3H), 3.57 - 3.46 (m, 1H), 3.21 - 2.97 (m, 3H), 2.95 - 2.80 (m, 2H), 2.73 (d, / = 10.3 Hz, 1H), 2.44 - 2.05 (m, 8H). MS: calc'd 626 (MH+), measured 626 (MH+).
Preparation of 2-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]spiro[3.3]heptane-6-carboxylic acid TFA salt (Compound 79-A):
Compound 79-A was prepared in analogy to compound Q in Example 19 by using methyl 2-aminospiro[3.3]heptane-6-carboxylate hydrochloride salt (PharmaBlock (Nanjing) R&D Co. Ltd , PBLG1036) instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 80:
5-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]pentanoic acid
Figure imgf000167_0001
Preparation of Example 80:
Figure imgf000167_0002
The title compound was prepared in analogy to Example 1 by using 5-[(8aS)-3-oxo- l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]pentanoic acid TFA salt (Compound 80-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 80 was obtained as a light yellow solid (18 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.02 (d, / = 3.0 Hz, 1H), 7.92 (d, / = 3.0 Hz, 1H), 7.54 (ddd, / = 1.5, 6.0, 8.8 Hz, 1H), 7.30 (dd, / = 2.5, 8.5 Hz, 1H), 7.22 - 7.09 (m, 1H), 6.20 (s, 1H), 4.76 (d, J = 16.1 Hz, 1H), 4.66 - 4.39 (m, 1H), 4.20 (td, / = 3.4, 11.7 Hz, 1H), 4.10 (td, / = 4.1, 14.8 Hz, 1H), 3.83 - 3.56 (m, 6H), 3.54 - 3.38 (m, 1H), 3.30 - 3.10 (m, 5H), 2.43 - 2.28 (m, 2H), 1.62 (dd, / = 3.1, 5.9 Hz, 4H). MS: calc'd 605 (MH+), measured 605 (MH+). Preparation of 5-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl]pentanoic acid TFA salt (Compound 80- A):
Compound 80-A was prepared in analogy to compound Q in Example 19 by using methyl 5-aminopentanoate hydrochloride salt instead of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt.
Example 81:
3-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclobutanecarboxylic acid
Figure imgf000168_0001
Pre aration of Example 81:
Figure imgf000168_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate (compound C-l) and 3-[(3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)methyl]cyclobutanecarboxylic acid TFA salt (Compound 81-A) instead of (R)-6- bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 81 was obtained as a light yellow solid (7 mg). 1H NMR (400 MHz, METHANOL- d4) d ppm 7.99 (d, / = 3.0 Hz, 1H), 7.84 (d, / = 2.3 Hz, 1H), 7.43 - 7.28 (m, 2H), 7.27 - 7.13 (m, 1H), 6.25 (s, 1H), 4.52 - 4.33 (m, 1H), 4.32 - 4.18 (m, 1H), 4.07 (q, / = 7.0 Hz, 3H), 3.68 - 3.47 (m, 2H), 3.32 - 2.98 (m, 7H), 2.65 (d, / = 7.5 Hz, 3H), 2.44 - 2.27 (m, 2H), 2.10 - 1.98 (m, 2H), 1.13 (t, J = 7.2 Hz, 3H). MS: calc'd 631 (MH+), measured 631 (MH+).
Preparation of 3-[(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2- yl)methyl]cyclobutanecarboxylic acid TFA salt (Compound 81-A):
Compound 81-A was prepared in analogy to compound Q in Example 19 by using methyl 3-(aminomethyl)cyclobutanecarboxylate hydrochloride salt (compound 81-B) instead of ethyl 3- amino-2,2-dimethyl-propanoate hydrochloride salt.
Preparation of methyl 3-(aminomethyl)cyclobutanecarboxylate hydrochloride salt (compound 81-B):
Figure imgf000169_0001
81 -B
Compound 81-B was prepared in analogy to compound W in Example 20 by using 3- (aminomethyl)cyclobutanecarboxylic acid (PharmaBlock (Nanjing) R&D Co. Ltd , CAS: 1310729-95-3) instead of DL-3-aminoisobutyric acid.
Example 82A and 82B (separated two single isomers):
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid
Figure imgf000170_0001
Figure imgf000170_0002
To a stirred solution of trans-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C, 176 mg, 0.5 mmol) in dry dimethylforaiamide (3.0 mL) was added diisopropylethylamine (1.0 mL), potassium iodide (125 mg, 0.75 mmol) and compound C-l (250 mg, 0.55 mmol). The reaction mixture was flushed with nitrogen and heated to 55°C for 2 hours. The reaction mixture was quenched by adding ice- water, extracted with ethyl acetate (30 mL) three times. The organic phase was separated, dried over Na2S04, filtrated and concentrated. The residue was purified by HPLC to give a mixture of two isomers which were further resolved by SFC to give two single isomers: 82A-1 (faster eluting, 77.3 mg, yield: 25%) and 82B-1 (slower eluting, 93 mg, yield: 30%) with 30% isopropanol (0.05%DEA)/CO2 on ChiralPak AD-3 column. MS: calc'd 617 (MH+), measured 617 (MH+).
The solution of compound 82A-1 (77.3 mg, 0.125 mmol) in tetrahydrofuran (0.62 mL) was added lithium hydroxide monohydrate (52.7 mg, 1.25 mmol) in water (0.62 mL). After the reaction mixture was stirred at 35°C for 2 hours, it was neutralized with IN hydrochloride solution to pH 3.0. The mixture was extracted with ethyl acetate (30 mL) three times. The combined organic phase was dried over Na2S04, filtrated and then concentrated. The residue was purified by Prep-HPLC to give Example 82A (56.2 mg). 1H NMR (400 MHz, METHANOL-d ) d ppm 7.97 (d, / = 3.0 Hz, 1H), 7.78 (d, / = 3.0 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.16 (s, 1H), 6.25 (s, 1H), 4.31 (d, / = 17.3 Hz, 1H), 4.10 - 4.00 (m, 2H), 3.91 (d, / = 16.8 Hz, 1H), 3.86 - 3.75 (m, 2H), 3.62 - 3.54 (m, 1H), 3.46 (dd, / = 5.4, 9.7 Hz, 1H), 3.32 - 3.28 (m, 1H), 3.21 - 3.08 (m, 1H), 2.90 (br. s., 1H), 2.55 (br. s., 1H), 2.46 (t, / = 4.9 Hz, 1H), 1.13 (t, / = 7.2 Hz, 3H), 0.77 - 0.66 (m, 4H). MS: calc'd 603 (MH+), measured 603 (MH+).
Example 82B (68.3 mg) was prepared in analogy to Example 82A. 1H NMR (400 MHz,
METHANOL-d ) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.29 (s, 2H), 7.21 - 7.13 (m, 1H), 6.22 (s, 1H), 4.24 (d, J = 17.1 Hz, 1H), 4.08 - 3.95 (m, 3H), 3.89 - 3.77 (m, 2H), 3.60 - 3.52 (m, 1H), 3.43 (dd, / = 5.3, 9.5 Hz, 1H), 3.32 - 3.28 (m, 1H), 3.22 - 3.12 (m, 1H), 3.06 (br. s., 1H), 2.66 (br. s., 1H), 2.50 - 2.42 (m, 1H), 1.12 (t, J = 7.0 Hz, 3H), 0.73 (s, 4H). MS: calc'd 603 (MH+), measured 603 (MH+).
Preparation of trans-methyl 2-cyclopropyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazine-8-carboxylate trifluoroacetic acid salt (Compound 82- C)
Figure imgf000172_0001
AV 82-C-1
82-C-2 mixtu
Figure imgf000172_0002
Figure imgf000172_0003
82-C-5
82-C
mixture of two trans isomers
Step 1: The mixture of compound AV (6.5 g, 16.7 mmol) and borane-THF complex solution 1.0 M in THF (40 mL, 40 mmol) was stirred at 32°C overnight. The reaction mixture was concentrated. The residue was dissolved in ethyl acetate (60 mL) and added 2.0 mL of hydrogen chloride solution (4.0 M in dioxane). The mixture was extracted with ethyl acetate (50 mL) three times. The combined organic phase was dried over Na2S04, filtrated and concentrated. The residue was purified by column to give compound 82-C-l (4.0 g).
Step 2: To a solution of oxalyl chloride (2.0 mL) in dry dichloromethane (60 mL) under nitrogen at -78°C was added dropwise of dimethyl sulfoxide (3.3 mL, 47 mmol) in dry dichloromethane (2.0 mL). After addition, the reaction mixture was stirred for 1 hour at -78°C. Then to the reaction mixture was added compound 82-C-l (4.0 g, 10.7 mmol) in dry dichloromethane (6.0 mL) dropwise and stirred for another hour at -78°C. The reaction was quenched by adding triethylamine (12 mL, 86 mmol) dropwise over 30 minutes. The resulting mixture was warmed up to room temperature, and the organic phase was washed by ice-water, separated and dried over Na2S04, then filtrated and concentrated to give crude compound 82-C-2 (3.72 g, crude), which was used directly.
Step 3: To a solution of compound 82-C-2 (930 mg, 2.5 mmol) in dichloromethane (10 mL) was added cyclopropylamine (260 μί, 3.75 mmol), catalytic amount of acetic acid (2 drops) and sodium triacetoxyborohydride (1.06 g, 5 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was quenched by adding ice- water, extracted with dichloromethane (30 mL) two times and the organic phase was washed with sodium bicarbonate solution and dried over Na2S04, then filtrated and concentrated to give crude compound 82-C-3 (1.03 g, crude).
Step 4: The mixture of compound 82-C-3 (1.03 g, 2.5 mmol) in dichloromethane (15 mL) was added diisopropylethylamine (1.0 mL) and 4-nitrophenyl chloroformate (1.0 g, 5.0 mmol). The reaction mixture was stirred at 40°C for 2 hours. The reaction was quenched by adding ice- water and extracted with dichloromethane (30 mL) two times. The organic phase was washed with sodium bicarbonate solution and dried over Na2S04, then filtrated and concentrated. The residue was purified by column to give compound 82-C-4 (1.4 g).
Step 5: The mixture of compound 82-C-4 (1.4 g, 2.42 mmol) and TFA/DCM=2/1 (6 mL) was stirred at room temperature for 30 minutes. The reaction mixture was concentrated and added toluene for co-evaporation to remove trifluoroacetic acid. The residue was dissolved in dichloromethane (15 mL), and then diisopropylethylamine (2 mL) was added. The reaction mixture was heated to 40°C overnight. To the reaction mixture was added di-tert-butyl dicarbonate (1.1 g, 5.0 mmol) and stirred for another 5 hours. The reaction mixture was quenched by adding ice-water, extracted with ethyl acetate (30 mL) two times. The organic phase was separated, dried over Na2S04, filtrated and concentrated. The residue was purified by column to give compound 82-C-5 (680 mg).
Step 6: The mixture of compound 82-C-5 (170 mg, 0.5 mmol) and TFA/DCM=2/1 (3 mL) was stirred at room temperature for 30 minutes. The reaction mixture was concentrated and added toluene for co-evaporation to remove trifluoroacetic acid to give crude compound 82-C which was used directly. Example 83A and 83B (separated two single isomers):
(8R,8aS)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl- 2-thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-8-carboxylic acid; and
(8S,8aR)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl- 2-thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a] razine-8-carboxylic acid
Figure imgf000174_0001
Preparation of Example 83A and 83B:
Figure imgf000175_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using methyl (4S)-6-(bromomethyl)-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate (compound C-5) instead of ethyl (4R)-6-(bromomethyl)-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate (compound C-l).
Example 83A was obtained as a light yellow solid (99 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.95 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.14 - 7.07 (m, 1H), 7.06 - 6.98 (m, 1H), 5.93 (s, 1H), 4.29 (d, J = 17.1 Hz, 1H), 3.88 (d, / = 17.3 Hz, 1H), 3.79 (br. s., 2H), 3.62 (s, 3H), 3.55 (s, 1H), 3.46 (d, / = 5.5 Hz, 1H), 3.26 (d, / = 9.8 Hz, 1H), 3.20 - 3.09 (m, 1H), 2.85 (d, / = 10.8 Hz, 1H), 2.56 (d, / = 2.3 Hz, 3H), 2.54 - 2.42 (m, 2H), 0.78 - 0.68 (m, 4H). MS: calc'd 587 (MH+), measured 587 (MH+).
Example 83B was obtained as a light yellow solid (72.9 mg). 1H NMR (400 MHz, METHANOL-d ) d ppm 7.94 (d, / = 3.3 Hz, 1H), 7.75 (d, / = 3.3 Hz, 1H), 7.09 (d, / = 4.8 Hz, 2H), 5.90 (s, 1H), 4.21 (d, / = 17.1 Hz, 1H), 3.97 (d, / = 17.1 Hz, 1H), 3.88 - 3.76 (m, 2H), 3.61 (s, 3H), 3.58 - 3.50 (m, 1H), 3.46 - 3.40 (m, 1H), 3.28 (s, 1H), 3.21 - 3.12 (m, 1H), 3.08 - 2.99 (m, 1H), 2.63 (d, / = 3.3 Hz, 1H), 2.56 (d, / = 2.3 Hz, 3H), 2.50 - 2.42 (m, 1H), 0.79 - 0.66 (m, 4H). MS: calc'd 587 (MH+), measured 587 (MH+). Example 83A was synthesized from compound 83A-1 (faster eluting) and Example 83B was synthesized from compound 83B-1 (slower eluting) on ChiralCel OJ-H column eluting with 25% methanol (0.05%DEA)/CO2.
Preparation of methyl (4S)-6-(bromomethyl)-4-(3,4-difluoro-2-methyl-phenyl)-2- thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (compound C-5):
Compound C-5 was prepared in analogy to compound C by using 3,4-difluoro-2- methylbenzaldehyde instead of 2-chloro-4-fluorobenzaldehyde.
Example 84A and 84B (separated two single isomers):
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid
Figure imgf000176_0001
Preparation of Example 84A and 84B:
Figure imgf000177_0001
Figure imgf000177_0002
The title two compounds were prepared in analogy to Example 82A and 82B by using methyl 2-isopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate
(compound 84-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 84A was obtained as a light yellow solid (20.3 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.11 (d, / = 3.0 Hz, 1H), 8.01 (d, / = 3.0 Hz, 1H), 7.39 (d, / = 2.0 Hz, 2H), 7.28 - 7.21 (m, 1H), 6.32 (s, 1H), 4.38 (d, / = 17.3 Hz, 1H), 4.08 (d, / = 6.5 Hz, 4H), 3.93 - 3.82 (m, 2H), 3.62 - 3.47 (m, 3H), 3.24 - 3.14 (m, 1H), 3.10 - 3.04 (m, 1H), 2.69 (d, / = 3.5 Hz, 1H), 1.25 - 1.11 (m, 9H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 84B was obtained as a light yellow solid (32.5 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.10 (s, 1H), 8.02 (s, 1H), 7.38 (d, / = 4.3 Hz, 2H), 7.29 - 7.23 (m, 1H), 6.30 (s, 1H), 4.36 (d, / = 16.6 Hz, 1H), 4.14 - 4.03 (m, 4H), 3.87 (d, / = 3.3 Hz, 2H), 3.56 (d, / = 9.8 Hz, 2H), 3.50 - 3.44 (m, 1H), 3.20 (s, 2H), 2.77 (d, / = 3.5 Hz, 1H), 1.24 - 1.10 (m, 9H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 84A was synthesized from compound 84A-1 (faster eluting) and Example 84B was synthesized from compound 84B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2. Preparation of methyl 2-isopropyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazine-8-carboxylate (compound 84-C):
Compound 84-C was prepared in analogy to compound 82-C by using isopropylamine instead of cyclopropylamine.
Example 85 A and 85B (separated two single isomers):
(8R,8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid
Figure imgf000178_0001
Preparation of Example 85 A and 85B:
Figure imgf000179_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using methyl (4S)-6-(bromomethyl)-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate (compound C-5) instead of ethyl (4R)-6-(bromomethyl)-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate (compound C-l) and methyl 2-isopropyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 84-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 85A was obtained as a light yellow solid (3.6 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 8.10 (d, / = 3.3 Hz, 1H), 7.99 (d, / = 3.0 Hz, 1H), 7.26 - 7.19 (m, 1H), 7.14 - 7.04 (m, 1H), 6.01 (s, 1H), 4.34 (d, / = 17.1 Hz, 1H), 4.11 (s, 1H), 3.98 (d, / = 17.3 Hz, 1H), 3.85 (d, / = 4.8 Hz, 2H), 3.65 (s, 3H), 3.61 - 3.54 (m, 1H), 3.50 (s, 2H), 3.22 - 3.13 (m, 1H), 3.03 - 2.96 (m, 1H), 2.70 - 2.60 (m, 1H), 2.56 (d, / = 2.3 Hz, 3H), 1.20 (dd, / = 6.8, 14.3 Hz, 6H). MS: calc'd 589 (MH+), measured 589 (MH+).
Example 85B was obtained as a light yellow solid (2.3 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 8.07 (d, J = 3.0 Hz, 1H), 7.96 (d, J = 3.3 Hz, 1H), 7.25 - 7.17 (m, 1H), 7.16 - 7.07 (m, 1H), 5.99 (s, 1H), 4.30 (d, / = 16.8 Hz, 1H), 4.16 - 3.99 (m, 2H), 3.92 - 3.82 (m, 2H), 3.65 (s, 3H), 3.59 - 3.53 (m, 1H), 3.51 - 3.43 (m, 2H), 3.24 - 3.09 (m, 2H), 2.78 - 2.68 (m, 1H), 2.55 (d, / = 2.3 Hz, 3H), 1.19 (dd, / = 6.8, 14.1 Hz, 6H). MS: calc'd 589 (MH+), measured 589 (MH+).
Example 85A was synthesized from compound 85A-1 (faster eluting) and Example 85B was synthesized from compound 85B-1 (slower eluting) on ChiralPak AD-3 column eluting with 20% isopropanol (0.05%DEA)/CO2.
Example 86 A and 86B (separated two single isomers):
(8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid
Figure imgf000180_0001
Preparation of Example 86 A and 86B:
Figure imgf000181_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using (R)- 6-bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carboxylic acid methyl ester (Compound C) instead of ethyl (4R)-6-(bromomethyl)-4-(2-chloro- 3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (compound C-l) and methyl 2-iert-butyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate
(compound 86-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 86A was obtained as a light yellow solid (64.8 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.98 (d, / = 3.0 Hz, 1H), 7.80 (d, / = 3.3 Hz, 1H), 7.52 - 7.45 (m, 1H), 7.24 (dd, / = 2.6, 8.7 Hz, 1H), 7.06 (d, / = 2.8 Hz, 1H), 6.19 (s, 1H), 4.32 (d, / = 17.3 Hz, 1H), 3.97 (br. s., 1H), 3.82 - 3.72 (m, 2H), 3.65 - 3.58 (m, 4H), 3.57 - 3.51 (m, 1H), 3.42 - 3.36 (m, 1H), 3.19 - 3.09 (m, 1H), 2.99 - 2.89 (m, 1H), 2.65 - 2.53 (m, 1H), 1.41 (s, 9H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 86B was obtained as a light yellow solid (71.1 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.0 Hz, 1H), 7.78 (d, / = 3.0 Hz, 1H), 7.46 (dd, J = 6.1, 8.7 Hz, 1H), 7.25 (dd, / = 2.6, 8.7 Hz, 1H), 7.13 - 7.05 (m, 1H), 6.15 (s, 1H), 4.25 (d, / = 17.3 Hz, 1H), 4.03 (br. s., 1H), 3.86 - 3.72 (m, 2H), 3.65 - 3.57 (m, 4H), 3.55 - 3.48 (m, 1H), 3.41 - 3.36 (m, 1H), 3.19 - 3.05 (m, 2H), 2.75 - 2.62 (m, 1H), 1.40 (s, 9H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 86A was synthesized from compound 86A-1 (faster eluting) and Example 86B was synthesized from compound 86B-1 (slower eluting) on ChiralPak AD-3 column eluting with 25% isopropanol (0.05%DEA)/CO2.
Preparation of methyl 2-tert-butyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazine-8-carboxylate (compound 86-C):
Compound 86-C was prepared in analogy to compound 82-C by using ie/t-butylamine instead of cyclopropylamine.
Example 87A and 87B (separated two single isomers):
(8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carbox lic acid
Figure imgf000182_0001
Preparation of Example 87A and 87B:
Figure imgf000183_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using methyl 2-iert-butyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate
(compound 86-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Compound 87B-1 (Single isomer. Structure is either one of the two structures showing above):Methyl (8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylate; or Methyl (8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro- phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a- tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine-8-carboxylate
Compound 87B-1 was obtained as a light yellow solid (316 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.97 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.34 - 7.23 (m, 2H), 7.16 (t, / = 8.5 Hz, 1H), 6.22 (s, 1H), 5.51 (s, 2H), 4.14 (d, J = 17.1 Hz, 1H), 4.08 - 4.00 (m, 2H), 3.89 (s, 1H), 3.81 - 3.69 (m, 5H), 3.58 - 3.52 (m, 1H), 3.35 (br. s., 1H), 3.27 (d, / = 9.5 Hz, 1H), 3.16 - 3.04 (m, 1H), 2.95 (d, / = 12.3 Hz, 1H), 2.52 (dt, J = 3.4, 12.0 Hz, 1H), 1.39 (s, 9H), 1.13 (t, J = 1.2 Hz, 3H). MS: calc'd 633 (MH+), measured 633 (MH+)
Example 87A was obtained as a light yellow solid (52.7 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.98 (d, / = 3.0 Hz, 1H), 7.79 (d, / = 3.0 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.17 (s, 1H), 6.25 (s, 1H), 4.39 - 4.28 (m, 1H), 4.09 - 4.01 (m, 2H), 3.99 - 3.86 (m, 1H), 3.76 (d, / = 9.8 Hz, 2H), 3.64 - 3.58 (m, 1H), 3.57 - 3.51 (m, 1H), 3.40 - 3.36 (m, 1H), 3.13 (br. s., 1H), 3.00 - 2.84 (m, 1H), 2.63 - 2.47 (m, 1H), 1.41 (s, 9H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 619 (MH+), measured 619 (MH+).
Example 87B was obtained as a light yellow solid (61.3 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.36 - 7.26 (m, 2H), 7.21 - 7.14 (m, 1H), 6.22 (s, 1H), 4.27 (d, / = 16.8 Hz, 1H), 4.09 - 3.97 (m, 3H), 3.86 - 3.71 (m, 2H), 3.65 - 3.55 (m, 1H), 3.55 - 3.46 (m, 1H), 3.39 - 3.34 (m, 1H), 3.20 - 3.02 (m, 2H), 2.66 (br. s., 1H), 1.40 (s, 9H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 619 (MH+), measured 619 (MH+)
Example 87A was synthesized from compound 87A-1 (faster eluting) and Example 87B was synthesized from compound 87B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2.
Example 88A and 88B (separated two single isomers):
(8R,8aS)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carbox lic acid
Figure imgf000184_0001
Preparation of Example 88A and 88B:
Figure imgf000185_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using methyl (4S)-6-(bromomethyl)-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate (compound C-5) instead of ethyl (4R)-6-(bromomethyl)-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate (compound C-l) and methyl 2-ieri-butyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 86-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 88A was obtained as a light yellow solid (37.2 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, 1H), 7.78 (d, / = 3.0 Hz, 1H), 7.14 - 7.09 (m, 1H), 7.08 - 6.99 (m, 1H), 5.94 (s, 1H), 4.32 (d, J = 17.1 Hz, 1H), 3.91 (d, J = 17.1 Hz, 1H), 3.79 - 3.71 (m, 2H), 3.66 - 3.58 (m, 4H), 3.56 - 3.50 (m, 1H), 3.36 (d, / = 9.8 Hz, 1H), 3.17 - 3.06 (m, 1H), 2.89 (d, J = 11.3 Hz, 1H), 2.56 (d, / = 2.3 Hz, 4H), 1.40 (s, 9H). MS: calc'd 603 (MH+), measured 603 (MH+).
Example 88B was obtained as a light yellow solid (61.2 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.95 (d, / = 3.3 Hz, 1H), 7.77 (d, / = 3.3 Hz, 1H), 7.14 - 7.02 (m, 2H), 5.91 (s, 1H), 4.25 (d, J = 17.1 Hz, 1H), 4.01 (d, / = 17.1 Hz, 1H), 3.85 - 3.72 (m, 2H), 3.66 - 3.56 (m, 4H), 3.54 - 3.46 (m, 1H), 3.37 (br. s., 1H), 3.20 - 3.02 (m, 2H), 2.69 (d, / = 10.3 Hz, 1H), 2.56 (d, / = 2.5 Hz, 3H), 1.40 (s, 9H). MS: calc'd 603 (MH+), measured 603 (MH+).
Example 88A was synthesized from compound 88A-1 (faster eluting) and Example 88B was synthesized from compound 88B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2.
Example 89:
Methyl 7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-2,5,^
carboxylate
Figure imgf000186_0001
Preparation of Example 89:
Figure imgf000186_0002
C X 89
The title compound was prepared in analogy to Example 1 by using methyl 3-oxo- 1, 2,5,6,7, 8-hexahydroimidazo[l,5-a]pyrazine-8a-carboxylate TFA salt (Compound X) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 90A and 90B (separated two single isomers):
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-l,l-dimethyl-3-oxo-6,8-dihydro-5H-oxazolo[3,4-a]pyrazin- 8a-yl] acetic acid; and
2-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-l,l-dimethyl-3-oxo-6,8-dihydro-5H-oxazolo[3,4-a]pyrazin- 8a-yl] acetic acid
Figure imgf000187_0001
Preparation f Example 90A and 90B:
Figure imgf000187_0002
. LiOH
Figure imgf000187_0003
The title two compounds were prepared in analogy to Example 82A and 82B by using (R)- 6-bromomethyl-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carboxylic acid methyl ester (Compound C) instead of ethyl (4R)-6-(bromomethyl)-4-(2-chloro- 3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (compound C-l) and methyl 2-(l,l-dimethyl-3-oxo-5,6,7,8-tetrahydrooxazolo[3,4-a]pyrazin-8a-yl)acetate (compound 90-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazine-8-carboxylate (compound 82-C).
Example 90A was obtained as a light yellow solid (13 mg). 1H NMR (400MHz, MeOD) δ ppm 7.92 (d, / = 3.3 Hz, 1H), 7.71 (d, / = 3.0 Hz, 1H), 7.43 (dd, / = 6.0, 8.8 Hz, 1H), 7.23 (dd, / = 2.5, 8.8 Hz, 1H), 7.06 (dt, / = 2.5, 8.4 Hz, 1H), 6.16 (s, 1H), 4.21 (d, / = 16.3 Hz, 1H), 3.87 - 3.71 (m, 3H), 3.61 (s, 3H), 3.52 (d, / = 11.5 Hz, 1H), 3.37 (br, 1H), 2.94 (d, / = 11.3 Hz, 1H), 2.63 (d, / = 16.1 Hz, 1H), 2.46 - 2.30 (m, 2H), 1.47 (s, 3H), 1.42 (s, 3H). LC/MS: calc'd 592 (MH+), exp 592 (MH+).
Example 90B was obtained as a light yellow solid (25 mg). 1H NMR (400MHz, MeOD) δ ppm 7.96 (d, / = 3.0 Hz, 1H), 7.75 (d, / = 3.0 Hz, 1H), 7.54 (dd, / = 6.3, 8.8 Hz, 1H), 7.21 (dd, / = 2.8, 8.8 Hz, 1H), 7.06 (dt, / = 2.5, 8.4 Hz, 1H), 6.16 (s, 1H), 4.09 - 3.90 (m, 2H), 3.89 - 3.71 (m, 2H), 3.66 - 3.55 (m, 4H), 3.36 (br, 1H), 2.82 (d, / = 8.3 Hz, 1H), 2.72 (d, / = 16.8 Hz, 1H), 2.43 (d, / = 11.3 Hz, 1H), 2.31 (dt, / = 4.0, 11.9 Hz, 1H), 1.57 (s, 3H), 1.47 (s, 3H); LC/MS: calc'd 592 (MH+), exp 592 (MH+).
Example 90A was synthesized from compound 90A-1 (faster eluting) and Example 90B was synthesized from compound 90B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2.
Preparation of methyl 2-(l,l-dimethyl-3-oxo-5,6,7,8-tetrahydrooxazolo[3,4-a]pyrazin- 8a-yl)acetate (compound 90-C):
Figure imgf000189_0001
Figure imgf000189_0002
Figure imgf000189_0003
Step 1: To a solution of DIPA (3.67 g, 36 mmol, 1.2 eq) in THF (18 mL) was added n-BuLi (2M, 18 mL, 1.2 eq) dropwise at -78°C over 15 min and the mixture was stirred for another 15 min at - 78°C. Then compound AH (10.3 g, 30 mmol, 1.0 eq) in THF (30 mL) was added dropwise to the reaction at -78°C, after the addition was completed, the mixture was stirred for another 30 min at -78°C. BOMC1 (7 g, 45 mmol) in THF (20 mL) was added dropwise over 20 min at -78°C, the reaction mixture was stirred for 16 h and the temperature was warmed to rt during this period. The reaction was quenched with 1M HC1 (50 mL), extracted with EA (100 mL) two times, the organic layer was dried and concentrated, the residue was purified on silica gel (EA/PE: 0 -20 ) to give compound 90-C-l as colorless oil (8.2 g).
Step 2: A mixture of compound 90-C-l (8.2 g, 17.6 mmol) and Pd(OH)2/C (500 mg, 20%) in MeOH (100 mL) was stirred at rt for 2 h under hydrogen, then the solid was filtered off, the filtrate was concentrated and the residue was purified on silica gel (EA/PE: 0%-40%) to give compound 90-C-2 as a colorless oil( 6.1 g). Step 3: To a solution of 90-C-2 (3.74 g, 0.01 mol, 1.0 eq) and imidazole (0.81 g, 0.012 mol, 1.2 eq) in DMF (20 mL) was added TBSC1 (1.65 g, 0.11 mol, 1.1 eq) slowly at rt, then the mixture was stirred at rt for 16 h, diluted with EA (50 mL) washed with water (50 mL) and brine (50 mL), the organic layer was dried over Na2S04 and concentrated to give compound 90-C-3 as a colorless oil (4.4 g). MS: calc'd 489 (MH+), measured 489 (MH+).
Step 4: To a solution of 90-C-3 (4.4 g, 9 mmol, 1.0 eq) in THF (50 mL) was added CH3MgBr (3.2M, 15 mL, 5.0 eq) dropwise at -40°C over 15 min, then the reaction mixture was stirred for 16 h and the temperature was warmed to rt during this period. The reaction was quenched with 1M HC1 (50 mL), extracted with EA (100 mL), the organic layer was dried and concentrated, and residue was purified on silica gel (EA/PE: 20 -40 ) to give compound 90-C-4 as colorless oil (1.9 g). MS: calc'd 415 (MH+), measured 415 (MH+).
Step 5: A solution of 90-C-4 (1.86 g, 4.5 mmol, 1.0 eq) and TBAF (1 M, 9 mL, 2.0 eq) in THF (20 mL) was stirred at rt for 2 h, diluted with EA (50 mL), washed with water (50 mL) and brine (50 mL), the organic layer was dried over Na2S04 and concentrated, the residue was purified on silica gel (EA/PE: 30 -70 ) to give compound 90-C-5 as colorless oil (1.2 g). MS: calc'd 301 (MH+), measured 301 (MH+).
Step 6: A solution of 90-C-5 (0.9 g, 3 mmol, 1.0 eq), PPh3 (1.57 g, 6 mmol, 2.0 eq ) and imidazole (0.41 g, 6 mmol, 2.0 eq) in THF (20 mL) was refluxed for 1 h, then Iodine (1.3 g, 4.5 mmol, 1.5 eq) was added and refluxed for 2 h. Then reaction diluted with EA (50 mL), washed with water (50 mL) and brine (50 mL), the organic layer was dried (Na2S04) and concentrated, the residue was purified on silica gel (EA/PE: 0%-25%) to give compound 90-C-6 as colorless oil (0.61 g). MS: calc'd 411 (MH+), measured 411 (MH+).
Step 7: A mixture of 90-C-6 (0.61 g, 1.5 mmol, 1.0 eq) and KCN (0.195 g, 3 mmol, 2.0 eq) in DMSO (10 mL) was stirred at 80 °C for 16 h. Then reaction diluted with EA (50 mL), washed with water (50 mL) and brine (50 mL), the organic layer was dried over Na2S04 and
concentrated, the residue was purified on silica gel (EA/PE: 0%-25%) to give compound 90-C-7 as colorless oil (0.41 g). MS: calc'd 310 (MH+), measured 310 (MH+).
Step 8: A mixture of 90-C-7 (0.41 g, 1.3 mmol, 1.0 eq) in HCl/MeOH (3M, 10 mL) was stirred at 80 °C for 16 h. Then reaction was concentrated to give compound 90-C as white solid (0.36 g). MS: calc'd 243 (MH+), measured 243 (MH+).
Example 91 A and 91B (separated two single isomers): (8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]me^^
a]pyrazine-8-carboxylic acid; and
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a etrahydro-lH-imidazo[l,5- a]pyrazine-8-carbox lic acid
Figure imgf000191_0001
Pre aration of Example 91 A and 91B:
Figure imgf000191_0002
The title two compounds were prepared in analogy to Example 82A and 82B by using methyl 2-methyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 91-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazine-8-carboxylate (compound 82-C). Example 91A was obtained as a light yellow solid (26 mg). 1H NMR (400MHz, MeOD) 7.97 (d, / = 3.3 Hz, 1H), 7.77 (d, 7 = 3.0 Hz, 1H), 7.36 - 7.26 (m, 2H), 7.22 - 7.11 (m, 1H), 6.25 (s, 1H), 4.30 (d, / = 17.3 Hz, 1H), 4.04 (q, / = 7.2 Hz, 2H), 3.95 - 3.82 (m, 3H), 3.61 - 3.45 (m, 2H), 3.31 - 3.11 (m, 2H), 2.93 - 2.81 (m, 4H), 2.49 (br, 1H), 1.13 (t, / = 7.0 Hz, 3H). LC/MS: calc'd 577 (MH+), exp 577 (MH+).
Example 91B was obtained as a light yellow solid (38 mg). 1H NMR (400MHz, MeOD) 7.96 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.39 - 7.25 (m, 2H), 7.17 (td, / = 2.0, 7.5, 9.1 Hz, 1H), 6.21 (s, 1H), 4.24 (d, / = 16.8 Hz, 1H), 4.04 (q, J = 1.1 Hz, 2H), 3.98 - 3.78 (m, 3H), 3.60 - 3.42 (m, 2H), 3.31 - 3.16 (m, 2H), 3.04 (d, / = 10.3 Hz, 1H), 2.83 (s, 3H), 2.61 (br, 1H), 1.12 (t, / = 7.0 Hz, 3H). LC/MS: calc'd 577 (MH+), exp 577 (MH+).
Example 91A was synthesized from compound 91A-1 (faster eluting) and Example 91B was synthesized from compound 91B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2.
Preparation of methyl 2-methyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine- 8-carboxylate (compound 91-C):
Compound 91-C was prepared in analogy to compound 82-C by using methyl amine instead of cyclopropylamine.
Example 92A and 92B (separated two single isomers):
Methyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate; and
Methyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carbox late
Figure imgf000192_0001
Preparation of Example 92A and 92B:
Figure imgf000193_0001
mixture of two trans isomers
The title two compounds were prepared in analogy to Example 82A and 82B by using iraw5,-2-ieri-butyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxamide
(compound 92-C) instead of iraws-methyl 2-cyclopropyl-3-oxo- 1,5, 6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C). The crude product was purified by HPLC to give a mixture of two isomers which were further resolved by SFC to give two single isomers: 92A (faster eluting) and 92B (slower eluting) with 30% isopropanol
(0.05%DEA)/CO2 on ChiralPak AD-3 column.
Example 92A was obtained as a light yellow solid (30 mg). 1H NMR (400MHz, MeOD) δ = 7.97 (d, / = 3.0 Hz, 1H), 7.74 (d, / = 3.3 Hz, 1H), 7.37 - 7.21 (m, 2H), 7.20 - 7.08 (m, 1H), 6.20 (s, 1H), 4.18 (d, J = 17.1 Hz, 1H), 4.02 (q, / = 7.0 Hz, 2H), 3.84 - 3.72 (m, 3H), 3.55 (t, / = 8.8 Hz, 2H), 3.14 (dt, / = 3.5, 12.7 Hz, 1H), 3.05 (d, / = 9.3 Hz, 1H), 3.00 - 2.89 (m, 1H), 2.45 (dt, / = 3.5, 11.9 Hz, 1H), 1.40 (s, 9H), 1.12 (t, / = 7.2 Hz, 3H). MS: calc'd 618 (MH+), exp 618 (MH+).
Example 92B was obtained as a light yellow solid (30 mg). 1H NMR (400MHz, MeOD) δ
= 7.98 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.36 - 7.23 (m, 2H), 7.20 - 7.09 (m, 1H), 6.25 (s, 1H), 4.24 (d, / = 17.3 Hz, 1H), 4.04 (q, J = 1.1 Hz, 2H), 3.85 - 3.68 (m, 3H), 3.57 (t, / = 8.8 Hz, 1H), 3.37 - 2.35 (m, 1H), 3.20 - 2.99 (m, 2H), 2.85 - 2.69 (m, 1H), 2.32 (dt, / = 3.4, 12.0 Hz, 1H), 1.49 - 1.34 (s, 9H), 1.13 (t, / = 7.0 Hz, 3H). MS: calc'd 618 (MH+), exp 618 (MH+).
Preparation of tra«s-2-tert-butyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-
8-carboxamide (com ound 92-C):
Figure imgf000193_0002
92-C-1 92-C-2 92-C-3 92-c
mixture of two trans isomers mixture of trans isomers Step 1: To a solution of compound 92-C-l (355 mg, 1 mmol) in THF (5 mL) was added lithium hydroxide monohydrate (124 mg, 3 mmol) in water (1 mL). After the reaction mixture was stirred at 35°C for 2 hours, it was neutralized with IN hydrochloride solution to pH 3.0. The mixture was extracted with ethyl acetate (30 mL) three times. The combined organic phase was dried over Na2S04, filtrated and then concentrated to give compound 92-C-2 as a white solid (340 mg). MS: calc'd 356 (MH+), exp 356 (MH+).
Step 2: A mixture of compound 92-C-2 (340 mg, 1 mmol), HATU (380 mg, 1 mmol), NH4C1 (275 mg, 5 mmol) and DIPEA (775 mg, 6 mmol) in THF(10 mL) was stirred 50°C for 2 hours. Then the undissolved material was filtered off and the filtrate was concentrated. The residue was purified on silica gel (EA/PE: 0%-40%) to give compound 92-C-3 as a white solid (200 mg). MS: calc'd 355 (MH+), exp 355 (MH+).
Step 3: A mixture of compound 92-C-3 (200 mg, 0.6 mmol) in DCM/TFA (5 mL, 2: 1) was stirred at room temperature for 2 hours, then the mixture was concentrated under reduced pressure to give compound 92-C as a slight yellow oil (200 mg), which was used directly in the next step. MS: calc'd 255 (MH+), exp 255 (MH+).
Preparation of tra«s-7-tert-butyl-8-methyl 2-tert-butyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-7,8-dicarboxylate (compound 92-C-l):
Compound 92-C-l was prepared in analogy to compound 82-C-5 by using ie/t-butylamine instead of cyclopropylamine.
Example 93:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-propoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid
Figure imgf000194_0001
Preparation of Example 93:
Figure imgf000195_0001
The title compound was prepared in analogy to Example 1 by using 3-[(8aS)-7-[[(4R)-4- (2-chloro-3-fluoro-phenyl)-5-propoxycarbonyl-2-thiazol-2-yl-l,4-dihydropyrimidin-6- yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid (compound C-6) and 3-[(8aS)-3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-propanoic acid (Compound Q) instead of (R)-6-bromomethyl-4-(2-chloro-4-fluoro- phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 93 was obtained as a light yellow solid (6 mg). 1H NMR (400MHz, MeOD) δ = 7.96 (d, / = 3.0 Hz, 1H), 7.75 (d, / = 3.0 Hz, 1H), 7.34 - 7.21 (m, 2H), 7.15 (dt, / = 1.6, 8.5 Hz, 1H), 6.24 (s, 1H), 4.19 - 4.06 (m, 1H), 4.03 - 3.81 (m, 5H), 3.51 (t, / = 8.9 Hz, 1H), 3.45 - 3.37 (m, 1H), 3.33 - 3.29 (m, 1H), 3.25 - 3.15 (m, 1H), 3.11 (dd, / = 4.0, 9.5 Hz, 1H), 2.97 - 2.78 (m, 2H), 2.41 - 2.29 (m, 1H), 2.19 (t, / = 10.9 Hz, 1H), 1.59 - 1.47 (m, 2H), 1.21 (d, / = 2.8 Hz, 6H), 0.76 (t, / = 7.4 Hz, 3H). MS: calc'd 633 (MH+), measured 633 (MH+).
Preparation of propyl (4R)-6-(bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-
2-yl-l,4-dihydropyrimidine-5-carboxylate (Compound C-6):
Compound C-6 was prepared in analogy to compound C by using w-propyl acetoacetate instead of methyl acetoacetate. Example 94:
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]- 2,2-dimethyl-butanoic acid
Figure imgf000196_0001
Pre aration of Example 94:
Figure imgf000196_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate (compound C-1) and (3R)-3-[(8aS)-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-2-yl]butanoic acid TFA salt (Compound 54-A) instead of (R)-6-bromomethyl-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[ l,2-c] [l,3]oxazin-6-one (Compound D). Example 57 was obtained as a light yellow solid (48 mg). 1H NMR (MeOD, 400MHz): δ = 7.97 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.02-7.39 (m, 3H), 6.24 (s, 1H), 3.99-4.16 (m, 2H), 3.73-3.95 (m, 3H), 3.47 (t, / = 9.0 Hz, 2H), 3.02-3.25 (m, 3H), 2.68-2.97 (m, 2H), 2.10-2.48 (m, 3H), 1.76 (br. s., 2H), 1.23 (s, 6H), 1.13 ppm (t, / = 7.2 Hz, 3H). MS: calc'd 633 (MH+), measured 633 (MH+). Example 95:
5-[7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8^^
yl]pyridine-2-carboxylic acid
Figure imgf000197_0001
Preparation of Example 95:
Figure imgf000197_0002
The title compound was prepared in analogy to Example 1 by using 5-(3-oxo-l,5,6,7,8,8 hexahydroimidazo[l,5-a]pyrazin-2-yl)pyridine-2-carboxylic acid TFA salt (Compound 95-A) instead of hexahydro-pyrazino[l,2-c][l,3]oxazin-6-one (Compound D). Example 95 was obtained as a light yellow solid (48 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 9.02 (s IH), 8.17 (s, 2H), 8.01 (s, IH), 7.88 (s, IH), 7.51-7.54 (m, 1 H), 7.30-7.28 (m, 1 H), 7.10-7.13 (m, 1 H), 6.20 (s, 1H), 4.41-4.63 (m, 2H), 4.17-4.35 (m, 3H), 3.51-3.75 (m, 7 H), 3.01-3.12 (m, 2H). MS: calc'd 626 (MH+), measured 626 (MH+).
Preparation of 5-(3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-2-yl)pyridine-2- carboxylic acid (Compound 95-A):
Figure imgf000198_0001
Step 1: A solution of 5-bromopyridine-2-carboxylic acid (5.0g, 24.75 mmol) in MeOH (30 mL) was added thionyl chloride (10 mL) dropwise at 0°C. Then the mixture was stirred for 12 hours at 60°C. After removal of solvent and the residual thionyl chloride, the crude product methyl 5-bromopyridine-2-carboxylate was obtained and used in the next step without further purification.
Step 2: A mixture of methyl 5-bromopyridine-2-carboxylate (compound 95-A-l, 0.72 g, 3.28 mmol), iert-butyl 3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazine-7-carboxylate (racemic compound M, 0.40 g, 1.64mmol), bis(dibenzylideneacetone) palladium (94.4 mg, 0.164 mmol), (+)-2,2'-bis(diphenylphosphino)-l,l '-binaphthyl (196.8 mg, 0.33 mmol), cesium carbonate (160.4 mg, 4.92 mmol) in dioxane (3 mL) was stirred for 3 hours at 130°C in microwave. After removal of solvent, the residue was purified by column to afford product 95- A-2 as white solid. MS: calc'd 377 (MH+), measured 377 (MH+).
Step 3: A mixture of compound 95-A-2 (0.24 g, 0.64 mmol), lithium hydroxide (0.13g, 3.2 mmol) in water (2 mL) and MeOH (5 mL) was stirred for 12 hours at room temperature. The reaction mixture was then neutralized with 1 N HCl to pH 6, extracted with ethyl acetate. The organic layer was dried over sodium sulfate. After removal of solvent, the residue was treated with TFA (2 mL) in DCM (10 mL). After the reaction mixture was stirred for 30 minutes, the solvent was removed to give the crude product, which was used in the next step directly. MS: calc'd 263 (MH+), measured 263 (MH+). Example 96:
(S)-6-[(S)-2-(2-Carboxy-2,2-difluoro-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5- carboxylic acid ethyl ester
Figure imgf000199_0001
Preparation of Example 96:
Figure imgf000199_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4S)-6- (bromomethyl)-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl- l,4-dihydropyrimidine-5- carboxylate (compound C-7) and 2,2-difluoro-3-((S)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-2- yl)-propionic acid trifluoroacetate salt (Compound 96-A) instead of (R)-6-bromomethyl-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[ l,2-c] [l,3]oxazin-6-one (Compound D). Example 96 was obtained as a light yellow solid (15 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 8.01 (d, IH), 7.90 (d, IH), 7.26 (m, IH), 7.07-7.15 (m, IH), 5.94-5.98 (m, IH), 4.69 (d, IH), 4.51 (d, 1H), 4.05-4.20 (m, 4H), 3.86-3.98 (m, 2H), 3.62-3.80 (m, 4H), 3.41-3.52 (m, 1H), 3.07-3.22 (m, 3H) , 2.52 (d, 3H), 1.15 (m, 3H). MS: calc'd 625 (MH+), measured 625 (MH+).
Preparation of 2,2-difluoro-3-((S)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-2-yl)- ropionic acid trifluoroacetate salt (compound 96-A):
Figure imgf000200_0001
S 96-A-1 96-A-2 96-A-3 96-A
Step 1. To a stirred solution of 3-amino-2,2-difluoro-propionic acid hydrochloride salt (400 mg, 1.10 mmol) in DCM (5 mL) was added DIPEA (142 mg, 1.10 mmol) at 0 °C, sequentially followed by a solution of compound S (350 mg, 1 mmol) in DCM ( 5 mL). The reaction mixture was stirred at 0 ° C for five minutes. Then NaBH(OAc)3 was added to the mixture. The resulting mixture was stirred at rt overnight. The reaction mixture was partitioned between DCM and water. The organic layer was separated, dried over Na2S04, concentrated in vacuum and isolated to give compound 96-A-l (320 mg).
Step 2. A mixture of compound 96-A-l (320 mg, 0.70 mmol) and Pd/C (30 mg) in MeOH (5 mL) was stirred with a hydrogen balloon at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated. The crude product 96-A-2 was obtained (226 mg) and used in the next step without further purification.
Step 3. To a solution of compound 96-A-2 (crude 226 mg, 0.70 mmol) in dichloromethane (3 ml) was added DIPEA (0.6 mL, 3.50 mmol) at 0°C, then triphosgene (103 mg, 0.35 mmol) was added to the reaction mixture. The resulting mixture was warmed to rt and stirred overnight. The reaction mixture was concentrated and the residue was directly used in the next step. The amount of crude product 96-A-3 was 340 mg.
Step 4. To a solution of compound 96-A-3 (crude 340 mg, 0.70 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (5 mL) at room temperature. After the reaction mixture was stirred for 1.5 hours, the solvent was removed to give the crude product 96-A (260 mg) which was used directly in the next step.
Preparation of ethyl (4S)-6-(bromomethyl)-4-(3,4-difluoro-2-methyl-phenyl)-2- thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate (compound C-7): Compound C-7 was prepared in analogy to compound C by using 3,4-difluoro-2- methylbenzaldehyde and ethyl acetoacetate instead of 2-chloro-4-fluorobenzaldehyde and methyl acetoacetate. Example 97 A and 97B (separated two single isomers):
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-8-carboxylic acid; and
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l 5-a]pyrazine-8-carboxylic acid
Figure imgf000201_0001
Preparation of Example 97A and 97B:
Figure imgf000202_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using trans-methyl 2-(cyclopropylmethyl)-3-oxo- 1,5, 6,7,8, 8a-hexahydroimidazo[l,5-a]pyrazine-8- carboxylate (compound 97-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 97A was obtained as a light yellow solid (25 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.98 (d, / = 3.0 Hz, 1H), 7.78 (d, / = 3.0 Hz, 1H), 7.35 - 7.26 (m, 2H), 7.20 - 7.11 (m, 1H), 6.25 (s, 1H), 4.30 (s, 1H), 4.10 - 3.99 (m, 2H), 3.95 - 3.86 (m, 2H), 3.81 (d, / = 11.5 Hz, 1H), 3.68 (d, / = 8.0 Hz, 1H), 3.65 - 3.58 (m, 1H), 3.37 - 3.34 (m, 2H), 3.25 - 3.16 (m, 1H), 3.25 - 3.16 (m, 1H), 3.15 - 3.07 (m, 2H), 2.91 (d, / = 11.5 Hz, 1H), 2.60 - 2.49 (m, 1H), 1.13 (t, J = 7.2 Hz, 3H), 1.03 - 0.93 (m, 1H), 0.61 - 0.53 (m, 2H), 0.28 - 0.23 (m, 2H). MS: calc'd 617 (MH+), measured 617 (MH+).
Example 97B was obtained as a light yellow solid (19 mg). 1H NMR (400 MHz,
METHANOL-d ) d ppm 7.33 - 7.23 (m, 3H), 7.15 (t, / = 8.3 Hz, 1H), 6.22 (s, 1H), 4.12 - 4.02 (m, 3H), 3.95 - 3.84 (m, 3H), 3.52 (t, / = 8.9 Hz, 1H), 3.44 - 3.38 (m, 1H), 3.29 (s, 1H), 3.24 - 3.09 (m, 2H), 2.93 (d, J = 11.0 Hz, 1H), 2.84 (d, / = 8.5 Hz, 1H), 2.48 (d, / = 0.8 Hz, 3H), 2.37 (dt, / = 3.4, 11.6 Hz, 1H), 2.18 (t, / = 10.9 Hz, 1H), 1.21 (d, / = 3.0 Hz, 6H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 617 (MH+), measured 617 (MH+). Example 97 A was synthesized from compound 97A-1 (faster eluting) and Example 97B was synthesized from compound 97B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2.
Preparation of trans-methyl 2-(cyclopropylmethyl)-3-oxo-l,5,6,7,8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 97-C):
Compound 97-C was prepared in analogy to compound 82-C by using cyclopropylmethanamine instead of cyclopropylamine.
Example 98:
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-(4-methylthiazol-2- yl)-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazin-2-yl] -2,2-dimethyl-propanoic acid
Figure imgf000203_0001
Preparation of Exam le 93
Figure imgf000203_0002
The title compound was prepared in analogy to Example 1 by using ethyl (4R)-6- (bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-(4-methylthiazol-2-yl)-l,4-dihydropyrimidine-5- carboxylate (compound C-8) and 3-[(8aS)-3-oxo- l,5, 6,7,8, 8a-hexahydroimidazo[l, 5-a]pyrazin- 2-yl]-2,2-dimethyl-propanoic acid (Compound Q) instead of (R)-6-bromomethyl-4-(2-chloro-4- fluoro-phenyl)-2-thiazol-2-yl- l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester (Compound C) and hexahydro-pyrazino[l,2-c] [l,3]oxazin-6-one (Compound D). Example 93 was obtained as a light yellow solid (60 mg). 1H NMR (400MHz, MeOD) δ = 7.33 - 7.23 (m, 3H), 7.15 (t, / = 8.3 Hz, 1H), 6.22 (s, 1H), 4.12 - 4.02 (m, 3H), 3.95 - 3.84 (m, 3H), 3.52 (t, / = 8.9 Hz, 1H), 3.44 - 3.38 (m, 1H), 3.29 (s, 1H), 3.24 - 3.09 (m, 2H), 2.93 (d, / = 11.0 Hz, 1H), 2.84 (d, / = 8.5 Hz, 1H), 2.48 (d, 7 = 0.8 Hz, 3H), 2.37 (dt, J = 3.4, 11.6 Hz, 1H), 2.18 (t, J = 10.9 Hz, 1H), 1.21 (d, / = 3.0 Hz, 6H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 633 (MH+), measured 633 (MH+).
Preparation of ethyl (4R)-6-(bromomethyl)-4-(2-chloro-3-fluoro-phenyl)-2-(4- methylthiazol-2-yl)-l,4-dihydropyrimidine-5-carboxylate (compound C-8):
Compound C-8 was prepared in analogy to compound C by using 4-methylthiazole-2- carbonitrile and ethyl acetoacetate instead of thiazole-2-carbonitrile and methyl acetoacetate.
Example 99:
2-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazine-l- carboxylic acid (mixture of two isomers
Figure imgf000204_0001
Preparation of Example 99:
Figure imgf000205_0001
The title two compounds were prepared in analogy to Example 82A and 82B by using iraw5,-6-oxo-2,3,4,7,8,8a-hexahydro-lH-pyrrolo[l,2-a]pyrazine-l-carboxylic acid (Compound 99-A) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazine-8-carboxylate (compound 82-C) without chiral separation of two trans isomers.
Example 99 was obtained as a mixture of two isomers (light yellow solid, 79 mg). 1H NMR (400MHz, MeOD) δ = 7.95 (d, / = 3.0 Hz, 1H), 7.75 (d, / = 3.3 Hz, 1H), 7.35 - 7.26 (m, 2H), 7.17 (t, / = 8.2 Hz, 1H), 6.22 (s, 1H), 4.25 (d, J = 17.1 Hz, 1H), 4.08 - 4.01 (m, 3H), 3.98 (s, 2H), 3.20 - 3.09 (m, 3H), 2.61 (t, / = 12.7 Hz, 1H), 2.52 - 2.42 (m, 2H), 2.34 - 2.23 (m, 1H), 2.08 - 1.97 (m, 1H), 1.12 (t, / = 7.2 Hz, 3H). MS: calc'd 562 (MH+), measured 562 (MH+).
Preparation of tra«s-6-oxo-2,3,4,7,8,8a-hexahydro-lH-pyrrolo[l,2-a]pyrazine-l- carboxylic acid (Compound 99-A):
Figure imgf000205_0002
82-C-2
99-A-1 99-A-2
mixture of two trans isomer
Figure imgf000205_0003
mixture of two trans isomer Step 1: To a stirred solution of compound 82-C-2 (12 g, 32.3 mmol) in DCM (100 mL) was added TEA (6.6 g, 64.5 mmol) and ethyl (triphenylphosphoranylidene) acetate (12.3 g, 35.5 mmol). The mixture was stirred at 25 °C for 15 h. Water (100 mL) was added, and the mixture was extracted with DCM (100 mL). The organic layer was separated and dried over Na2S04. The solvent was removed and the residue was purified by column to give compound 99-A-l (10 g). 1H NMR (400MHz, CDC13) δ = 4.90 - 4.76 (m, 1H), 4.71 - 4.48 (m, 1H), 4.24 - 4.08 (m, 2H), 4.03 - 3.90 (m, 1H), 3.85 - 3.71 (m, 5H), 3.21 - 2.87 (m, 2H), 2.31 (dq, / = 8.5, 16.5 Hz, 2H), 2.22 - 2.05 (m, 1H), 1.98 - 1.80 (m, 1H), 1.57 - 1.40 (m, 21H), 1.33 - 1.23 (m, 3H).
Step 2: To a stirred solution of compound 99-A-l (20 g, 45.2 mmol) in MeOH (600 mL) was added Pd/C (10 g). The mixture was stirred at 30 °C (50 Psi) for 15 h. The mixture was filtered and the solvent was removed in vacuum to give crude product, which was purified by column to give compound 99-A-2 (17 g, crude).
Step 3: To a stirred solution of compound 99-A-2 (17 g, 38.2mmol) in anhydrous DCM (90 mL) was added TFA (180 mL). After the reaction mixture was stirred for 3 hours, the solvent was removed in vacuum to give crude product 99-A-3 (19 g, crude).
Step 4: To a stirred solution of compound 99-A-3 (11 g, 25.1 mmol) in anhydrous DCM (250 mL) was added DIPEA (16 g, 125.6mmol). After the mixture was refluxed for 4 hours, the solvent was removed to give the crude product 99-A (7 g), which was used directly in the next step.
Example 101A and 101B (separated two single isomers):
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isobutyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid; and
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isobutyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid
Figure imgf000207_0001
Figure imgf000207_0002
The title two compounds were prepared in analogy to Example 82A and 82B by using trans-methyl 2-isobutyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 101-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 101A was obtained as a light yellow solid (10 mg). 1H NMR (400 MHz, METHANOL-d4) d ppm 7.98 (d, / = 3.3 Hz, 1H), 7.78 (d, / = 3.3 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.19 - 7.13 (m, 1H), 6.25 (s, 1H), 4.31 (d, J = 17.1 Hz, 1H), 4.09 - 4.01 (m, 2H), 3.94 - 3.86 (m, 2H), 3.83 - 3.76 (m, 1H), 3.60 - 3.48 (m, 2H), 3.29 (d, / = 9.5 Hz, 1H), 3.25 - 3.16 (m, 1H), 3.10 - 2.98 (m, 2H), 2.90 (d, J = 11.0 Hz, 1H), 2.57 - 2.45 (m, 1H), 1.99 - 1.88 (m, 1H), 1.13 (t, / = 7.0 Hz, 3H), 0.95 (dd, / = 4.9, 6.7 Hz, 6H). MS: calc'd 619 (MH+), measured 619 (MH+).
Example 101B was obtained as a light yellow solid (14 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.36 - 7.27 (m, 2H), 7.19 - 7.14 (m, 1H), 6.21 (s, 1H), 4.24 (d, / = 16.8 Hz, 1H), 4.07 - 3.93 (m, 3H), 3.92 - 3.82 (m, 2H), 3.59 - 3.45 (m, 2H), 3.29 - 3.18 (m, 2H), 3.03 (dd, / = 7.5, 11.0 Hz, 3H), 2.66 - 2.56 (m, 1H), 1.98 - 1.88 (m, 1H), 1.12 (t, 7 = 7.0 Hz, 3H), 0.94 (d, 7 = 6.8 Hz, 6H). MS: calc'd 619 (MH+), measured 619 (MH+).
Example 101A was synthesized from compound lOlA-1 (faster eluting) and Example
101B was synthesized from compound lOlB-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2.
Preparation of trans-methyl 2-isobutyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazine-8-carboxylate (compound 101-C):
Compound 101-C was prepared in analogy to compound 82-C by using 2-methylpropan-l- amine instead of cyclopropylamine.
Example 102A and 102B (separated two single isomers):
(8R,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6,8,8a-tetrahydro- lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid; and
(8S,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid
Figure imgf000208_0001
Preparation of Example 102A and 102B:
Figure imgf000209_0001
Figure imgf000209_0002
The title two compounds were prepared in analogy to Example 82A and 82B by using trans-methyl 3-oxo-l,5,6,7,8,8a-hexahydrooxazolo[3,4-a]pyrazine-8-carboxylate (compound 102-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazine-8-carboxylate (compound 82-C).
Example 102A was obtained as a light yellow solid (29 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, 1H), 7.78 (d, / = 3.0 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.20 - 7.13 (m, 1H), 6.26 (s, 1H), 4.63 - 4.53 (m, 1H), 4.44 (dd, / = 6.0, 9.3 Hz, 1H), 4.28 (d, / = 17.1 Hz, 1H), 4.15 - 3.97 (m, 4H), 3.77 (dd, / = 2.3, 13.3 Hz, 1H), 3.47 (d, / = 9.8 Hz, 1H), 3.30 (d, / = 3.5 Hz, 1H), 2.96 (dd, / = 2.1, 12.2 Hz, 1H), 2.68 - 2.58 (m, 1H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 564 (MH+), measured 564 (MH+).
Example 102B was obtained as a light yellow solid (27 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.95 (d, / = 3.3 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.35 - 7.28 (m, 2H), 7.20 - 7.14 (m, 1H), 6.23 (s, 1H), 4.61 - 4.53 (m, 1H), 4.40 (dd, / = 6.3, 9.3 Hz, 1H), 4.23 - 4.17 (m, 1H), 4.13 - 4.02 (m, 4H), 3.80 (dd, / = 2.5, 13.6 Hz, 1H), 3.46 (d, / = 9.8 Hz, 1H), 3.39 - 3.27 (m, 1H), 3.08 (dd, / = 2.3, 12.3 Hz, 1H), 2.73 (dt, 7 = 3.6, 12.2 Hz, 1H), 1.13 (t, 7 = 7.2 Hz, 3H). MS: calc'd 564 (MH+), measured 564 (MH+).
Example 102A was synthesized from compound 102A-1 (faster eluting) and Example
102B was synthesized from compound 102B-1 (slower eluting) on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2. Preparation of trans-methyl 3-oxo-l,5,6,7,8,8a-hexahydrooxazolo[3,4-a]pyrazine-8- c rboxylate (compound 102-C):
mi
Figure imgf000210_0001
Step I: To a stirred solution of compound 82-C-l (8.6 g, 23 mmol) and pyridine (3.64 g, 46 mmol) in DCM (80 mL) was added a solution of (4-nitrophenyl) carbonochloridate (6.95g, 34.5 mmol) in DCM (20 mL) at 0 °C. Then the mixture was warmed to rt and stirred for about 2-3 hrs. The solvent was diluted with DCM (100 mL) and the mixture was washed successively with 0.6N HC1 (50 mL), aq. NaHCO3(50 mL) and brine. The organic layer was dried over Na2S04, filtered and concentrated in vacuum. The obtained crude product was purified by column chromatography on silica to get the title product 102-C-l (9.5 g). 1H NMR (400 MHz, CDC13) d ppm 8.30 (d, / = 8.8 Hz, 2H), 7.43 (t, / = 8.5 Hz, 2H), 5.30-5.09 (m, 1H), 4.88-4.71 (m, 1H), 4.54 - 4.23 (m, 2H), 4.08-3.93 (m, 1H), 3.91-3.77 (m, 5H),3.33-2.97 (m, 1H), 3.33-2.97 (m, 1H), 1.51-1.47(t, 18 H)
Step II: To a solution of compound 102-C-l (9.5 g, 17.6 mmol) in DCM (70 mL) was added TFA (70 mL) at room temperature. Then the mixture was stirred for about 3 h. The solvent was removed under reduced pressure to give the crude product 102-C-2 (10 g crude) as TFA salt which was used in the next step without further purification.
Step III: To a stirred solution of compound 102-C-2 (crude, 10 g, 17.6 mmol) in DCM (160 mL) was added DIPEA (28 mL) at room temperature. Then the mixture was heated to reflux and stirred for about 4 h. The crude product was purified by column chromatography on silica to give the title compound 102-C (2 g). MS: calc'd 201 (MH+), measured 201 (MH+).
Example 103A and 103B (separated two single isomers):
Ethyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-(hydroxymethyl)-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate; and Ethyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-(hydroxymethyl)-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dih dropyrimidine-5-carboxylate
Figure imgf000211_0001
The title two compounds were prepared in analogy to Example 82A-1 and 82B-1 by using trans-2-tert-buty\-S-( ydroxymet yl)- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazin-3-one (compound 103-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8,8a- hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 103A (faster eluting on ChiralPak AD-3 column with 30% isopropanol
(0.05%DEA)/CO2) was obtained as a light yellow solid (43 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.95 (d, / = 3.0 Hz, 1H), 7.74 (d, / = 3.0 Hz, 1H), 7.35 - 7.26 (m, 2H), 7.19 - 7.11 (m, 1H), 6.25 (s, 1H), 4.43 (d, / = 17.6 Hz, 1H), 4.13 - 4.01 (m, 3H), 3.97 - 3.84 (m, 1H), 3.75 (dd, / = 4.0, 12.5 Hz, 1H), 3.69 - 3.60 (m, 2H), 3.58 - 3.51 (m, 1H),3.28 (dd, / = 7.2, 8.7 Hz, 1H), 3.01 (dt, / = 3.1, 12.4 Hz, 1H), 2.81 - 2.71 (m, 1H), 2.53 - 2.41 (m, 2H), 1.39 (s, 9H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Example 103B (slower eluting on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2) was obtained as a light yellow solid (25 mg). 1H NMR (400 MHz,
METHANOL-d ) d ppm 7.98 - 7.92 (m, 1H), 7.77 - 7.70 (m, 1H), 7.33 - 7.23 (m, 2H), 7.19 - 7.11 (m, 1H), 6.24 (s, 1H), 4.53 (d, / = 17.8 Hz, 1H), 4.08 - 3.95 (m, 3H), 3.74 - 3.62 (m, 4H), 3.57 - 3.47 (m, 1H), 3.26 (dd, / = 7.4, 8.7 Hz, 1H), 3.07 - 2.99 (m, 1H), 2.94 (d, J = 11.8 Hz, 1H), 2.61 (dt, / = 3.5, 11.8 Hz, 1H), 2.50 - 2.40 (m, 1H), 1.39 (s, 9H), 1.16 - 1.10 (m, 3H). MS: calc'd 605 (MH+), measured 605 (MH+).
Preparation of trans -methyl 3-oxo-l,5,6,7,8,8a-hexahydrooxazolo[3,4-a]pyrazine-8- carboxylate (compound 102-C):
Figure imgf000212_0001
92-C-1 103-C-1 103-C-2
mixture of two trans isomers mixture of two trans isomers
Step I: LiOH.H20 (1.26 g, 30 mmol) in H20 (10 mL) was added to a solution of compound 92-C-l (3.55 g, 10 mmol) in methanol (40 mL) at rt. After the mixture was stirred at rt for 5h, methanol was removed under reduced pressure and the mixture was adjusted to pH=5 with 2N HC1 solution. The mixture was extracted with ethyl acetate (50 mL, 3 times). The combined organic phase was dried and concentrated to afford crude product 103-C-l (3.14 g) which was used in the next step without further purification. MS: calc'd 342 (MH+), measured 342 (MH+).
Step II: BH3.THF (1M in THF, 30 mL) was added to a solution of compound 103-C-l (3 g,
8.8 mmol) in THF (20 mL) at rt. After the reaction mixture was refluxed for 3 hours, it was cooled to 0 °C. Methanol was added slowly to previous reaction mixture to quench the reaction. The solvent was removed and the residue was purified by column chromatography to afford product 103-C-2 (2.47 g). MS: calc'd 328 (MH+), measured 328 (MH+).
Step III: TFA (2 mL) was added to a stirring solution of compound 103-C-2 (2 g, 6.1 mmol) in CH2C12 (20 mL) at rt. After 3 hours, LC-MS indicated that the start materials were consumed. The solvent was removed to give the crude product 103- C which was used in the next step without further purification. MS: calc'd 228 (MH+), measured 228 (MH+). Example 104A and 104B (separated two single isomers): Ethyl (4R)-6-[[(8aR)-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine- 5-carboxylate; and
Ethyl (4R)-6-[[(8aS)-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin- 7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5- carbox late
Figure imgf000213_0001
The title two compounds were prepared in analogy to Example 82A-1 and 82B-1 by using
2-isopropyl- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazin-3-one (compound 104-C) instead of trans-methyl 2-cyclopropyl-3-oxo-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazine-8-carboxylate (compound 82-C).
Example 104A (faster eluting on ChiralPak AD-3 column with 30% isopropanol
(0.05%DEA)/CO2) was obtained as a light yellow solid (71 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.96 (d, / = 3.3 Hz, 1H), 7.75 (d, / = 3.0 Hz, 1H), 7.32 - 7.24 (m, 2H), 7.15 (t, / = 8.3 Hz, 1H), 6.24 (s, 1H), 4.12 - 4.01 (m, 4H), 3.94 - 3.85 (m, 2H), 3.80 (dd, / = 2.0, 13.3 Hz, 1H), 3.51 (t, / = 8.9 Hz, 1H), 3.18 - 3.04 (m, 2H), 2.99 (dd, / = 2.8, 10.8 Hz, 1H), 2.79 - 2.67 (m, 1H), 2.29 (t, / = 10.9 Hz, 1H), 2.25 - 2.17 (m, 1H), 1.20 - 1.10 (m, 9H). MS: calc'd 561 (MH+), measured 561 (MH+). Example 103B (slower eluting on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2) was obtained as a light yellow solid (77 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.96 (d, / = 3.1 Hz, 1H), 7.75 (d, / = 3.3 Hz, 1H), 7.33 - 7.23 (m, 2H), 7.15 (t, / = 8.5 Hz, 1H), 6.24 (s, 1H), 4.13 - 4.00 (m, 4H), 3.94 - 3.83 (m, 3H), 3.45 (t, / = 8.9 Hz, 1H), 3.22 - 3.12 (m, 1H), 3.00 (dd, / = 4.0, 9.3 Hz, 1H), 2.93 - 2.80 (m, 2H), 2.34 (dt, / = 3.4, 11.6 Hz, 1H), 2.15 (t, / = 10.9 Hz, 1H), 1.18 - 1.09 (m, 9H). MS: calc'd 561 (MH+), measured 561 (MH+).
Preparation of 2-isopropyl- 1 ,5,6,7,8,8a-hexahydroimidazo[ 1 ,5 -a] pyrazin-3-one (compound 104-C):
Figure imgf000214_0001
104-C-1 i"4"1- ie/t-Butyl 2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazine-7-carboxylate (compound 104-C-l) (1 mmol) was dissolved in CH2C12 (3 mL) followed by the slow addition of TFA (1 mL) at 0 °C. After the reaction mixture was stirred at rt for 1 hour, the solvent was removed in vacuum to give the crude product 104-C, which was used directly in the next step.
Preparation of tert-Butyl 2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-7-carboxylate (compound 104-C-l):
Compound 104-C-l was prepared in analogy to Compound 67-D by using zsopropyl amine instead of 2-aminoethanol. Example 105A and 105B (separated two single isomers):
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-8-carboxylic acid; and
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-8-carboxylic acid
Figure imgf000215_0001
Pre aration of Example 105A and 105B:
Figure imgf000215_0002
The title two compounds were prepared in analogy to Example 82A-1 and 82B-1 by using 2-(2,2-difluoroethyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-3-one (compound 105-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[l,5-a]pyrazine-8- carboxylate (compound 82-C).
Example 105A (faster eluting on ChiralPak AD-3 column with 30% isopropanol
(0.05%DEA)/CO2) was obtained as a light yellow solid (22 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, 1H), 7.77 (d, / = 3.0 Hz, 1H), 7.34 - 7.26 (m, 2H), 7.19 - 7.12 (m, 1H), 6.25 (s, 1H), 6.17 - 5.83 (m, 1H), 4.31 (d, / = 17.1 Hz, 1H), 4.08 - 4.00 (m, 2H), 3.96 - 3.86 (m, 2H), 3.80 (dd, / = 2.0, 13.6 Hz, 1H), 3.74 - 3.68 (m, 1H), 3.66 - 3.56 (m, 3H), 3.28 - 3.16 (m, 1H), 2.95 - 2.87 (m, 2H), 2.53 (dt, 7 = 3.4, 12.0 Hz, 1H), 1.13 (t, 7 = 7.2 Hz, 3H). MS: calc'd 627 (MH+), measured 627 (MH+).
Example 105B (slower eluting on ChiralPak AD-3 column eluting with 30% isopropanol
(0.05%DEA)/CO2) was obtained as a light yellow solid (22 mg). 1H NMR (400 MHz,
METHANOL-d ) d ppm 7.96 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.0 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.17 (t, / = 8.1 Hz, 1H), 6.21 (s, 1H), 6.16 - 5.83 (m, 1H), 4.23 (d, / = 16.6 Hz, 1H), 4.06 - 4.00 (m, 2H), 3.98 - 3.81 (m, 3H), 3.72 - 3.66 (m, 1H), 3.65 - 3.55 (m, 3H), 3.29 - 3.17 (m, 2H), 3.04 (d, / = 10.3 Hz, 1H), 2.66 - 2.54 (m, 1H), 1.12 (t, J = 7.2 Hz, 3H). MS: calc'd 627 (MH+), measured 627 (MH+).
Preparation of 2-(2,2-difluoroethyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-3- one (compound 105-C):
Figure imgf000216_0001
105-C-1 105-L
ie/t-Butyl 2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazine-7- carboxylate (compound 105-C-l) (1 mmol) was dissolved in CH2C12 (3 mL) followed by the slow addition of TFA (1 mL) at 0 °C. After the reaction mixture was stirred at rt for 1 hour, the solvent was removed in vacuum to give the crude product 105-C, which was used directly in the next step.
Preparation of tert-butyl 2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-7-carboxylate (compound 105-C-l):
Compound 105-C-l was prepared in analogy to Compound 67-D by using 2,2- difluoroethanamine instead of 2-aminoethanol.
Example 106A and 106B (separated two single isomers):
Ethyl (4R)-6-[[(8aR)-2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate; and
Ethyl (4R)-6-[[(8aS)-2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine-5-carboxylate
Figure imgf000217_0001
Pre aration of Example 106A and 106B:
Figure imgf000217_0002
The title two compounds were prepared in analogy to Example 82A-1 and 82B-1 by using 2-(2-hydroxy-2-methyl-propyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5-a]pyrazin-3-one (compound 106-C) instead of trans-methyl 2-cyclopropyl-3-oxo- 1,5,6,7, 8, 8a-hexahydroimidazo[ 1,5- a]pyrazine-8-carboxylate (compound 82-C).
Example 106A (faster eluting on ChiralPak AD-3 column with 30% isopropanol
(0.05%DEA)/CO2) was obtained as a light yellow solid (18 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.96 (d, / = 3.0 Hz, 1H), 7.76 (d, / = 3.3 Hz, 1H), 7.33 - 7.24 (m, 2H),
7.15 (t, / = 8.2 Hz, 1H), 6.25 (s, 1H), 4.14 - 4.01 (m, 3H), 3.97 - 3.88 (m, 2H), 3.80 (dd, / = 2.0, 13.3 Hz, 1H), 3.75 - 3.69 (m, 1H), 3.36 (d, / = 4.3 Hz, 1H), 3.24 - 3.15 (m, 2H), 3.13 - 3.07 (m, 1H), 3.01 (dd, / = 2.9, 10.9 Hz, 1H), 2.76 (d, / = 11.3 Hz, 1H), 2.36 (t, / = 10.9 Hz, 1H), 2.22 (dt, / = 3.1, 11.6 Hz, 1H), 1.22 (s, 6H), 1.13 (t, / = 7.2 Hz, 3H). MS: calc'd 591 (MH+), measured 591 (MH+).
Example 106B (slower eluting on ChiralPak AD-3 column eluting with 30% isopropanol (0.05%DEA)/CO2) was obtained as a light yellow solid (26 mg). 1H NMR (400 MHz,
METHANOL-d4) d ppm 7.97 (d, / = 3.3 Hz, 1H), 7.76 (d, / = 3.3 Hz, 1H), 7.34 - 7.24 (m, 2H),
7.16 (t, / = 8.2 Hz, 1H), 6.24 (s, 1H), 4.13 - 4.01 (m, 3H), 3.96 - 3.84 (m, 3H), 3.66 (t, / = 9.2 Hz, 1H), 3.30 - 3.16 (m, 3H), 3.14 - 3.03 (m, 1H), 2.95 - 2.83 (m, 2H), 2.36 (dt, / = 3.4, 11.6 Hz, 1H), 2.22 (t, / = 10.9 Hz, 1H), 1.21 (s, 6H), 1.13 (t, / = 7.0 Hz, 3H). MS: calc'd 591 (MH+), measured 591 (MH+).
Preparation of 2-(2-hydroxy-2-methyl-propyl)-l,5,6,7,8,8a-hexahydroimidazo[l,5- a]pyrazin-3-one (compound 106-C):
Figure imgf000218_0001
106-C-1 106_C
ie/t-Butyl 2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-7-carboxylate (compound 106-C-l) (1 mmol) was dissolved in CH2CI2 (3 mL) followed by the slow addition of TFA (1 mL) at 0 °C. After the reaction mixture was stirred at rt for 1 hour, the solvent was removed in vacuum to give the crude product 106-C, which was used directly in the next step.
Preparation of tert-butyl 2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazine-7-carboxylate (compound 106-C-l):
Compound 105-C-l was prepared in analogy to Compound 67-D by using l-amino-2- methyl-propan-2-ol instead of 2-aminoethanol.
Example 107: HBV inhibition assays
Cells and culture conditions:
HepG2.2.15 and HepDE19 are stably- transfected cell lines containing the HBV genome. Both cell lines are derived from the hepatoblastoma cell line Hep G2 (American Type Culture Collection, ATCC® HB-8065™) by the published procedures described in references: MA Selles et al. Proc. Natl. Acad. Sci. USA 1987, 84, 1005-1009 and H Guo et al. Journal of Virology 2007, 81, 12472-12484, respectively. Both cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM)-F12 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μ§/ι ί streptomycin, and 0.5 mg/mL of G418.
While HepG2.2.15 cells constitutively support HBV replication and production of virus particles, HepDE19 cells are inducible by tetracycline. Addition of ^g/mL tetracycline in culture medium suppresses HBV replication in HepDE19 cells, whereas switching to tetracycline-free medium resumes this process.
Anti-HBV activity in vitro: HepG2.2.15 cells were seeded into 96-well plates (3 x 104 cells in 100 μL· media per well) and incubated overnight at 37 °C. The test compounds were serially half-log diluted in DMSO, then diluted 100 times in culture media. 100 μΙ_, of diluted compounds were added into the plates to reach 0.5% final concentration of DMSO in every well. Five days after compound treatment, culture supernatant was collected for further analysis.
For quantitative PCR detection of extracellular HBV DNA, 100 μΙ_, of culture supernatant was collected and processed in MagNA Pure 96 Nucleic Acid Purification System (Roche Applied Science) for viral DNA extraction. The extracted samples were subjected to HBV DNA quantification by qPCR. The effective compound concentration at which HBV replication is inhibited by 50% (EC50) was determined as shown in Table 1.
The compounds of the present invention were tested for their capacity to inhibit a HBV activity and activation as described herein. The Examples were tested in the above assays as described herein and found to have EC50 <0.2 μΜ in HepG2.2.15 assay. Particular compounds of formula (I) or other compounds of the present invention were found to have EC50 <0.02 μΜ in HepG2.2.15 assay.
Table 1: Anti-HBV activity data of particular compounds in HepG2.2.15 cells
Example No. ΕΟ50 (μΜ) Example No. ΕΟ50 (μΜ)
1 0.104 2 0.054
3 0.023 4 0.003
5 0.159 6 0.014
7 0.014 8 0.011
9 0.064 10 0.057
11 0.001 12 0.149
13 0.066 14 0.002
15 0.110 16 0.041
17 0.039 18 0.108
19 0.003 20 0.052
21 0.016 22 0.003
23 0.003 24 0.001
25 0.002 26 0.002
27 0.003 28 0.030
29 0.007 30 0.095
31 0.100 32 0.199 33 0.030 34 0.008
35 0.011 36 0.006
37 0.017 38 0.005
39 0.030 40 0.034
41 0.014 42 0.006
43 0.006 44 0.016
45 0.026 46 0.026
47 0.051 48 0.022
49 0.008 50 0.015
51 0.031 52 0.030
53 0.019 54 0.008
55 0.005 56 0.026
57 0.032 58 0.019
59 0.011 60 0.006
61 0.012 62 0.006
63 0.012 64 0.008
65 0.009 66 0.004
67 0.438 68 0.143
69 0.013 70 0.005
71 0.014 72 0.009
73 0.009 74 0.036
75 0.024 76 0.007
77 0.146 78 0.387
79 0.008 80 0.032
81 0.010 82A/82B 0.145/0.002
83B 0.009 84A/84B 0.045/0.001A/85B 0.259/0.006 86B 0.004A/87B 0.062/0.001 87B-1 0.004A/88B 0.677/0.005 89 0.007A/90B 0.096/0.300 91A/91B 0.150/0.002A/92B 0.078/0.0007 93 0.012
94 0.004 95 0.011
96 0.150 97A/97B 0.037/0.0009
98 0.011 99 0.014 101A/101B 0.040/0.0008 102A/102B 0.147/0.014
103A/103B 0.140/0.010 104A/104B 0.131/0.004
105A/105B 0.188/0.003 106A/106B 0.032/0.003
Cytotoxicity and selectivity index:
HepDE19 cells were seeded into 96- well plates (5 x 10 cells per well) and treated with compounds for EC50 determination. Five days after treatment, cell viability was measured by addition of 20 μΐ^ of CCK-8 reagent. Two hours after incubation at 37°C, the absorbance at wavelengths of 450 nm and 630 nm (OD450 and OD63o) was recorded by a plate reader. The concentration results in the death of 50% of the host cells (CC50) of each compound were determined.
The relative effectiveness of the compound in inhibiting viral replication compared to inducing cell death was defined as the selectivity index (CC50 value/ECso value). Based on CC50 and EC50 data, selectivity indexes were determined.
Results of CC50 and the corresponding selectivity index are given in Table 2.
Table 2: CC50 and selectivity index of particular compounds
Selectivity index Selectivity index
Example No. CC50 (μΜ) Example No. CC50 (μΜ)
(CC50/EC50) (CC50 EC50)
4 79 23872 11 52 30635
14 23 13016 19 >100 >30303
21 >100 >6211 22 >100 >34482
24 53 37857 26 28 18620
34 81 10655 35 >100 >9259
36 >100 >18181 38 100 21276
41 >100 >7194 42 >100 >15625
44 >100 >6369 54 >100 >12500
55 >100 >20000 59 >100 >9091
60 68 11333 61 >100 >8333
62 >100 >16667 63 91 7583
64 67 8375 65 >100 >11111
66 60 15000 70 63 12600
71 >100 >7143 73 70 7778
76 >100 >14286 79 52 6500 81 85 8500 82B >100 >50000
83B >100 >11111 84B >100 >100000
85B >100 >16667 86B >100 >25000
87B >100 >100000 88B >100 >20000
89 75 10714 91B >100 >50000
92B 66 94285 93 86 7167
94 48 12000 97B >100 >100000
98 73 6636 99 >100 >7142
101B >100 >100000 102B >100 >7142
104B 27 >6750 105B >100 >33333
106B 65 21666
Example 108: Human microsomal metabolic stability
Human Microsomes (BD Gentest) were preincubated with test compound for 10 minutes at 37°C in 100 mM phosphate buffer, pH 7.4. The reactions were initiated by adding NADPH or NADPH regenerating system to give a final incubation volume of 400 μ For NADPH system, the final incubations contained 1 μΜ test compound, 0.5 mg/mL liver microsomal protein, 1 mM NADPH in 100 mM phosphate buffer, pH 7.4. For the NADPH regenerating system, the final incubations contained 1 μΜ test compound, 0.5 mg/mL liver microsomal protein, 3 mM glucose 6-phosphate, 1 mM NADP, 3 mM MgCl2 and 0.05 mg/mL glucose 6-phosphate dehydrogenase in 100 mM phosphate buffer, pH 7.4. After incubation times of 0, 3, 6, 9, 15 and 30 minutes at 37 °C, 1 sample was obtained from each time point and 50 μΐ^ of each sample was removed and transferred to 150 of methanol solution which was maintained at 4 °C and contained 2 μΜ tolbutamide as internal standard. Following precipitation and centrifugation, the amount of compound remaining in the samples were determined by LC-MS/MS. Controls of no NADPH or no NADPH regenerating system at zero and 30 minutes were also prepared and analyzed.
Results of metabolic stability study in human microsome are given in Table 3.
Table 3 Metabolic stability in human microsome
Human Microsomal Human Microsomal
Example number Clearance Example number Clearance
(mL/min/kg) (mL/min/kg)
19 0.4 20 0.1
21 2.7 25 0.4
28 4.4 29 0.3
30 1.7 31 0.3 32 1.6 33 2.5
34 1.8 35 0.3
36 4.4 37 2.5
38 2.0 39 0.4
41 2.0 42 2.0
43 3.1 44 1.7
45 0 46 0
47 0 48 3.8
49 0 50 3.6
51 2.0 52 0.0
53 5.1 54 4.6
55 0.0 56 0.0
59 2.3 60 0.0
61 0.4 62 1.7
63 5.3 64 5.6
65 6.2 66 7.1
67 4.7 68 4.5
72 5.2 73 8.1
74 1.0 75 0.0
76 0.8 78 6.7
79 3.6 80 8.3
81 0.1 82A/82B 1.7/2.7
83A/83B 0.0/2.9 84A/84B 0.0/3.6
85A/85B 4.9/0 86B 4.7
87B 5.0 88B 4.5
90A/90B 0.3/0 91B 5.8
99 6.1 101B 6.1
102B 6.2
Example 109: Lysa solubility
Samples were prepared in duplicate from 10 mM DMSO stock solutions. After evaporation of DMSO with a centrifugal vacuum evaporator, the residue was solved in 0.05 M phosphate buffer (pH 6.5), stirred for one hour and shook for two hours. After one night, the solution was filtered using a microtiter filter plate. Then the filtrate and its 1/10 dilution were analyzed by direct UV measurement or by HPLC-UV. In addition a four-point calibration curve was prepared from the 10 mM stock solutions and used for the solubility determination of the compounds. The results were in μg/mL. In case the percentage of sample measured in solution after evaporation divided by the calculated maximum of sample amount was over 80%, the solubility was reported as higher than this value.
Results of Lysa are given in Table 4.
Table 4: Solubility data of particular compounds
Example No. Lysa ^g/mL) Example No. Lysa ^g/mL)
19 >727.0 20 >780.0
21 >786.0 28 337
30 610 31 >775.0
32 >701.0 33 >748.0
34 326 35 >754.0
36 485 37 422
38 627 39 >770.0
41 >804.0 42 >785.0
44 207 45 >690.0
46 >744 47 >767
48 >807 49 312
50 339 51 589
53 >723 54 387
55 470 56 >740
59 >685 60 436
61 >742 62 374
63 >751 64 >669
65 194 67 >794
68 >794 71 232
72 551 73 564
74 >716 75 >774
76 565 78 >793
79 180 80 >616 81 279 82A/82B >765/>760
83A/83B >740/780 84A/84B 570/770
85A/85B >660/770 86B >740
88B >745 90A/90B >730/>740
91B >705 95 307
99 >710 102B >665
Example 110: Cytochrome P450 (Cyp450) induction screening assay _ mRNA induction MATERIALS
Cell culture
Human cryopreserved hepatocytes (Life Technologies, Carlsbad, USA) were thawed and cultured in collagen I coated 96-well plates with a density of 52,000 cells/well. After attachment, medium was changed and cells were pre-cultured overnight in hepatocyte maintenance medium (HMM; Lonza, Switzerland).
Test compounds were dosed to the cells next morning at an indicated concentration (up to 10 μΜ) in HMM culture media containing gentamycin and a constant 0.1 % DMSO. Similarly, dilutions of the positive inducer compounds omeprazole (prototypical inducer of human
CYP1A2; final concentrations: 1 and 10 μΜ), phenobarbital (prototypical inducer of human CYP2B6; final concentrations: 100 and 1000 μΜ) and rifampicin (prototypical inducer of human CYP3A4; final concentrations: 1 and 10 μΜ) were prepared from 1000 fold DMSO stock solutions in HMM containing gentamycin. Medium change was then performed and cells were exposed for 24 hours to test compounds, positive inducer compounds, or vehicle (0.1 % DMSO), respectively.
At the end of the compound exposure period, medium was removed and cells lysed using 100 μίΛνεΙΙ MagNA Pure LC RNA isolation tissue lysis buffer (Roche Diagnostics AG,
Rotkreuz, Switzerland). Plates were then sealed and frozen at -80°C until further workup.
mRNA isolation, processing and qRT-PCR
mRNA isolation was performed using the MagNA Pure 96 system (Roche Diagnostics AG, Rotkreuz, Switzerland) and the respective cellular RNA large volume kit (Roche Diagnostics AG, Rotkreuz, Switzerland) from thawed samples diluted 1: 1 with PBS. The volume of the cell lysis and an elution volume of 100 μΐ^ were used. 20 μΐ^ of the resulting mRNA suspension was then used for reverse transcription using 20 μΐ^ of the transcript or first stand cDNA synthesis kit (Roche prime Supply, Mannheim, Germany). The resulting cDNA was diluted with 40 μL· oΐ H20 before using for qRT-PCR. qRT-PCR was performed by using the forward and the reverse primer, the corresponding UPL (all from Microsynth, Balgach, Switzerland) and the Taqman Fast advanced master mix (Applied Biosystems), on an ABI 7900 machine (Applied Biosystems).
Calculations
qRT-PCR Ct- values for the respective P450s were put into relation to the Ct-value of RN18S1 (microsynth, Balgach, Switzerland) of the same sample. Doing so, a respective Act- value was calculated. Using the average of all Act- values for the vehicle control samples, a AAct- value was calculated for each sample (AAct-value(sample) = Act-value(sample) - average of Act- value of all vehicle controls). The fold induction of the respective sample was calculated as 2Λ(- AAct). The individual fold induction values were then averaged per treatment condition (usually n=3 biological replicates).
Relative induction values to the respective positive inducer compound condition (10 μΜ omeprazole for CYP1A2; 1000 μΜ Phenobarbital for CYP2B6; 10 μΜ rifampicin for CYP3A4) were then calculated from the fold induction values as follows:
Relative induction (%) = 100x(T-V)/(P-V)
T: fold induction of test compound condition
P: fold induction of positive inducer compound
V: fold induction of vehicle controls
Results of CYP3A4 induction are given in Table 5.
Table 5: Relative induction values of particular compounds to 10 μΜ rifampicin
Example No. % of Positive control (10 μΜ Rifampicin)
11 17
19 1
21 2.4
22 0
25 0
27 0.2
30 7.3
34 0.2
36 6
38 0.2
42 0.6
43 0.2 20
0
0.1
2.2
0
0
1.3B 6B 11B 4.0B 3.7B 1.7

Claims

Claims
1. A compound of formula (I)
Figure imgf000228_0001
wherein
R1 is hydrogen, halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen, hydroxyCi_6alkyl, aminocarbonyl, Ci_6alkoxycarbonyl or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
X is carbonyl or sulfonyl;
Y is -CH2-, -O- or -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, haloCi_6alkyl, C3-7cycloalkyl-CmH2m-, Ci_
6alkoxycarbonyl-CmH2m-,-CtH2t-COOH, -haloCi_6alkyl-COOH, -(Ci-6alkoxy)Ci-6alkyl- COOH, -Ci_6alkyl-0-Ci_6alkyl-COOH, -C3-7cycloalkyl-CmH2m-COOH, -CmH2m-C3_ 7cycloalkyl-COOH, hydroxy-CtH2r, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m- carboxypyridinyl-CmH2m- ;
W is -CH2-, -C(Ci_6alkyl)2-, -O- or carbonyl;
n is 0 or 1 ;
m is 0-7;
t is 1-7; or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
A compound according to claim 1, wherein
is hydrogen, chloro, bromo or methyl;
R is hydrogen or fluoro;
R is hydrogen, chloro or fluoro;
R4 is methyl, ethyl or propyl;
R5 is hydrogen, hydroxymethyl, aminocarbonyl, methoxycarbonyl or carboxy;
R6 is hydrogen, methyl-O-carbonyl or carboxymethyl;
X is carbonyl or sulfonyl;
Y is -CH2-, -0-, -N(R7)-,
wherein R is hydrogen, methyl, difluoroethyl, isopropyl, isobutyl, t-butyl, cyclopropyl , cyclopropylmethyl, methyl-O-carbonylisopropyl, carboxyethyl, carboxydifluoroethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl,
carboxycyclopropylmethyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl,
carboxymethoxyethyl, carboxymethoxypropyl, hydroxyethyl,
hydroxymethyl(gemdimethyl)butyl, hydroxy(gemdimethyl)ethyl, carboxyphenyl, carboxypyridinyl or carboxyphenylmethyl;
W is -CH2-, -C(CH3)2-, -O- or carbonyl;
n is 0 or 1 ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
3. A compound of formula (IA) according to claim 1,
Figure imgf000230_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci_6alkyl;
R5 is hydrogen, hydroxyCi_6alkyl, aminocarbonyl, Ci_6alkoxycarbonyl or carboxy;
R6 is hydrogen, Ci_6alkoxycarbonyl or carboxy-CmH2m-;
Y is -N(R7)-,
wherein R is hydrogen, Ci_6alkyl, haloCi_6alkyl, C3_7cycloalkyl-CmH2m-, Ci_
6alkoxycarbonyl-CmH2m-,-CtH2t-COOH, -haloCi_6alkyl-COOH, -(Ci_6alkoxy)Ci_6alkyl- COOH, -Ci-6alkyl-0-Ci-6alkyl-COOH, -C3-7cycloalkyl-CmH2m-COOH, -CmH2m-C3_ 7cycloalkyl-COOH, hydroxy-CtH2r, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m- carboxypyridinyl-CmH2m- ;
W is -CH2- or carbonyl;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
4. A compound according to claim 1 or 3 or pharmaceutically acceptable salts, or
enantiomers or diastereomers thereof, wherein
R1 is chloro, bromo or methyl; is hydrogen or fluoro;
is hydrogen, chloro or fluoro;
is methyl, ethyl or propyl;
is hydrogen, hydroxymethyl, aminocarbonyl, methoxycarbonyl or carboxy;
is hydrogen, methyl-O-carbonyl or carboxymethyl;
is -N(R7)-,
wherein R is hydrogen, methyl, difluoroethyl, isopropyl, isobutyl, t-butyl, cyclopropyl , cyclopropylmethyl, methyl-O-carbonylisopropyl, carboxyethyl, carboxydifluoroethyl, carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxy(methyl)ethyl, carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutyl, carboxycyclobutylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl,
carboxycyclopropylmethyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl,
carboxymethoxyethyl, carboxymethoxypropyl, hydroxyethyl,
hydroxymethyl(gemdimethyl)butyl, hydroxy(gemdimethyl)ethyl, carboxyphenyl, carboxypyridinyl or carboxyphenylmethyl;
is -CH2- or carbonyl.
5. A compound of formula (IAA) according to claim 1 or 3,
Figure imgf000231_0001
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen; is hydrogen or halogen;
is Ci_6alkyl;
is hydrogen, aminocarbonyl or carboxy;
is hydrogen;
R7 is Ci-6alkyl, haloCi_6alkyl, C3-7cycloalkyl, C3_7cycloalkyl-CmH2m-, -CtH2t-COOH, -CmH2m- C3_7cycloalkyl-COOH or carboxyphenyl;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
A compound according to any one of claims 1, 3 or 5 or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
is chloro or methyl;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
is methyl or ethyl;
is hydrogen, aminocarbonyl or carboxy;
is hydrogen;
Figure imgf000232_0001
is methyl, isopropyl, isobutyl, t-butyl, difluoroethyl, cyclopropyl, cyclopropylmethyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxycyclopropylmethyl, carboxycyclobutylmethyl or carboxyphenyl.
7. A compound of formula (IB) according to claim 1,
Figure imgf000233_0001
wherein
R1 is
R2 is
R3 is
R4 is
R5 is
R6 is
Y is
W is
n is 0 or 1 ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
8. A compound according to claim 1 or 7 or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof, wherein
R1 is hydrogen, chloro or bromo;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
R4 is methyl or ethyl;
R5 is hydrogen;
R6 is hydrogen or carboxymethyl;
Y is -CH2- or -0-; W is -CH2-, -C(CH3)2- or -0-;
n is 0 or 1.
Figure imgf000234_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen, aminocarbonyl or carboxy;
R6 is hydrogen or Ci_6alkoxycarbonyl
X is carbonyl;
Y is -O- or -N(R7)- or -CH2-,
wherein R is hydrogen, Ci_6alkyl, haloCi_6alkyl, C3_7cycloalkyl, C3_7cycloalkyl-CmH2m-, - CtH2t-COOH -CmH2m-C3_7cycloalkyl-COOH , hydroxy-CtH2r, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
10. A compound according to claim 1 or 9 or pharmaceutically acceptable salts, or
enantiomers or diastereomers thereof, wherein is chloro, bromo or methyl;
is hydrogen or fhioro;
is hydrogen or f ioro;
is methyl, ethyl or propyl;
is hydrogen, aminocarbonyl or carboxy;
is hydrogen or methyl-O-carbonyl;
is carbonyl;
is -0-, -N(R7)- or -CH2-,
wherein R is hydrogen, methyl, isopropyl, difluoroethyl, isobutyl, t-butyl, cyclopropyl, cyclopropylmethyl, carboxy(gemdimethyl)ethyl, carboxy(methyl)ethyl,
carboxycyclopropylmethyl , carboxyphenyl, carboxycyclopentyl, carboxycyclohexyl, carboxy(gemdimethyl)propyl, carboxy(gemdimethyl)butyl, carboxycyclobutylmethyl, carboxyspiro[3.3]heptyl, hydroxyethyl, hydroxy(gemdimethyl)ethyl or
carboxyphenylmethyl.
A compound of formula (IE) according to claim 1,
Figure imgf000235_0001
wherein
R1 is halogen or Ci_6alkyl;
R is hydrogen or halogen;
R is hydrogen or halogen;
R4 is Ci-6alkyl; R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m-;
Y is -0-,-N(R7)- or -CH2-,
wherein R7 is Ci_6alkyl, C3-7cycloalkyl, -CtH2t-COOH, -C3_7cycloalkyl-CmH2m-COOH, - CmH2m-C3_7cycloalkyl-COOH , -(Ci-6alkoxy)Ci-6alkyl-COOH, -Ci-6alkyl-0-Ci-6alkyl-
COOH, carboxyspiro[3.3]heptyl or carboxyphenyl-CmH2m-;
W is -CH2- or -C(Ci_6alkyl)2-;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
12. A compound according to claim 1 or 11 or pharmaceutically acceptable salts, or
enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
hydrogen or fluoro;
is hydrogen or fluoro;
is methyl or ethyl;
is hydrogen or carboxy;
is hydrogen or carboxymethyl;
is -0-, -N(R7)- or -CH2-,
wherein R is isopropyl, methyl, isobutyl, t-butyl, cyclopropyl, carboxyethyl,
carboxypropyl, carboxybutyl, carboxy(gemdimethyl)methyl, carboxy(gemdimethyl)ethyl, carboxy(methyl)ethyl, carboxycyclobutyl, carboxycyclopropylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxymethylcyclopropyl, carboxy(gemdimethyl)propyl,
carboxy(ethyl)ethyl, carboxy(methoxy)ethyl, carboxycyclobutylmethyl,
carboxyspiro[3.3]heptyl, carboxymethoxyethyl, carboxymethoxypropyl,
carboxyphenylmethyl or carboxyphenyl;
is -CH2- or -C(CH3)2-.
A compound of formula (IE) according to claim 1,
Figure imgf000237_0001
wherein
R1 is halogen or Ci_6alkyl;
R2 is hydrogen or halogen;
R3 is hydrogen or halogen;
R4 is Ci-6alkyl;
R5 is hydrogen or carboxy;
R6 is hydrogen or carboxy-CmH2m-;
Y is -N(R7)-,
wherein R7 is hydrogen, C1-6alkyl, C3-7cycloalkyl, -CtH2t-COOH, -CmH2m-C3-7cycloalkyl-
COOH or carboxyphenyl;
W is -CH2-;
m is 0-7;
t is 1-7;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
14. A compound according to claim 1 or 13 or pharmaceutically acceptable salts, or
enantiomers or diastereomers thereof, wherein
R1 is chloro or methyl;
R2 is hydrogen or fluoro;
R3 is hydrogen or fluoro;
R4 is methyl or ethyl; R5 is hydrogen or carboxy;
R6 is hydrogen or carboxymethyl;
Y is -N(R7)-,
wherein R is hydrogen, methyl, t-butyl, cyclopropyl, carboxy(gemdimethyl)ethyl, carboxy(gemdimethyl)propyl, carboxy(methyl)ethyl, carboxycyclopropylmethyl, carboxycyclopentyl, carboxycyclohexyl, carboxycyclobutylmethyl or carboxyphenyl; W is -CH2-.
15. A compound according to any one of claims 1 to 14 or pharmaceutically acceptable salts, or enantiomers or diastereomers, wherein the 2-thiazolyl group is further substituted by Ci_6alkyl.
16. A compound according to claim 15 or pharmaceutically acceptable salts, or enantiomers or diastereomers, wherein the 2-thiazolyl group is further substituted by methyl. 17. A compound according to any one of claims 1 to 16, selected from
Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(6-oxo- 1,3,4,8, 9,9a-hexahydropyrazino[ 1,2- c] [ 1 ,3] oxazin-2-yl)methyl] -2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[(4-oxo-6,7,9,9a-tetrahydro-lH-pyrazino[2,l- c] [ 1 ,4] oxazin-8-yl)methyl] -2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7-yl]methyl]-
4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-3-oxo-5,6,8,8a-tetrahydro-lH-oxazolo[3,4-a]pyrazin-7-yl]methyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4R)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4-
(2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4S)-6-[[(8aR)-6-oxo-l,3,4,7,8,8a-hexahydropyrrolo[l,2-a]pyrazin-2-yl]methyl]-4- (3,4-difluorophenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate; Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[(6-oxo-3,4,7,8,9,9a-hexahydro-lH-pyrido[l,2- a]pyrazin-2-yl)methyl] -2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl]- 4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-3-oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl]-
4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4R)-6-[[(8aS)-3-oxo- 1,2,5,6,8, 8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl] -4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Ethyl (4R)-6-[[(8aR)-3-oxo- 1,2,5,6,8, 8a-hexahydroimidazo[l,5-a]pyrazin-7-yl]methyl] -4- (2-bromo-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aR)-l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7-yl]methyl]-
4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(8aS)-l,3-dioxo-5,6,8,8a-tetrahydroimidazo[l,5-a]pyrazin-7-yl]methyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(3aS)-l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin-
5- yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
Methyl (4R)-6-[[(3aR)-l,l-dioxo-2,3,3a,4,6,7-hexahydro-[l,2,5]thiadiazolo[2,3-a]pyrazin- 5-yl]methyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chlorophenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2- methyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2- methyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-prop anoic acid;
Ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-methoxy-l,l-dimethyl-2-oxo-ethyl)-3- oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ; Methyl 7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarb
di ydropyrimidin-6-yl]methyl] -3-oxo-2,5, 6, 8-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine-8a- carboxylate;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(2-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-cyclopropyl-3-oxo- 1 ,5,6,8-tetrahydroimidazo[ 1 ,5-a]pyrazin- 8a- yl] acetic acid;
2- [(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-isopropyl-3-oxo- 1 ,5,6,8-tetrahydroimidazo[ 1 ,5-a]pyrazin-8a- yl] acetic acid;
(R)-6-[(S)-2-(l-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
3- [(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3- methyl-butanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3- methyl-butanoic acid;
l-[[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid; l-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbony
di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3- methyl-butanoic acid;
1- [[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
3-[(2S,8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclobutanecarboxylic acid;
3-[(8aR)-7-[[(4R)-4-(2-chloro-4-f uoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclobutanecarboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-dif uoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3-f uoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid; and
7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid.
2- [l-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclopropyl] acetic acid; 2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclopropyl] acetic acid;
2-[l-[(8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]cyclopropyl] acetic acid;
(lR,2R)-2-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl- l,4-di ydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
(lS,2R)-2-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
(lR,2S)-2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
(lS,2S)-2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclopentanecarboxylic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]butanoic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-butanoic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3,3- dimethyl-butanoic acid;
(R)-6-[(S)-2-(2-Carboxy-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-((R)-2-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester; (R)-6-[(S)-2-((S)-2-Carboxy-l-methyl-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2- acid methyl ester;
6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-((R)-2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-((lR,3S)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-((R)-(S)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-((lR,3R)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-((lR,3R)-3-Carboxy-cyclopentyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[2-(4-Carboxy-benzyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2- chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[2-(4-Carboxy-benzyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4-(2- chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
2-[2-[7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]ethoxy] acetic acid;
2-[3-[7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]propoxy] acetic acid; methyl (4R)-4-(2-chloro-4-fluoro-phenyl)-6-[[2-(5-hydroxy-4,4-dimethyl-pentyl)-3-oxo- 5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ;
ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-hydroxyethyl)-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate; ethyl (4R)-4-(2-chloro-3-fluoro-phenyl)-6-[[2-(2-hydroxyethyl)-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazin-7-yl]methyl]-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5-carboxylate;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]cyclohexanecarboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chlorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
2- [[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l, 5-a]pyrazin-2- yl]methyl]butanoic acid;
3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
3- [(8aS)-7-[[4-(4-chlorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4-dihydropyrimidin- 6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2- methoxy-propanoic acid;
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] spiro[3.3]heptane-6-carboxylic acid; 5-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]pentanoic acid;
3-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclobutanecarboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazine- 8-carboxylic acid; (8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl- 1 ,4-di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[l,5-a]pyrazine- 8-carboxylic acid;
(8R,8aS)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,^
carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,^
carboxylic acid;
(8R,8aS)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl- 1 ,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5, 6,8, 8a-tetrahydro- lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl- 1 ,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5, 6,8, 8a-tetrahydro- lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
methyl (8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-2,5, 6, 8-tetrahydro-lH-imidazo[l,5-a]pyrazine-8a- carboxylate;
2-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-l,l-dimethyl-3-oxo-6,8-dihydro-5H-oxazolo[3,4-a]pyrazin-8a- yl] acetic acid;
2-[(8aR)-7-[[(4R)-4-(2-chloro-4-f uoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-l,l-dimethyl-3-oxo-6,8-dihydro-5H-oxazolo[3,4-a]pyrazin-8a- yl] acetic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-methyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine- 8-carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-methyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazine- 8-carboxylic acid;
Methyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ; Methyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydropyrimidine-5- carboxylate;
3- [(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-propoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
4- [(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-butanoic acid;
5-[7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl]pyridine-2-carboxylic acid;
(S)-6-[(S)-2-(2-Carboxy-2,2-difluoro-ethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(3,4-difluoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carbo acid ethyl ester;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-(4-methylthiazol-2- yl)- 1 ,4-dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro- lH-imidazo[ 1 ,5-a]pyrazin-2- yl]-2,2-dimethyl -propanoic acid;
2-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -6-oxo- 1 ,3,4,7,8,8a-hexahydropyrrolo[ 1 ,2-a]pyrazine- 1- carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-isobutyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-isobutyl-3-oxo-5,6,8,8a-tetrahydro- lH-imidazo[ 1 ,5- a]pyrazine-8-carboxylic acid; (8R,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
(8S,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
Ethyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-(hydroxymethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
Ethyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-(hydroxymethyl)-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
Ethyl (4R)-6-[[(8aR)-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate; and
Ethyl (4R)-6-[[(8aS)-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-7- yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydropyrimidine-5-carboxylate;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-dffl
a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l^ a]pyrazine-8-carboxylic acid;
Ethyl (4R)-6-[[(8aR)-2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ;
and Ethyl (4R)-6-[[(8aS)-2-(2-hydroxy-2-methyl-propyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[l,5-a]pyrazin-7-yl]methyl]-4-(2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidine- 5 -carboxylate ;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
18. A compound according to any one of claims 1 to 17, selected from 3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-propanoic acid;
3-[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
(R)-6-[(S)-2-(4-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid ethyl ester;
(R)-6-[(S)-2-(3-Carboxy-phenyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7-ylmethyl]-4- (2-chloro-4-fhioro-phenyl)-2-thiazol-2-yl- 1 ,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
3-[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3- methyl-butanoic acid;
l-[[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
l-[[(8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
l-[[(8aS)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2- yl] methyl] cyclopropanecarboxylic acid;
3-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid; and
3-[(8aS)-7-[[(4S)-4-(3,4-dif uoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-propanoic acid; 4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl]-2,2- dimethyl-butanoic acid;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-l,4- di ydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -3,3- dimethyl-butanoic acid;
(R)-6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hexahydro-imidazo[l,5-a]pyrazin-7- ylmethyl]-4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carboxylic acid methyl ester;
6-[(S)-2-(l-Carboxy-cyclobutylmethyl)-3-oxo-hex
ylmethyl]-4-((R)-2-chloro-3-fluoro-phenyl)-2-thiazol-2-yl-l,4-dihydro-pyrimidine-5-carb acid ethyl ester;
3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-f uoro-2-methyl-phenyl)-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-prop anoic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-cyclopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-cyclopropyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl- l,4-dihydropyrimidin-6-yl]methyl]-2-isopropyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5- a]pyrazine-8-carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol- 2-yl-l,4-dihydropyriirddin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazine- 8-carboxylic acid;
(8S,8aR)-2-tert-butyl-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2- yl-l,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]pyrazine-8- carboxylic acid; (8S,8aR)-2-tert-butyl-7-[[(4S)-4-(3,4-difluoro-2-methyl-phenyl)-5-methoxycarbonyl-2- thiazol-2-yl-l,4-dihydropyrimidin-6-yl]methyl] -3-0X0-5, 6,8, 8a-tetrahydro-lH-imidazo[ 1,5- a]pyrazine-8-carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-methyl-3-oxo-5,6,8,8a-tetrahydro-lH-imidazo[l,5-a]p 8-carboxylic acid;
Methyl (4R)-6-[[(8R,8aS)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
Methyl (4R)-6-[[(8S,8aR)-2-tert-butyl-8-carbamoyl-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazin-7-yl]methyl] -4-(2-chloro-4-fluoro-phenyl)-2-thiazol-2-yl- 1 ,4- dihydropyrimidine- 5 -carboxylate ;
4-[(8aS)-7-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-imidazo[l,5-a]pyrazin-2-yl] -2,2- dimethyl-butanoic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro-lH- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
(8S,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -2-(cyclopropylmethyl)-3-oxo-5,6,8,8a-tetrahydro- 1H- imidazo[ 1 ,5-a]pyrazine-8-carboxylic acid;
2-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -6-oxo- 1 ,3,4,7,8,8a-hexahydropyrrolo[ 1 ,2-a]pyrazine- 1- carboxylic acid;
(8R,8aR)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
(8S,8aS)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl] -3-oxo-5,6, 8, 8a-tetrahydro-lH-oxazolo[3,4-a]pyrazine-8- carboxylic acid;
(8R,8aS)-7-[[(4R)-4-(2-chloro-3-f uoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-difluoroethyl)-3-oxo-5,6,8,8a-tetrahydro-lH-imidaz a]pyrazine-8-carboxylic acid; and (8S,8aR)-7-[[(4R)-4-(2-chloro-3-fluoro-phenyl)-5-ethoxycarbonyl-2-thiazol-2-yl-l,4- dihydropyrimidin-6-yl]methyl]-2-(2,2-dffl
a]pyrazine-8-carboxylic acid;
or pharmaceutically acceptable salts, or enantiomers or diastereomers thereof.
19. A process for the preparation of a compound according to any one of claims 1 to 18 comprising the reaction of a compound of formula (A)
with
Figure imgf000252_0001
se;
wherein R1 to R6, X, Y, W and n are defined as in any one of claims 1 to 16.
20. A compound according to any one of claims 1 to 18 for use as therapeutically active substance. 21. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 18 and a therapeutically inert carrier.
22. The use of a compound according to any one of claims 1 to 18 for the treatment or prophylaxis of hepatitis B virus infection.
23. The use of a compound according to any one of claims 1 to 18 for the preparation of a medicament for the treatment or prophylaxis of hepatitis B virus infection.
24. A compound according to any one of claims 1 to 18 for the treatment or prophylaxis of hepatitis B virus infection. 25. A compound according to any one of claims 1 to 18 as HBV capsid inhibitor.
26. A compound according to any one of claims 1 to 18, when manufactured according to a process of claim 19. 27. A method for the treatment or prophylaxis of hepatitis B virus infection, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 18.
28. The invention as hereinbefore described.
PCT/EP2015/054454 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection WO2015132276A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
UAA201610076A UA117518C2 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JP2016572899A JP6306750B2 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis B virus infection
SI201530620T SI3114128T1 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SG11201607332UA SG11201607332UA (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
DK15710127.0T DK3114128T3 (en) 2014-03-07 2015-03-04 New 6-fused heteroaryld dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
PL15710127T PL3114128T3 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
RS20190265A RS58384B1 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES15710127T ES2714110T3 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryl dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
MYPI2016703231A MY188114A (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201691726A EA030115B9 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR1020167023287A KR101926243B1 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
BR112016020566-9A BR112016020566B1 (en) 2014-03-07 2015-03-04 NOVEL HETEROARYL-DIHYDRO-PYRIMIDINES FUSED IN POSITION 6 FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
LTEP15710127.0T LT3114128T (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2016011515A MX350439B (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
NZ721520A NZ721520A (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CR20160337A CR20160337A (en) 2014-03-07 2015-03-04 NEW HETEROARILDIHYDROPIRIMIDINES 6-FUSIONATED FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
CN201580012257.1A CN106061978B (en) 2014-03-07 2015-03-04 The heteroaryl dihydro-pyrimidin condensed for treating and preventing hepatitis b virus infected new 6-
EP15710127.0A EP3114128B1 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2935811A CA2935811C (en) 2014-03-07 2015-03-04 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR1020187034667A KR101933844B1 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AU2015226206A AU2015226206B2 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
IL246449A IL246449B (en) 2014-03-07 2016-06-26 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ZA2016/04784A ZA201604784B (en) 2014-03-07 2016-07-12 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PH12016501631A PH12016501631A1 (en) 2014-03-07 2016-08-16 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HRP20190352TT HRP20190352T1 (en) 2014-03-07 2019-02-21 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/073068 2014-03-07
CNPCT/CN2014/073068 2014-03-07
CNPCT/CN2014/083027 2014-07-25
CNPCT/CN2014/083027 2014-07-25
CN2015070895 2015-01-16
CNPCT/CN2015/070895 2015-01-16

Publications (1)

Publication Number Publication Date
WO2015132276A1 true WO2015132276A1 (en) 2015-09-11

Family

ID=52684200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/054454 WO2015132276A1 (en) 2014-03-07 2015-03-04 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Country Status (32)

Country Link
US (4) US9233978B2 (en)
EP (1) EP3114128B1 (en)
JP (1) JP6306750B2 (en)
KR (2) KR101933844B1 (en)
CN (3) CN107513073A (en)
AU (1) AU2015226206B2 (en)
BR (1) BR112016020566B1 (en)
CA (1) CA2935811C (en)
CL (1) CL2016002179A1 (en)
CR (1) CR20160337A (en)
DK (1) DK3114128T3 (en)
EA (1) EA030115B9 (en)
ES (1) ES2714110T3 (en)
HK (1) HK1245784A1 (en)
HR (1) HRP20190352T1 (en)
HU (1) HUE041734T2 (en)
IL (1) IL246449B (en)
LT (1) LT3114128T (en)
MA (1) MA39721A (en)
MX (1) MX350439B (en)
MY (1) MY188114A (en)
NZ (1) NZ721520A (en)
PE (1) PE20161338A1 (en)
PH (1) PH12016501631A1 (en)
PL (1) PL3114128T3 (en)
PT (1) PT3114128T (en)
RS (1) RS58384B1 (en)
SG (1) SG11201607332UA (en)
SI (1) SI3114128T1 (en)
TW (2) TWI603972B (en)
UA (1) UA117518C2 (en)
WO (1) WO2015132276A1 (en)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150252057A1 (en) * 2014-03-07 2015-09-10 Hoffmann-La Roche Inc. Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
WO2016146598A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2017064156A1 (en) 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2017076791A1 (en) * 2015-11-03 2017-05-11 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2017140750A1 (en) 2016-02-19 2017-08-24 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
WO2018036941A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
WO2018050571A1 (en) 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2018090862A1 (en) * 2016-11-18 2018-05-24 四川科伦博泰生物医药股份有限公司 Dihydropyrimidine compound and preparation method and use thereof
WO2018133846A1 (en) * 2017-01-23 2018-07-26 上海长森药业有限公司 Cyclothiourea compound and use thereof
US10071961B2 (en) 2013-10-23 2018-09-11 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10196376B2 (en) 2011-12-21 2019-02-05 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2019076310A1 (en) * 2017-10-18 2019-04-25 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
WO2019086141A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019086142A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2019516714A (en) * 2016-05-20 2019-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel pyrazine compounds with oxygen, sulfur and nitrogen linkers for the treatment of infections
WO2019126622A1 (en) * 2017-12-21 2019-06-27 Janssen Sciences Ireland Unlimited Company Isoxazole compounds for the treatment of diseases associated with hbv infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10398677B2 (en) 2013-04-03 2019-09-03 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP2019527731A (en) * 2016-07-29 2019-10-03 ニュウェーブ ファーマシューティカル インコーポレーテッド Novel therapeutics for the treatment of HBV infection
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10457638B2 (en) 2013-05-17 2019-10-29 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3590943A1 (en) 2015-07-02 2020-01-08 Janssen Sciences Ireland Unlimited Company Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10632112B2 (en) 2014-02-05 2020-04-28 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
WO2020089460A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
WO2020089459A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089453A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089452A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv)
WO2020089456A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089455A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
WO2020125730A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
WO2020125729A1 (en) 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
WO2020193459A1 (en) 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier
CN111825676A (en) * 2019-04-15 2020-10-27 广东东阳光药业有限公司 Dihydropyrimidine compound and application thereof in medicine
CN111848627A (en) * 2019-04-30 2020-10-30 东莞市东阳光新药研发有限公司 Dihydropyrimidine compound and application thereof in medicine
WO2020221811A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
WO2020221816A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2020221826A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
WO2020245246A1 (en) 2019-06-06 2020-12-10 F. Hoffmann-La Roche Ag Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255017A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2021018238A1 (en) * 2019-07-31 2021-02-04 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
WO2021018237A1 (en) * 2019-07-31 2021-02-04 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
WO2021053126A1 (en) 2019-09-20 2021-03-25 F. Hoffmann-La Roche Ag Method of treating hbv infection using a core protein allosteric modulator
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2021130195A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Method of treating virus infection using a tlr7 agonist
WO2021130270A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2021130266A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11129834B2 (en) 2016-04-15 2021-09-28 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
WO2021219523A1 (en) 2020-04-28 2021-11-04 F. Hoffmann-La Roche Ag Process for the preparation of a chiral piperazine-2-carboxylic acid
US11166954B2 (en) 2016-11-18 2021-11-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Dihydropyrimidine compound and preparation method and use thereof
WO2022029209A1 (en) 2020-08-05 2022-02-10 F. Hoffmann-La Roche Ag Oligonucleotide treatment of hepatitis b patients
WO2022078479A1 (en) * 2020-10-16 2022-04-21 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022111719A1 (en) * 2020-11-30 2022-06-02 Sunshine Lake Pharma Co., Ltd. Salts of dihydropyrimidine derivatives, complexes and uses thereof in medicine
US11447489B2 (en) 2017-12-28 2022-09-20 Hoffmann-La Roche Inc. Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis B virus infection
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11639350B2 (en) 2017-06-27 2023-05-02 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027752A1 (en) 2010-07-22 2012-02-02 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
US9266904B2 (en) * 2013-05-17 2016-02-23 Hoffmann-La Roche Inc. 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
WO2015078391A1 (en) 2013-11-27 2015-06-04 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
MX2016012573A (en) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals.
EP3150600B1 (en) * 2014-05-30 2018-06-27 Qilu Pharmaceutical Co., Ltd. Dihydropyrimido loop derivative as hbv inhibitor
TWI687432B (en) 2014-10-29 2020-03-11 美商基利科學股份有限公司 Methods for treating filoviridae virus infections
CN105859708B (en) 2015-02-07 2020-01-21 广东东阳光药业有限公司 Salts of dihydropyrimidine derivatives and their use in medicine
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
BR112018005048B8 (en) 2015-09-16 2021-03-23 Gilead Sciences Inc use of an antiviral compound or salt thereof for the treatment of a coronaviridae infection
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
WO2017136403A1 (en) * 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017140821A1 (en) 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
BR112018067964B1 (en) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING IT AND USE OF SAID COMPOUND
DE202016102339U1 (en) * 2016-05-03 2016-06-22 Freund Maschinenfabrik Gmbh & Co. Kg Sliding block for a saw blade in a band saw machine
SG11201810834WA (en) 2016-06-10 2018-12-28 Enanta Pharm Inc Hepatitis b antiviral agents
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
TW201811788A (en) 2016-09-09 2018-04-01 瑞士商諾華公司 Polycyclic pyridone compounds as antivirals
CR20190181A (en) 2016-10-14 2019-08-21 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
TWI784370B (en) 2017-01-31 2022-11-21 美商基利科學股份有限公司 Crystalline forms of tenofovir alafenamide
EP4331677A3 (en) 2017-03-14 2024-05-29 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
SG11201908569QA (en) 2017-03-21 2019-10-30 Arbutus Biopharma Corp Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
US10836787B2 (en) 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CA3068128A1 (en) * 2017-06-26 2019-01-03 North & South Brother Pharmacy Investment Company Limited Dihydropyrimidine compounds and uses thereof in medicine
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Hepatitis b antiviral agents
CN111315749A (en) 2017-11-17 2020-06-19 诺华股份有限公司 Novel dihydroisoxazole compounds and their use in the treatment of hepatitis b
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
JP2021507906A (en) 2017-12-20 2021-02-25 ノバルティス アーゲー Fusion tricyclic pyrazolo-dihydropyrazinyl-pyridone compound as an antiviral agent
CN111511754B (en) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
KR102526964B1 (en) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Substituted pyrrolizine compounds as HBV replication inhibitors
JP2021514982A (en) 2018-02-28 2021-06-17 ノバルティス アーゲー Indole-2-carbonyl compounds and their use for the treatment of hepatitis B
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (en) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN112041311B (en) 2018-04-19 2023-10-03 吉利德科学公司 PD-1/PD-L1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI826492B (en) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
BR112021005091A2 (en) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterocycles functionalized as antiviral agents
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN113271946A (en) 2018-11-21 2021-08-17 英安塔制药有限公司 Functionalized heterocyclic compounds as antiviral agents
TW202415643A (en) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
WO2020135439A1 (en) * 2018-12-25 2020-07-02 广东东阳光药业有限公司 Deuterated dihydropyrimidine compound and use thereof as drug
CN113543851A (en) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2'3' -cyclic dinucleotides and their prodrugs
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137518A (en) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202210480A (en) 2019-04-17 2022-03-16 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202104210A (en) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv protease inhibitors
CN113825758B (en) * 2019-05-14 2023-08-01 正大天晴药业集团股份有限公司 Crystal forms of anti-HBV tetrahydroisoxazolo [4,3-c ] pyridines
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
MX2022003658A (en) 2019-09-30 2022-04-25 Gilead Sciences Inc Hbv vaccines and methods treating hbv.
WO2021078221A1 (en) * 2019-10-24 2021-04-29 广东东阳光药业有限公司 Dihydropyrimidine compound and use thereof in drug
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4077305A4 (en) * 2019-12-20 2024-01-10 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
CN117736207A (en) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 Diacylglycerol kinase modulating compounds
CA3163424A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
JP7554841B2 (en) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド Methods for preparing 1'-cyanonucleosides
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP2023518433A (en) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using them
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
KR20230018473A (en) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 How to treat remdesivir
CN115996928A (en) 2020-06-24 2023-04-21 吉利德科学公司 1' -cyanonucleoside analogs and uses thereof
WO2022013136A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease
PE20230779A1 (en) 2020-08-07 2023-05-09 Gilead Sciences Inc PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE
CA3188373A1 (en) 2020-08-24 2022-03-03 Scott E. Lazerwith Phospholipid compounds and uses thereof
AU2021331214B2 (en) 2020-08-27 2024-01-04 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN111892544A (en) * 2020-08-31 2020-11-06 南通大学 3- (aminomethyl) -4- (4-fluorophenyl) piperazine-1-carboxylic acid tert-butyl ester and synthesis method thereof
WO2022052923A1 (en) * 2020-09-08 2022-03-17 和博医药有限公司 Dihydropyrimidine compound and application thereof
TWI811812B (en) 2020-10-16 2023-08-11 美商基利科學股份有限公司 Phospholipid compounds and uses thereof
TW202406932A (en) 2020-10-22 2024-02-16 美商基利科學股份有限公司 Interleukin-2-fc fusion proteins and methods of use
CN115003673B (en) * 2020-12-09 2023-08-11 上海维申医药有限公司 Dihydropyrimidine compound, preparation method and application thereof
CN114853761A (en) * 2021-02-05 2022-08-05 刘沛 Bifunctional derivative containing dihydropyrimidine and application thereof
EP4289842A1 (en) * 2021-02-05 2023-12-13 Hepagene Therapeutics (HK) Limited Phenyldihydropyrimidine compound and use thereof
EP4293022A1 (en) * 2021-02-09 2023-12-20 Shanghai Visonpharma Co., Ltd. Dihydropyrimidine compound, preparation method therefor and application thereof
TW202310852A (en) 2021-05-13 2023-03-16 美商基利科學股份有限公司 Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (en) 2021-06-23 2024-01-12 吉利德科学公司 Diacylglycerol kinase modulating compounds
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN114702497B (en) * 2021-12-23 2023-03-21 华南理工大学 Crystal form of dihydropyrimidine derivative, preparation method thereof and application thereof in medicines
CN114702498B (en) * 2021-12-23 2022-12-16 华南理工大学 Acid addition salts of dihydropyrimidine derivatives and their use in medicine
TW202400185A (en) 2022-03-02 2024-01-01 美商基利科學股份有限公司 Compounds and methods for treatment of viral infections
WO2023167938A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
AU2023227862A1 (en) 2022-03-03 2024-09-26 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20240199676A1 (en) 2022-03-03 2024-06-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2023239665A1 (en) 2022-06-06 2023-12-14 Gilead Sciences, Inc. Methods for treatment of viral infections including sars-cov-2
US20240051962A1 (en) 2022-06-29 2024-02-15 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20240043466A1 (en) 2022-06-30 2024-02-08 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013126A1 (en) * 2000-03-17 2001-09-20 Bayer Ag New 6-aminoalkyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity
WO2005085462A1 (en) 2004-02-27 2005-09-15 Dsm Ip Assets B.V. Enzymatic preparation of an enantiomerically enriched beta-2-amino acids
US20070072934A1 (en) 2005-09-22 2007-03-29 The Scripps Research Institute Alkoxy indolinone based protein kinase inhibitors
WO2008090115A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009103176A1 (en) 2008-02-22 2009-08-27 Neurotune Ag Nitrogen-containing bycyclic compounds active on chronic pain conditions
WO2010023480A1 (en) 2008-08-29 2010-03-04 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2012019426A1 (en) 2010-08-09 2012-02-16 上海恒瑞医药有限公司 Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
WO2014184328A1 (en) * 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012549A1 (en) 2000-03-15 2001-09-20 Bayer Ag New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections
DE10012824A1 (en) 2000-03-16 2001-09-20 Bayer Ag New 6-hydroxyhydrocarbyl or 6-thiohydrocarbyl-dihydropyrimidine-5-carboxylic acid derivatives, useful for the treatment of viral infections, especially hepatitis B infections
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
WO2010069147A1 (en) 2008-12-17 2010-06-24 张中能 Dihydropyrimidine derivatives, compositions thereof and their use
CN104650069B (en) * 2013-11-19 2019-04-19 广东东阳光药业有限公司 4- methyl Dihydropyrimidines and its application in drug
DK3114128T3 (en) * 2014-03-07 2019-03-25 Hoffmann La Roche New 6-fused heteroaryld dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
KR20170113658A (en) * 2015-03-16 2017-10-12 에프. 호프만-라 로슈 아게 Combination therapy with TLR7 agonists and HBV capsid assembly inhibitors
EP3370759A1 (en) * 2015-11-03 2018-09-12 H. Hoffnabb-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
AR107633A1 (en) * 2016-02-19 2018-05-16 Hoffmann La Roche PROCEDURE FOR THE PREPARATION OF ACID 4-PHENYL-5-ALCOXICARBONIL-2-TIAZOL-2-IL-1,4-DIHYDROPIRIMIDIN-6-IL- [METHYL] -3-OXO-5,6,8,8A-TETRAHIDRO- 1H-IMIDAZO [1,5A] PIRAZIN-2-IL-CARBOXYL
CN109689059A (en) * 2016-08-24 2019-04-26 豪夫迈·罗氏有限公司 The combination treatment of HBV Mouth Disease Virus Proteins inhibitor and nucleosides or nucleotide analog
EP3970750A1 (en) * 2016-09-13 2022-03-23 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP2022525522A (en) * 2019-03-25 2022-05-17 エフ．ホフマン－ラ ロシュ アーゲー Solid form of compound of HBV core protein allosteric modifier
JP2022548652A (en) * 2019-09-20 2022-11-21 エフ．ホフマン－ラ ロシュ アーゲー Methods of treating HBV infection using core protein allosteric modulators

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013126A1 (en) * 2000-03-17 2001-09-20 Bayer Ag New 6-aminoalkyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity
WO2005085462A1 (en) 2004-02-27 2005-09-15 Dsm Ip Assets B.V. Enzymatic preparation of an enantiomerically enriched beta-2-amino acids
US20070072934A1 (en) 2005-09-22 2007-03-29 The Scripps Research Institute Alkoxy indolinone based protein kinase inhibitors
WO2008090115A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009103176A1 (en) 2008-02-22 2009-08-27 Neurotune Ag Nitrogen-containing bycyclic compounds active on chronic pain conditions
WO2010023480A1 (en) 2008-08-29 2010-03-04 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2012019426A1 (en) 2010-08-09 2012-02-16 上海恒瑞医药有限公司 Phthalazinone derivative, and preparation method and pharmaceutical use thereof
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
WO2014184328A1 (en) * 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ALLAN, ROBIN D.; FONG, JOYCE, AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 39, no. 6, 1986, pages 855 - 64
ANSEL, H. ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1995, pages: 196,1456 - 1457
ANSEL, HOWARD C. ET AL.: "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, LIPPINCOTT, WILLIAMS & WILKINS
BASTIN R.J. ET AL., ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 4, 2000, pages 427 - 435
BREZILLON N ET AL., PLOS ONE, 2011, pages E25096
DERES K. ET AL., SCIENCE, 2003, pages 893
FELD J. ET AL., ANTIVIRAL RESEARCH, 2007, pages 168 - 177
GAO H.; RENSLO A. R., J. ORG. CHEM., vol. 72, 2007, pages 8591 - 8592
GENNARO, ALFONSO R. ET AL.: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS
GRYGORENKO O. O. ET AL., SYNTHETIC COMMUNICATIONS, vol. 41, 2011, pages 1644 - 1649
H GUO ET AL., JOURNAL OF VIROLOGY, vol. 81, 2007, pages 12472 - 12484
MERTIN A. ET AL., SYNLETT, vol. 2, 1991, pages 87 - 9
ROWE, RAYMOND C.: "Handbook of Pharmaceutical Excipients", 2005, PHARMACEUTICAL PRESS
SANDSTROEM A. ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, no. 10, 2008, pages 5590 - 5605
SELLES ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 1005 - 1009
YINGXIAN ZHU
ZLOTNICK A. ET AL., J. VIROL., 2002, pages 4848 - 4854

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196376B2 (en) 2011-12-21 2019-02-05 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US10995064B2 (en) 2012-08-28 2021-05-04 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10941113B2 (en) 2013-02-28 2021-03-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10398677B2 (en) 2013-04-03 2019-09-03 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10457638B2 (en) 2013-05-17 2019-10-29 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10377709B2 (en) 2013-10-23 2019-08-13 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10071961B2 (en) 2013-10-23 2018-09-11 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10632112B2 (en) 2014-02-05 2020-04-28 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US20150252057A1 (en) * 2014-03-07 2015-09-10 Hoffmann-La Roche Inc. Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9233978B2 (en) * 2014-03-07 2016-01-12 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
AU2016232353B2 (en) * 2015-03-16 2019-05-16 F. Hoffmann-La Roche Ag Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
WO2016146598A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
US20180000824A1 (en) * 2015-03-16 2018-01-04 Hoffmann-La Roche Inc. Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
US11771699B2 (en) 2015-03-16 2023-10-03 Hoffmann-La Roche Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
EP3590943A1 (en) 2015-07-02 2020-01-08 Janssen Sciences Ireland Unlimited Company Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017064156A1 (en) 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JP2020100636A (en) * 2015-11-03 2020-07-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Combination therapy of HBV capsid assembly inhibitor and interferon
WO2017076791A1 (en) * 2015-11-03 2017-05-11 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and an interferon
US10596173B2 (en) 2015-11-03 2020-03-24 Hoffmann-La Roche Inc. Combination therapy of an HBV capsid assembly inhibitor and an interferon
CN108135979A (en) * 2015-11-03 2018-06-08 豪夫迈·罗氏有限公司 The combination treatment of HBV Mouth Disease Virus Proteins inhibitor and interferon
JP2018531272A (en) * 2015-11-03 2018-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Combination therapy of HBV capsid assembly inhibitor and interferon
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
WO2017140750A1 (en) 2016-02-19 2017-08-24 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
AU2017219189B2 (en) * 2016-02-19 2021-04-01 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
US10927116B2 (en) 2016-02-19 2021-02-23 Hoffmann-La Roche Inc. Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
JP2019507144A (en) * 2016-02-19 2019-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6,8,8a-tetrahydro-1H-imidazo [1] Process for the preparation of [5-a] pyrazin-2-yl] -carboxylic acid
EP3954691A1 (en) 2016-02-19 2022-02-16 F. Hoffmann-La Roche AG Process for the preparation of enantiomeric derivatives 4-phenyl-6-methyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine
KR102255228B1 (en) * 2016-02-19 2021-05-25 에프. 호프만-라 로슈 아게 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro- Method for producing 1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
KR20180104177A (en) * 2016-02-19 2018-09-19 에프. 호프만-라 로슈 아게 5-alkoxycarbonyl-2-thiazol-2-yl-l, 4-dihydropyrimidin-6-yl] methyl] -3-oxo-5,6,8,8a-tetrahydro- Preparation of 1H-imidazo [1,5-a] pyrazin-2-yl] -carboxylic acid
CN108718527A (en) * 2016-02-19 2018-10-30 豪夫迈·罗氏有限公司 Be used to prepare 4- phenyl -5- alkoxy carbonyl groups -2- thiazol-2-yl-Isosorbide-5-Nitrae-dihydro-pyrimidin -6- bases] methyl] -3- oxos -5,6,8,8a- tetrahydrochysene -1H- imidazos [1,5-a] pyrazine -2- bases]-formic acid method
CN108718527B (en) * 2016-02-19 2022-06-28 豪夫迈·罗氏有限公司 Process for preparing compounds
US11129834B2 (en) 2016-04-15 2021-09-28 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
JP2019516714A (en) * 2016-05-20 2019-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel pyrazine compounds with oxygen, sulfur and nitrogen linkers for the treatment of infections
JP6991213B2 (en) 2016-07-29 2022-01-14 グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド New therapeutic agents for the treatment of HBV infection
JP2019527731A (en) * 2016-07-29 2019-10-03 ニュウェーブ ファーマシューティカル インコーポレーテッド Novel therapeutics for the treatment of HBV infection
WO2018036941A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
CN109689059A (en) * 2016-08-24 2019-04-26 豪夫迈·罗氏有限公司 The combination treatment of HBV Mouth Disease Virus Proteins inhibitor and nucleosides or nucleotide analog
JP2019526562A (en) * 2016-08-24 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Combination therapy of HBV capsid assembly inhibitor and nucleoside (Thi) analogue
EP3970750A1 (en) * 2016-09-13 2022-03-23 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
AU2017326400B2 (en) * 2016-09-13 2023-03-30 F. Hoffmann-La Roche Ag Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
JP2022130672A (en) * 2016-09-13 2022-09-06 エフ．ホフマン－ラ ロシュ アーゲー Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP7101663B2 (en) 2016-09-13 2022-07-15 エフ．ホフマン－ラ ロシュ アーゲー Combination therapy of TLR7 agonist and HBV capsid assembly inhibitor
WO2018050571A1 (en) 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
US11337982B2 (en) 2016-09-13 2022-05-24 Hoffmann-La Roche, Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
JP2019526610A (en) * 2016-09-13 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Combination therapy of TLR7 agonist and HBV capsid assembly inhibitor
US10696669B2 (en) 2016-11-18 2020-06-30 Sichuan Kelun-Biotech Biopharmaceuticals Co., Ltd. Dihydropyrimidine compound and preparation method and use thereof
CN109790145B (en) * 2016-11-18 2020-09-22 四川科伦博泰生物医药股份有限公司 Dihydropyrimidine compound and preparation method and application thereof
WO2018090862A1 (en) * 2016-11-18 2018-05-24 四川科伦博泰生物医药股份有限公司 Dihydropyrimidine compound and preparation method and use thereof
US11166954B2 (en) 2016-11-18 2021-11-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Dihydropyrimidine compound and preparation method and use thereof
CN109790145A (en) * 2016-11-18 2019-05-21 四川科伦博泰生物医药股份有限公司 Dihydropyrimidines and its preparation method and application
WO2018133846A1 (en) * 2017-01-23 2018-07-26 上海长森药业有限公司 Cyclothiourea compound and use thereof
US11639350B2 (en) 2017-06-27 2023-05-02 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
US11261190B2 (en) * 2017-10-18 2022-03-01 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
AU2018351400B2 (en) * 2017-10-18 2022-12-15 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
EP3697792A4 (en) * 2017-10-18 2021-10-13 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
WO2019076310A1 (en) * 2017-10-18 2019-04-25 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
WO2019086141A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019086142A1 (en) 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2019126622A1 (en) * 2017-12-21 2019-06-27 Janssen Sciences Ireland Unlimited Company Isoxazole compounds for the treatment of diseases associated with hbv infections
US11447489B2 (en) 2017-12-28 2022-09-20 Hoffmann-La Roche Inc. Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis B virus infection
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
WO2020089459A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089460A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
WO2020089453A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020089452A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv)
WO2020089456A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089455A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2020125729A1 (en) 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
US20230165865A1 (en) * 2018-12-20 2023-06-01 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
EP3898632A4 (en) * 2018-12-20 2023-02-22 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
WO2020125730A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11873302B2 (en) 2019-03-25 2024-01-16 Hoffmann-La Roche Inc. Solid forms of a compound of HBV core protein allosteric modifier
WO2020193459A1 (en) 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier
CN111825676A (en) * 2019-04-15 2020-10-27 广东东阳光药业有限公司 Dihydropyrimidine compound and application thereof in medicine
CN111825676B (en) * 2019-04-15 2023-10-17 广东东阳光药业股份有限公司 Dihydropyrimidine compounds and application thereof in medicines
WO2020221816A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
WO2020221811A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
WO2020221826A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
CN111848627A (en) * 2019-04-30 2020-10-30 东莞市东阳光新药研发有限公司 Dihydropyrimidine compound and application thereof in medicine
WO2020221824A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN114026095A (en) * 2019-06-06 2022-02-08 豪夫迈·罗氏有限公司 Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl ] methyl ] -3-oxo-5, 6,8,8 a-tetrahydro-1H-imidazo [1,5-a ] pyrazin-2-yl ] -carboxylic acid
WO2020245246A1 (en) 2019-06-06 2020-12-10 F. Hoffmann-La Roche Ag Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
WO2020255017A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2021018237A1 (en) * 2019-07-31 2021-02-04 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
WO2021018238A1 (en) * 2019-07-31 2021-02-04 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
WO2021053126A1 (en) 2019-09-20 2021-03-25 F. Hoffmann-La Roche Ag Method of treating hbv infection using a core protein allosteric modulator
WO2021130195A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Method of treating virus infection using a tlr7 agonist
WO2021130266A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
WO2021130270A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
WO2021219523A1 (en) 2020-04-28 2021-11-04 F. Hoffmann-La Roche Ag Process for the preparation of a chiral piperazine-2-carboxylic acid
WO2022029209A1 (en) 2020-08-05 2022-02-10 F. Hoffmann-La Roche Ag Oligonucleotide treatment of hepatitis b patients
WO2022078479A1 (en) * 2020-10-16 2022-04-21 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN114573589A (en) * 2020-11-30 2022-06-03 广东东阳光药业有限公司 Salts of dihydropyrimidine derivatives, complexes and their use in medicine
CN114573589B (en) * 2020-11-30 2023-10-20 广东东阳光药业股份有限公司 Salts, complexes of dihydropyrimidine derivatives and their use in medicine
WO2022111719A1 (en) * 2020-11-30 2022-06-02 Sunshine Lake Pharma Co., Ltd. Salts of dihydropyrimidine derivatives, complexes and uses thereof in medicine

Also Published As

Publication number Publication date
EP3114128A1 (en) 2017-01-11
HUE041734T2 (en) 2019-05-28
EP3114128B1 (en) 2019-01-02
CA2935811A1 (en) 2015-09-11
US20150252057A1 (en) 2015-09-10
JP2017507186A (en) 2017-03-16
US9233978B2 (en) 2016-01-12
IL246449B (en) 2020-09-30
ES2714110T3 (en) 2019-05-27
MX2016011515A (en) 2016-12-20
US10081627B2 (en) 2018-09-25
RS58384B1 (en) 2019-04-30
MX350439B (en) 2017-09-06
PL3114128T3 (en) 2019-06-28
EA201691726A1 (en) 2016-12-30
US20180370969A1 (en) 2018-12-27
TW201546075A (en) 2015-12-16
SI3114128T1 (en) 2019-04-30
CN106061978B (en) 2018-10-23
KR101926243B1 (en) 2018-12-06
BR112016020566B1 (en) 2022-11-29
TW201726682A (en) 2017-08-01
TWI606050B (en) 2017-11-21
US10428069B2 (en) 2019-10-01
MA39721A (en) 2017-01-11
KR20160105978A (en) 2016-09-08
PT3114128T (en) 2019-02-27
PE20161338A1 (en) 2016-12-12
CL2016002179A1 (en) 2017-02-17
HRP20190352T1 (en) 2019-04-05
AU2015226206A1 (en) 2016-07-07
CR20160337A (en) 2016-09-20
UA117518C2 (en) 2018-08-10
HK1245784A1 (en) 2018-08-31
US20200062753A1 (en) 2020-02-27
EA030115B1 (en) 2018-06-29
SG11201607332UA (en) 2016-10-28
TWI603972B (en) 2017-11-01
EA030115B9 (en) 2018-09-28
US20160083383A1 (en) 2016-03-24
IL246449A0 (en) 2016-08-31
JP6306750B2 (en) 2018-04-04
NZ721520A (en) 2023-03-31
CA2935811C (en) 2018-09-18
CN109232613A (en) 2019-01-18
DK3114128T3 (en) 2019-03-25
PH12016501631A1 (en) 2017-02-06
MY188114A (en) 2021-11-21
CN107513073A (en) 2017-12-26
LT3114128T (en) 2019-03-25
KR20180130016A (en) 2018-12-05
CN106061978A (en) 2016-10-26
BR112016020566A2 (en) 2017-08-15
AU2015226206B2 (en) 2017-03-16
KR101933844B1 (en) 2018-12-28

Similar Documents

Publication Publication Date Title
US10428069B2 (en) 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US9758530B2 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US10562905B2 (en) Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseases
US20160237078A9 (en) Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15710127

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 246449

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2935811

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015226206

Country of ref document: AU

Date of ref document: 20150304

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 001260-2016

Country of ref document: PE

Ref document number: CR2016-000337

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: NC2016/0000368

Country of ref document: CO

REEP Request for entry into the european phase

Ref document number: 2015710127

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015710127

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12016501631

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20167023287

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016572899

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/011515

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: IDP00201605999

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 201691726

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201610076

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016020566

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016020566

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160906